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Abstract 
Background and aim: Dysmenorrhea (painful menstruation) and premenstrual syndrome 
(PMS) are the two most prevalent menstrual disorders affecting women of reproductive 
age. It is estimated that overall up to 85% of menstruating women suffer from one or more 
of the conditions. Moderate to severe forms of the conditions can significantly impact on 
the quality-of-life of women and cause considerable economic lost. Despite their potential 
public health significance, uncertainty remains in regard to the long-term trend and 
potential lifestyle risk factors for both conditions. This is mainly due to the cross-sectional 
design and retrospective data collection of the underlying studies. There is also a lack of 
studies which have followed the same group of women long enough to examine the 
variation of symptoms over time and to relate these with changes of potential time-varying 
risk factors. This thesis examines the prevalence, the long-term trend and the potential 
modifiable lifestyle risk factors of dysmenorrhea and PMS in Australian women, with the 
aim of contributing to the evidence base for preventative health policy-making. 
Methods: This thesis used self-reported data from women born in 1973–78 who 
participated in the Australian Longitudinal Study on Women’s Health (ALSWH), a 
prospective cohort study of random samples from the national health insurance database 
(Medicare). The 1973–78 cohort includes 14,247 women aged 18–23 years at baseline 
(1996), who were surveyed every three years after Survey 2 (2000), with the last survey 
conducted in 2012. For the purpose of this research, data from Surveys 2–6 were used. 
Applying various statistical methods, including t-test, χ2 test, frequency over time, lasagne 
plot, latent class analysis, regression analysis including multinominal logistic regression, 
generalised estimating equations, and generalised linear mixed model, this research 
mainly examined 1) the prevalence, the variability, the trend and the trajectories of 
dysmenorrhea and PMS; and 2) the associations between a number of potential 
modifiable lifestyle risk factors and dysmenorrhea or PMS. In addition, exploratory 
analyses was performed to assess the impact of the conditions on self-reported quality-of-
life. Sensitivity analyses were performed when necessary, including multiple imputations 
for missing data, to investigate the robustness and the reliability of the estimates. 
Findings: Over the 13-year follow-up, dysmenorrhea and PMS affected 21% to 26% and 
33% to 41% of Australian women born between 1973 and 1978 respectively. Substantial 
variation in symptom status was observed for both conditions at the individual level over 
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time, with the majority of women reporting experiencing the conditions intermittently. Four 
population subgroups with unique symptom trajectories were identified for both conditions: 
normative (38.3%), low (28.0%), recovering (17.2%) and chronic (16.5%) groups for 
dysmenorrhea after adjusting for oral contraceptive pill use and pregnancy and/or giving 
birth in the past 12 months; and normative (22.1%), late onset (21.9%), recovering (26.5%) 
and chronic (29.5%) groups for PMS. Women in the chronic groups were those who had 
high probability of reporting the respective conditions consistently over time. Among 
women reporting dysmenorrhea or PMS, self-reported quality-of-life as measured by the 
36-item Short Form Health Survey (SF-36) questionnaire was significantly worse than 
among women not reporting dysmenorrhea or PMS. Compared with women without 
dysmenorrhea, women with dysmenorrhea reported worse physical and mental health; 
whereas PMS predominantly impacted negatively on the mental health of affected women. 
After adjusting for potential confounders, moderate associations were demonstrated 
between the conditions and a number of health risks: 
 Smoking was associated with higher risk of dysmenorrhea using latent class 
analysis combined with multinominal logistic regression. Compared with never 
smokers, baseline smokers were at 40% higher odds of being in the chronic 
trajectory group. The odds was even higher, 60%, among women with an earlier 
age of smoking initiation (<14 years).  
 A dose-response association was observed between illicit drug use and PMS with 
illicit drug use in the last 12 months and multiple drug use showing a higher risk of 
reporting PMS. Compared with never drug use, multiple drug use in the last 12 
months showed 30% higher odds of reporting PMS in the generalised estimating 
equations model. A 40% higher odds was revealed for drug users who first used 
illicit drugs before age 15 years. 
 A U-shaped relationship was demonstrated between body mass index (BMI) and 
dysmenorrhea in the generalised estimating equations model. Compared with 
women with a normal BMI, underweight and obese women showed a higher risk of 
reporting dysmenorrhea (34% and 22% respectively). The risk of dysmenorrhea 
disappeared among obese women when they lost weight and acquired a healthier 
body weight.  
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Conclusion: Dysmenorrhea and PMS are common in Australian women with a stable 
prevalence at the population level but exhibit great variation among individuals over time. 
Four subgroups with unique trajectories were identified for each condition in this group of 
Australian women. Repeatedly over time, approximately one in every six women was likely 
to experience dysmenorrhea, and nearly one in three PMS. Moderate associations were 
demonstrated between smoking and dysmenorrhea and between illicit drug use and PMS, 
with a higher risk demonstrated for early age at first use of the substance. Both 
underweight and obesity also showed moderately increased risk for dysmenorrhea. The 
results may have some potential public health importance in supporting interventions to 
prevent substance use, especially early use, and to maintain a healthy body weight. 
However, this research was unable to establish causality and the nature of these 
associations needs further clarification in future studies. 
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Chapter 1. Introduction 
1.1 Background 
The common disorders related to menstruation, including dysmenorrhea (painful 
menstruation), premenstrual syndrome (PMS), menorrhagia (heavy menstrual bleeding), 
and irregular periods, are a major cause of morbidity for women of reproductive age [1, 2]. 
Among these menstrual disorders, dysmenorrhea and PMS are the two most prevalent [3, 
4]. The reported prevalence of menstrual disorders varies widely in the literature, due to a 
range of factors including varying study designs, population studied, severity of symptoms 
included, and symptom-reporting method used [5, 6]. Regardless of the variations in the 
prevalence reported, it is estimated that overall up to 85% of menstruating women suffer 
from one or more menstrual conditions [7, 8]. However, the majority of these conditions 
are mild to moderate in nature, with more severe forms occurring in a relatively small 
group of women; for example, the severe forms of dysmenorrhea and PMS may each 
affect up to 20% of menstruating women [9, 10]. Although there is no consistent definition 
on the terms ‘mild, moderate or severe’ across the literature, there is some consensus on 
their use. In general, mild form of the conditions can cause some uncomfortable or feelings 
of unease but does not interfere with women’s work or study. Moderate and severe forms, 
on the other hand, may interfere with personal and social life in affected women and cause 
significant impairment of functioning, resulting in reduced productivity or absence from 
work or school [11, 12]. 
Moderate and severe forms of dysmenorrhea or PMS can significantly impact on the 
quality-of-life of affected women, interfering with their studies, employment, interpersonal 
relationships, and social functioning [13, 14]. A study of female veterans who reported 
premenstrual symptoms noted a significantly lower health status in every domain of the 
36-item Short Form Health Survey (SF-36) questionnaire except for energy/vitality than 
those reporting none; whereas women who reported dysmenorrhea had significantly lower 
scores in the domains of physical and social functioning, physical role functioning, bodily 
pain, and general health perceptions [1]. This is supported by findings suggesting that the 
health-related quality-of-life (HRQoL) burden associated with premenstrual dysphoric 
disorder (PMDD), a severe form of PMS, is comparable with other chronic conditions such 
as back pain, arthritis and type 2 diabetes [1, 15].  
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Compared with women without dysmenorrhea or PMS, women with these conditions have 
reported decreased work productivity, increased work absenteeism and healthcare use, 
even though there is variation among different cultural groups [13, 16]. The indirect costs 
of PMS, mainly related to lost productivities, have been estimated to be greater than the 
direct costs, resulting in US$4,333 (2005 dollar) additional costs per women per year [17].  
Currently, there are uncertainties in the epidemiological data on the magnitude, the trend 
over time and the risk factors for dysmenorrhea and PMS. This is reflected in the 2010 
global burden of disease (GBD) study [18], which has estimated that the mean disability-
adjusted life years (DALYs) related to PMS, the only menstrual disorder included in the 
study, was 1.3 million (95% uncertainty interval 0.6, 3.3 million). Ranked at 140 among the 
176 selected causes with potential public health significance, it was one of the estimates 
with the highest uncertainty intervals (Figure 1-1). Further support from the literature 
indicates that the menstrual disorder-associated burden is likely to be underestimated 
despite the frequent occurrence of the symptoms due to their cyclical nature [1, 19].  
 
Figure 1-1: DALY rank with 95% uncertainty interval by cause in 2010 [18] 
The uncertainty in the data underpins the limitations of existing literature on menstrual 
disorders, which often adopts cross-sectional design, retrospective data collection and is 
not population-based [20-22]. Most importantly, there is a lack of studies which have 
followed the same group of women long enough to examine the variations in symptoms 
over time and to relate these variations with the changes of time-varying risk factors. The 
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prospective and longitudinal nature (over 16 years of follow-up) of the Australian 
Longitudinal Study on Women’s Health (ALSWH) provides a unique opportunity to 
investigate the frequency of dysmenorrhea and PMS among a nationally representative 
sample of Australian women of reproductive age, whether the symptoms change over time, 
and the modifiable lifestyle risk factors of the conditions.  
1.2 Thesis rational 
As described before, the vast majority of women of reproductive age are affected by one 
or more menstrual disorders, the most prevalent being dysmenorrhea and PMS, which 
may significantly impact on their quality-of-life and cause considerable economic and 
societal burdens [1, 13, 23, 24]. A better understanding of the magnitude of the conditions 
in the local context and their trend over time may help policy-makers to plan their resource 
allocation to better meet the needs of affected women. In addition, there are some 
suggestions on symptom variations over time among women experiencing the conditions 
over time [11, 25, 26], however this has not been studied extensively. More importantly, 
given that few available treatment options are proven to be universally effective without 
substantial side effects—especially for PMS, lifestyle modifications have been proposed as 
the first line intervention for women with mild to moderate symptoms [12, 23]. However, 
current evidence on the association between potential modifiable lifestyle risk factors and 
both menstrual conditions are largely mixed or limited; thus more research is needed to 
better quantify any associations in order to assist in the development of appropriate 
counselling and management strategies. In turn, evidence-based advice may enable 
women to better self-manage the symptoms, to improve their quality-of-life and to reduce 
the burden that can be attributed to them. Furthermore, the evidence generated may also 
help to facilitate the development of preventative health policies. 
In the process of identifying the target risk factors to be investigated in this thesis, two 
sources were used. First, separate literature reviews were conducted to identify gaps in 
risk factors for dysmenorrhea and PMS. Of particular interest to this project are modifiable 
lifestyle factors. The literature revealed that the evidence on the associations between 
most lifestyle risk factors and dysmenorrhea or PMS is either limited or inconsistent, 
particularly for body mass index (BMI), smoking, alcohol consumption, illicit drug use, and 
dietary factors. Further, there is sparse evidence from longitudinal studies that have 
examined the associations of interest. Thus these areas constitute the gaps in the 
literature which call for further research. 
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Following the literature reviews, the Australian burden of disease and injury study [27] was 
consulted in an effort to identify potential risk factors which are of national importance. 
According to that study, nearly a third of total health loss in Australia in 2003 was 
explained by 14 selected health risks (Table 1-1). Among the lifestyle risk factors listed, 
high body mass, physical inactivity, tobacco, alcohol and illicit drug use, low consumption 
of fruit and vegetables were identified as leading contributors to health loss related to a 
range of causes. Given the significance of these risk factors at the population level and the 
high concordance of the results from the two sources, these factors (highlighted in italics in 
the table) were targeted as potential exposure variables in the current research. The 
consumption of fruit and vegetables was excluded due to lack of data as Food Frequency 
Questionnaires were only collected at two surveys (Survey 3 and 5) in ALSWH, hence an 
extensive study of the long-term relationship across multiple time points was not possible. 
Table 1-1: The 14 leading risk factors of health loss in Australia, 2003 [27] 
Risk factor Attributable health lossa (%) 
Tobacco	use 7.8 
High blood pressure 7.6 
High body mass 7.5 
Physical inactivity 6.6 
High blood cholesterol levels 6.2 
Alcohol consumption 2.3 
Low consumption of fruit and vegetables 2.1 
Illicit drug use 2.0 
Occupational exposures and hazards 2.0 
Intimate partner violence 1.1 
Child sexual abuse 0.9 
Urban air pollution 0.7 
Unsafe sex 0.6 
Osteoporosis 0.2 
a. Health loss that is explained by past and current exposure to health risks. 
1.3 Objectives and hypothesis 
With the overall aim of generating an evidence base to support effective self-management 
strategies and the development of preventative health policies, the specific objectives of 
this research were to: 
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 determine the prevalence and long-term trend of dysmenorrhea and PMS in young 
Australian women 
 identify population subgroups with distinct trajectories for dysmenorrhea and PMS 
 investigate the association between dysmenorrhea or PMS and potential modifiable 
lifestyle risk factors, either among the whole population or in population subgroups 
with similar symptom trajectories. 
It is hypothesised that there are subgroups of women with identifiable patterns of change 
for dysmenorrhea and PMS status over time and that there are modifiable lifestyle risk 
factors for dysmenorrhea and PMS. 
1.4 Outline of thesis 
Chapter 1 provides a brief introduction of the thesis including its rational and objectives. 
Following this, Chapter 2 provides an overview of the research methodologies applied in 
this project, with details of the methods used for each of the individual papers incorporated 
in Chapters 3–8 of the thesis. The basic study rationale and design of the ALSWH, in 
which this research is nested, are summarised to provide some background knowledge. 
Chapter 3 then presents the results from separate literature reviews conducted on the 
prevalence and risk factors for dysmenorrhea (Paper 1) and PMS, with the aim of 
identifying gaps in the literature on their magnitude and the risk factors, particularly among 
modifiable lifestyle risks addressed in this thesis. 
Following that, in Chapter 4 the prevalence and the trajectories of dysmenorrhea and 
PMS over time among young Australian women (Paper 2) is determined, filling the gap in 
the literature of study on the long-term pattern of the disorders. The burden of the 
conditions on quality-of-life of the affected women is then explored. In Chapter 5 the 
population-level associations between dysmenorrhea or PMS and a range of 
sociodemographic, lifestyle, reproductive and, when applicable, psychological factors are 
examined, with the aim of identifying specific modifiable lifestyle factors in this particular 
population for further in-depth study. Based on the results from Chapter 5, Chapter 6 
(cigarette smoking, Paper 3), Chapter 7 (illicit drug use, Paper 4) and Chapter 8 (body 
mass index, Paper 5) are reproductions of journal articles which have been published, 
evaluating the relationships of individual risk factors with dysmenorrhea or PMS. Each 
chapter forms a self-contained piece of research that consists of a brief literature review, 
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the research methodology, results and discussion. Due to the same database and, in 
some occasions, commonalities in analyses methods used, there is some unavoidable 
repetition in the method section across the chapters. 
The research findings are summarised in Chapter 9. Subsequent to this is a discussion on 
the long-term trend of dysmenorrhea and PMS, the association between them and the 
modifiable lifestyle risk factors studied, and the implications for health care providers and 
policy setting. Last, a discussion on the strengths and limitations of the current research 
and suggestions for future research are presented. 
The thesis then concludes with a list of referenced literature and appendices on the 
supplementary materials of the published papers in peer-reviewed journals, the BMJ 
global press release and The University of Queensland national media release issued on 
Paper 3 ‘Smoking and trajectories of dysmenorrhoea among young Australian women’.  
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Chapter 2. Methodology 
The overall research design and population studied are summarised here, together with a 
discussion on the power of the study and issues related to missing data. As the 
methodology used for each chapter varied according to the objectives of each study, the 
specific methods are described in each individual chapter.  
2.1 Study design 
This is a cohort study, nested within the prospective longitudinal study ALSWH which has 
been funded by the Australian Government Department of Health. The ALSWH aims to 
examine the relationships between biological, psychological, social and lifestyle factors 
and women’s physical and emotional well-being, and their use of and satisfaction with 
health care. Further details of the study methods have been reported previously [28].  
A staged approach, as displayed in Figure 2-1, was adopted for this research. First, two 
separate comprehensive literature reviews on the prevalence and risk factors of 
dysmenorrhea and PMS were conducted to obtain an overview of the current 
understanding of the conditions and to identify gaps in the literature. Then, using data from 
ALSWH’s young cohort of women born in 1973–78, a series of analyses were performed 
to determine the prevalence and the patterns of change of dysmenorrhea and PMS status 
over time at both the individual and subgroup-level (trajectories) in this group of young 
Australian women. In addition, the impact of the menstrual conditions on quality-of-life over 
time was also assessed by comparing SF-36 responses among women with and without 
the conditions. Following that, the associations between dysmenorrhea or PMS and a 
range of potential risk factors were investigated at the population level. Modifiable lifestyle 
risks that were significantly associated with the dysmenorrhea or PMS in this study 
population, which were also identified as leading causes of disease burden in Australia, 
were then examined in further detailed analyses. 
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Figure 2-1: Flowchart of study design and main variables studied  
Stage 2.2 
Identify population subgroups 
with distinct symptom 
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analysis) 
Stage 1: Literature review 
Prevalence & risk factors of dysmenorrhea 
& pre-menstrual syndrome (PMS) 
Stage 2.1 
Determine prevalence 
& patterns of change 
of dysmenorrhea and 
PMS (lasagne plot) 
Stage 2: Trend analysis 
Determine prevalence, trend, & impact on quality-of-life 
Stage 3.1 
Identify population-level 
risk factors focusing on 
lifestyle risks (GEE) 
Stage 3: Risk factors analysis 
Determine risk factors and strength of associations 
Stage 3.2 
Examine the associations of specific 
modifiable lifestyle risks with 
respective outcomes (multinominal 
logistic regression, GEE) 
Risk factors 
Sociodemographics 
Lifestyle 
Reproductive 
Psychosocial 
Stage 2.3 
Compare SF-36 summary scores 
(t-test) & determine association 
between symptom status & SF-36 
(generalised estimates equation 
(GEE)) 
Specific lifestyle risks 
Smoking 
Illicit drug use 
Obesity 
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2.2 Study population 
As stated previously, this research used data from the ALSWH. Briefly, the Australian 
national health insurance database (Medicare), which includes all citizens and permanent 
residents of Australia, was used as the sampling frame. Three cohorts of women aged 18 
to 23 (young), 45 to 50 (middle aged) and 70 to 75 years (older) were randomly selected 
and invited to participate in the study in 1996. In order to compare the health and issues 
related to well-being and health care use between women living in rural and remote parts 
of Australia and women in urban areas, there was over-sampling of women living in rural 
and remote areas (selected at twice the proportions of women living in urban areas) to 
ensure adequate inclusion of these women since 70% of Australian women live in major 
cities. The ALSWH collects self-reported data from over 40,000 women living in all states 
and territories of Australia using questionnaires mailed to the participants every two to four 
years.  
For the purpose of this project, only data from the 1973–78 cohort, including 14,247 
women aged 18 to 23 years at baseline (1996), were used. Due to uncertainties about the 
accuracy of the Medicare database which was used as the sampling frame, response 
rates for this first survey cannot be exactly specified. Despite this, it is estimated that 41% 
to 42% of the 1973–78 cohort responded to the initial invitation to participate [29]. When 
compared with the national census, the women were found to be broadly representative of 
Australian women of this age group regarding country of birth, marital status and housing 
situation; although, there are slight differences in that more women included in the survey 
were Australian-born, had a diploma or university degree and were not in the labour force 
[29]. The characteristics of the 1973–78 cohort, together the information on attrition and 
response rate, from six waves of the survey over a period of more than 16 years are 
summarised in Table 2-1. Questionnaires were sent to participants every three years after 
Survey 2, with the most recent survey being conducted in 2012. Among the cohort, 
between 62% and 69% responded to each subsequent survey. The major reason for non-
response among the 1973–78 cohort is that the research team has been unable to contact 
the women (between 21% and 28% of the cohort at subsequent surveys), despite using all 
possible methods of maintaining contact [30]. 
Informed consent was obtained from all participants with ethical approval granted from the 
Human Research Ethics Committees of The University of Newcastle and The University of 
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Queensland. Permission to use the data was granted for this study from the Publications, 
Analyses and Sub-studies Committee of the ALSWH in August 2012. 
Table 2-1: Characteristics of ALSWH 1973–78 cohort surveys 
 Survey wave 
Characteristics 1 2 3 4 5 6 
Survey year 1996 2000 2003 2006 2009 2012 
Age (years) 18–23 22–27 25–30 28–33 31–36 34–39 
Sample size 14,247 9,688 9,081 9,145 8,200 8,010 
Number ineligible -- 255 560 861 1,023 1,251 
 Deceased -- 22 33 49 57 76 
 Withdraw -- 230 518 800 951 1,157 
Total non-respondents -- 4,304 4,606 3,041 5,024 5,078 
Retention rate as % eligible -- 69.2% 66.3% 68.3% 62.0% 61.6% 
2.3 Measurements 
All data were collected through self-report at each survey. The outcomes of interest were 
based on questions regarding specific menstrual conditions: ‘In the last 12 months have 
you had: premenstrual tension, severe period pain?’ to infer PMS and dysmenorrhea 
respectively. The outcomes were dichotomised: women were considered to have had a 
recent history of each condition if their response to the question was ‘sometimes’ or ‘often’, 
and to be symptom-free if their response was ‘never’ or ‘rarely’. The rational to 
dichotomise the outcomes this way, instead of categorisation using ‘often’ vs the rest, is 
that the proportion of women with a response to the survey questions as ‘often’ is very 
small, especially across the multiple surveys over time, resulting in great loss of statistical 
power of this longitudinal research. In addition, both dysmenorrhea and PMS status varied 
considerably over time for the majority of women experiencing them. Therefore, although 
dichotomisation of the outcomes using ‘often’ vs the rest would capture the experience of a 
small group of women troubled the most by the conditions, it excludes a larger group of 
women (with a response as ‘sometimes’) who are nevertheless negatively impacted upon 
by the conditions despite a less frequent occurrence. 
Various demographic and lifestyle variables were included: age was examined as either a 
continuous variable or was categorised as 22–23, 24–25, and 26–27 years at Survey 2. As 
it was used as a covariate in the multivariable-adjusted analyses, the one with statistically 
significant association (p<0.05) with outcome of interest were entered into the final models. 
Categories of highest level of education achieved were collapsed into less than high 
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school, high school/trade certificate, and diploma or higher education. Marital status was 
categorised as married/de facto, divorced/separated/widowed, and single. Based on a 
survey question that consistently asked about women’s employment status, employment 
status was dichotomised as unemployed and employed which may include both full- and 
part-time employment. This is also to be in line with the reporting of employment in most of 
the literature. Difficulty coping with income was classified as impossible, difficult all the 
time, difficult sometimes, not too bad, and easy. Area of residence was categorised as 
either urban or rural or remote, based on an index of distance to the nearest urban centre. 
The measure was based on the RRMA (Rural, Remote and Metropolitan Areas) Index 
developed by Department of Primary Industries and Energy and Department of Human 
Services and Health and used nationally for the Australian census at the time the ALSWH 
was designed [31]. Language spoken at home was grouped into English, a European 
language other than English, Asian, and other.  
BMI was calculated according to the recommendation of the World Health Organization 
(WHO) [32] as <18.5, 18.5 to <25, 25 to <30, and ≥30 kg/m2. Current smoking status was 
categorised as never smoker, ex-smoker (those who had quit smoking for at least the last 
six months), currently smokes (those who smoked fewer than 10, 10 to 19, or ≥ 20 
cigarettes per day). Alcohol consumption was categorised based on National Health and 
Medical Research Council guidelines [33] as non-drinker or rarely drinks, low-risk drinker 
(an average of two or fewer alcoholic drinks per day), and risky or high-risk drinker (an 
average of more than two drinks per day). Illicit drug use was grouped into never used, not 
used in the last 12 months (exclusive Marijuana or multiple drug use) and used in the last 
12 months (exclusive Marijuana or multiple drug use). Physical activity was categorised 
according to the Mets.mins method (the product of metabolic units (Mets) and duration of 
activity in minutes) of estimating activity as sedentary, low, moderate and high [34].  
In addition, the following reproductive characteristics were included: oral contraceptive pills 
(OCPs) were dichotomised as used or not used; number of births was collapsed into 0, 1 
and 2 or more (including live birth and still birth); age at menarche was categorised into 
three groups as 8 to 11, 12 to 14 and ≥15 years taking into account the average menarche 
age in Australia [35]; presence of endometriosis was dichotomised as yes or no. 
Psychological factors were also included where necessary: depression was classified 
according to the Centre for Epidemiologic Studies Depression  scale [36] as yes (≥10) and 
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no (<10); history of any form of physical, mental, emotional or sexual abuse or violence, 
either as a child or at any other time was classified as yes, no, and do not want to answer. 
2.4 Power of the study 
This research is based on an existing dataset with known sample size. For the ALSWH 
1973–78 cohort, there are nearly 8,000 women who have reported data on outcomes of 
interest, dysmenorrhea and PMS, in all available surveys (Table 2-3). 
Based on the available sample size, the approximate power that can be achieved to detect 
a significant association between the outcome and the exposure is estimated taking into 
account the different strength of associations. As measurement error in exposures can 
lead to loss of power of tests of significance for regression parameters [37], it was also 
taken into account when calculating the power. Assuming, conservatively, a correlation 
between true and measured exposure of 0.5, a sample size of 8,000 and significance level 
at 0.05, the power that can be achieved is presented in Table 2-2. It is clear that, at the 
specified prevalence level of the outcomes of interest, the study generally has more than 
90% power to detect a relatively modest association with the available sample size. 
Table 2-2: Power calculation at different prevalence level 
Prevalence Odds ratio Power Odds ratio Power 
0.1 1.3 94% 1.2 70% 
0.2 1.3 100% 1.2 90% 
0.3 1.3 100% 1.2 96% 
 
2.5 Statistical analysis 
2.5.1 Analysis	plan	
Statistical analyses were performed using SAS version 9.3 or 9.4 for Windows (SAS 
Institute Inc, Cary, North Carolina, USA). Descriptive statistics were generated for all 
variables. Exposures and potential confounders were compared between the two groups 
(women with dysmenorrhea or PMS versus women without the respective conditions) 
using t-tests or chi-square tests for continuous and categorical variables respectively. 
As demonstrated in Figure 2-1, a staged approach was used in this research with the 
analyses being conducted in two steps.  
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First, the prevalence of dysmenorrhea and PMS were examined cross-sectionally at each 
survey and then compared across surveys to reveal the trend over time at population level. 
Patterns of individual-level change of dysmenorrhea and PMS status over time at different 
surveys were also examined and visually displayed using lasagne plot for longitudinal 
categorical variables [38]. Due to the sample design of over-sampling of women from rural 
and remote areas, prevalence estimates were weighted by the area of residence to avoid 
potential bias. Latent class analysis was performed separately for dysmenorrhea and PMS 
to identify population subgroups with distinct symptom trajectories based on the patterns of 
change of the symptoms over time.  
Second, multinomial regression analysis or longitudinal logistic regression analysis, with 
time varying covariates was performed to investigate the associations between exposure 
variables and dysmenorrhea or PMS. Generalised estimating equation (GEE) was used to 
account for the repeated measures of variables over time. Univariate analyses were 
performed first to identify exposure variables that were significantly associated with 
dysmenorrhea or PMS. Multivariable-adjusted analyses were then conducted to relate 
different risk factors with dysmenorrhea or PMS, after controlling for known or potential 
confounders identified through both literature review and univariate analyses.  
2.5.2 Missing	data	
The number of missing values for dysmenorrhea and PMS from each wave of the survey 
is presented in Table 2-3. Apart from Survey 1 with about 4% missing values for both 
dysmenorrhea and PMS, the numbers of missing values are generally negligible in the 
other surveys.  
Table 2-3: Number (%) of participants with missing values for each outcome by survey 
Survey Participants, N Participants with missing value, n (%) 
  Dysmenorrhea PMS 
Survey 1 14,247 599 (4.2) 609 (4.3) 
Survey 2 9,688 17 (0.2) 17 (0.2) 
Survey 3 9,081 25 (0.3) 25 (0.3) 
Survey 4 9,145 89 (1.0) 102 (1.1) 
Survey 5 8,200 123 (1.5) 116 (1.4) 
Survey 6 8,010 50 (0.6) 59 (0.7) 
It should be noted that a high attrition was seen among the ALSWH 1973–78 cohort at 
Survey 2 (32%), whereas drop-out rates at all other surveys were less than 12% using 
Survey 2 as baseline. The high attrition may potentially introduce bias and impact on the 
14 
generalisability of the study results. A previous study has compared the characteristics of 
the drop-outs and completers and indicated that non-responders at Survey 2 in this cohort 
were more likely to be born in a non-English-speaking country, have less education, be a 
current smoker, and have more difficulty managing their income [39]. Comparison of the 
prevalence among respondents and non-respondents at Survey 1 for both dysmenorrhea 
(39.8% and 41.3% respectively) and PMS (44.6% and 42.8% respectively) did not show 
any evidence of differential drop-out, indicating the random nature of the attrition for the 
outcomes of interest. Furthermore, the impact of the attrition on prevalence and the 
association between self-rated health and sociodemographic and health characteristics 
across the first four survey waves has been investigated, using mixed models under the 
assumption that data are missing at random [40]. The study indicated that there was no 
serious bias in estimates of associations between risk factors and health outcomes in 
longitudinal models.  
Despite this reassuring evidence, the effect of missing data was examined taking a few 
different approaches. First, the proportion of missing data for the main exposures were 
examined at each stage of the analysis and, when necessary, the characteristics of the 
women with missing data were compared with the completers to predict the potential 
impact on the study results. Second, sensitivity analyses using multiple imputation to 
impute missing data were performed, when deemed necessary, to investigate the impact 
of missing data on the estimates assuming a missing-at-random missing data mechanism.  
Furthermore, together with the high attrition from Survey 1 to Survey 2, there is potentially 
substantial over-reporting of both dysmenorrhea and PMS at Survey 1 among the cohort, 
as shown in Table 2-4. This is known as the ‘telescoping’ effect which is common in self-
reported data [41, 42]. We further examined whether the high prevalence in Survey 1 was 
due to younger age; however, the results showed there was no evidence of consistent age 
effect on either dysmenorrhea or PMS. Consequently, Survey 1 was excluded from this 
project, with the exception in Chapter 8 where BMI at Survey 1 was used to calculate BMI 
transition from Survey 1 to 2. Therefore, data from five waves of the survey over 13 
years—Survey 2 in 2000 to Survey 6 in 2012—were included and baseline refers to 
Survey 2.  
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Table 2-4: Prevalence of dysmenorrhea and PMS across six surveys, indicting over-reporting of both menstrual conditions 
Menstrual condition Survey wave 
 1 2 3 4 5 6 
Dysmenorrhea 39.9 25.6 23.5 23.4 20.9 23.1 
Premenstrual syndrome 45.7 34.7 34.5 35.2 33.4 40.5 
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Chapter 3. Literature review 
Two separate literature reviews were performed to summarise current findings on the 
prevalence and risk factors of dysmenorrhea and PMS. A similar approach was adopted 
for both reviews with a comprehensive method used to retrieve and select relevant 
literature to provide a synthesis of the most up-to-date literature with better-designed 
studies including longitudinal studies, case-control studies, or cross-sectional studies with 
large community-based samples. Review articles providing relevant information were 
included as supplementary information as they generally did not apply same inclusion 
criteria. Published studies in English providing relevant information were identified by 
searching PubMed and Embase. The general search terms used were ((‘menstruation 
disturbances’[Majr] OR (‘menstruation’[tiab] AND ‘disturbances’[tiab]) OR ‘menstruation 
disturbances’[tiab] OR (‘menstrual’[tiab] AND ‘disorders’[tiab]) OR ‘menstrual 
disorders’[tiab])). These were then combined with specific terms for each condition as 
detailed in the relevant sections. The search restricted the population to adult women 
(aged 18 years and over) and the year of publishing from 2002 to August 2012. An 
updated search on the literature was performed monthly until July 2015 to capture new 
studies, if any.  
3.1 The prevalence and risk factors of dysmenorrhea (Paper 1) 
Dysmenorrhea is defined as a severe, painful cramping sensation in the lower abdomen 
that is often accompanied by other symptoms, such as sweating, headaches, nausea, 
vomiting, diarrhoea and tremulousness—all occurring just before or during the menses 
[23]. There are two types of dysmenorrhea. Primary dysmenorrhea, which begins with the 
onset of menstruation, generally first occurs in women younger than 20 years after their 
ovulatory cycles become established. The pain can be severe and can also involve the low 
back and thighs. It gradually resolves over 12 to 72 hours. The pathogenesis of primary 
dysmenorrhea shows a close association between elevated prostaglandin F2α (PGF2α) 
levels in the secretory endometrium and the symptoms and severity of dysmenorrhea [23]. 
During menses, increased myometrial contractions, as a result of elevated PGF2α levels, 
decrease uterine blood flow and cause ischemia and sensitisation of pain fibres. In 
addition, PGF2α and PGE2 also affect other organs such as the bowel and result in 
nausea, vomiting, and diarrhoea [23]. The diagnosis is made largely through history and 
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physical examination. Women with primary dysmenorrhea generally have a normal pelvic 
examination. Daily diary has been suggested to be a more accurate way to quantify 
dysmenorrhoea over time, however this has not been widely adopted in research [11, 43]. 
Secondary dysmenorrhea, on the other hand, generally appears after many years of 
painless menses, and it is caused or is associated with a range of pelvic and other 
conditions. It often precedes and is relieved by the onset of menstruation [23]. Pelvic 
disease should be considered in patients who do not respond to proven treatments for 
primary dysmenorrhea, such as non-steroid anti-inflammation drugs and oral 
contraceptives. The pain experienced is secondary to the pathologic process or a specific 
result of a condition. Some of the common conditions related to dysmenorrhea include 
cervical stenosis, ectopic endometrial tissue, adenomyosis, fibroids, pelvic inflammation, 
pelvic congestion, and conditioned behaviour [23, 44]. 
The rest of this section largely presents a paper describing a comprehensive literature 
review on the prevalence and risk factors of dysmenorrhea. The paper was published in 
the peer-reviewed journal Epidemiological Reviews 2014 issue as following: 
Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol 
Rev. 2014;36(1):104–113. 
Website: http://epirev.oxfordjournals.org/content/36/1/104.long 
Epidemiologic reviews by Society for Epidemiologic Research (U.S.); International 
Epidemiological Association; Johns Hopkins Bloomberg School of Public Health. 
Reproduced with permission of OXFORD UNIVERSITY PRESS in the format Republish in 
a thesis/dissertation via Copyright Clearance Centre.  
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Abstract 
Background: Dysmenorrhea is a common menstrual complaint with a major impact on 
women's quality-of-life, work productivity and healthcare use.  
Method: A comprehensive review was performed on longitudinal or case-control or cross-
sectional studies with large community-based samples to accurately determine the 
prevalence and/or incidence and risk factors of dysmenorrhea. 
Results: 15 primary studies, published between 2002 and 2011, met the inclusion criteria. 
The prevalence of dysmenorrhea varies between 16% and 91% in women of reproductive 
age, with severe pain in 2% to 29% of women studied. Women's age, parity and use of 
oral contraceptives were inversely associated with dysmenorrhea, and high stress 
increased the risk of dysmenorrhea. The effect sizes were generally modest to moderate, 
with odds ratios varying between one and four. Family history of dysmenorrhea strongly 
increased its risk (odds ratio 3.8–20.7). Inconclusive evidence was found for modifiable 
factors such as cigarette smoking, diet, obesity, depression and abuse. 
Conclusion: Dysmenorrhea is a significant disorder affecting a large proportion of women 
of reproductive age; however, severe pain limiting daily activities is less common. This 
review confirms that dysmenorrhea improves with increased age, parity and use of oral 
contraceptives, and has a positive association with stress and family history of 
dysmenorrhea.  
Key words: dysmenorrhea, painful menstruation, menstrual pain, prevalence, incidence, 
risk factors, natural history 
Abbreviations: BMI, body mass index; CI, confidence interval; OCP, oral contraceptive pill; 
OR, odds ratio 
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3.1.1 Introduction	
Dysmenorrhea or painful menstruation is defined as a severe, painful cramping sensation 
in the lower abdomen that is often accompanied by other symptoms, such as sweating, 
headaches, nausea, vomiting, diarrhoea and tremulousness—all occurring just before or 
during the menses [23]. There are two types of dysmenorrhea: primary dysmenorrhea 
refers to pain with no obvious pathologic pelvic disease and almost always first occurs in 
women younger than 20 years after their ovulatory cycles become established [23]. 
Secondary dysmenorrhea is caused by underlying pelvic conditions or pathology and is 
more common in women older than 20 years [23, 44]. Dysmenorrhea is considered the 
most common symptom of all menstrual complaints and attributes a greater burden of 
disease than any other gynaecological complaint in developing countries [3]. Among 
women of reproductive age worldwide, dysmenorrhea is more prevalent than the other two 
common types of chronic pelvic pain, namely dyspareunia and non-cyclical chronic pelvic 
pain [45]. Being a debilitating condition for many women, it has a major impact on health-
related quality-of-life, work productivity and health care use [1, 46-49]. As a result, 
dysmenorrhea is responsible for considerable economic losses due to the cost of 
medications, medical care, and decreased productivity [23]. 
The prevalence of dysmenorrhea reported in the literature varies substantially. A greater 
prevalence was generally observed in young women, with estimates ranging from 67% to 
90% for those aged 17 to 24 years [50, 51]. A recent large Australian study of senior high 
school girls found that a higher proportion, 93%, of teenagers reported menstrual pain [52]. 
The studies in adult women are less consistent in reporting prevalence of dysmenorrhea 
and often focus on a specific group, with rates varying from 15% to 75% [50]. Severe pain 
sufficient to limit daily activities is considerably less common, affecting approximately 7% 
to 15% of women [50]; although a study of adolescents and young adults aged 26 years or 
less reported that 41% of the participants had limitations in their daily activities due to 
dysmenorrhea [47]. 
A range of risk factors for dysmenorrhea have been identified in the literature although 
mixed results have been observed for many of these factors. In general, increased severity 
of dysmenorrhea has been suggested to relate to older age [53-55], smoking [53, 56, 57], 
higher BMI [43], earlier age at menarche [43, 55], nulliparity [55, 58], longer and heavier 
menstrual flow [43, 55], and family history of dysmenorrhea [59]. Women using oral 
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contraceptives generally report less severe dysmenorrhea [53, 55, 60]. Depression and 
stress have also been shown to increase the risk of dysmenorrhea [49, 61]. Other common 
factors, such as education [62], marital status [53], employment [58], alcohol consumption 
[43, 57], and physical activity [43, 55], show largely negative or inconclusive results. 
Currently there is a large body of literature on dysmenorrhea, the majority of which 
provides only a snapshot view of the disorder from cross-sectional studies and suffers 
from selection bias as they are based on convenience samples of mainly young college 
students. To our knowledge, there is no current review which has taken these design 
factors into account. Therefore, this review aims to ascertain more accurate estimates of 
the prevalence and incidence of dysmenorrhea in the community, and to determine its risk 
factors by examining evidence from recent longitudinal and population-based studies. The 
additional aim of this review is to identify gaps in the literature to inform further research 
focus. 
3.1.2 Methodology	
This review is part of a wider literature review on the epidemiology related to 
dysmenorrhea and premenstrual syndrome/premenstrual dysphoric disorder, focusing on 
the prevalence and/or incidence and risk factors of dysmenorrhea. Published studies in 
English providing relevant information on dysmenorrhea were identified by searching 
PubMed and Embase, restricting the population to adult women (aged 18 years and over) 
and the year of publishing from 2002 to August 2012. Search terms used related to this 
review are ‘dysmenorrhea’[MeSH] OR ‘dysmenorrhea’[tiab] OR (‘painful’[tiab] AND 
‘menstruation’[tiab]) OR ‘painful menstruation’[tiab]) OR (‘menstrual’[tiab] AND ‘pain’[tiab]) 
OR ‘menstrual pain’[tiab].  
To better infer the temporal relationship and to avoid selection bias, only studies adopting 
a longitudinal study design, case-control studies, or cross-sectional studies with large 
community-based samples were included in this review. Data from included studies were 
extracted into a standard form including the key characteristics of the studies, main 
findings, limitations and conclusions. The definition of dysmenorrhea, gathered through 
self-reporting, interview or daily diary recording, varied from abdominal or low back pain or 
cramps of any severity during menstrual bleeding in the previous month to the previous 12 
months. The majority of studies did not limit the severity of pain or distinguish between the 
types of dysmenorrhea, such as primary or secondary dysmenorrhea. The severity and the 
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type of dysmenorrhea were noted if the study has clearly stated these. The reference lists 
of the studies included in this review were scanned to check for any additional studies not 
captured by the electronic database search.  
Quality assessment was performed for the primary studies using a checklist for appraising 
medical literature for cohort/case-control/cross-sectional studies (attached in Appendix A) 
[63]. The checklist addresses potential biases introduced by study design, sample 
representativeness, comparability of groups (if applicable), quality of measurements, 
completeness of data, and confounding. A study was rated as good quality if no problem 
or only minor problems were identified; and as poor quality if four or more major problems 
were identified, for the above mentioned domains. An overall judgement on the quality was 
made based on the appraisal of each domain, taking into account their expected effect on 
the results. Review articles providing relevant information on dysmenorrhea were included 
as supplementary information as they do not apply the same inclusion criteria. 
In summary, this review used a comprehensive approach to identify and select relevant 
literature to provide a qualitative synthesis of the most up-to-date, better-designed, and 
relevant literature on the rate and risk factors for dysmenorrhea. 
3.1.3 Results	
A total of 2,276 articles were retrieved through the search. After applying the selection 
criteria described above and scanning the reference lists of included studies, 15 primary 
studies were included: three longitudinal studies and 12 population-based cross-sectional 
studies. Three systematic reviews were included as supplementary information, two 
providing information on prevalence and one on risk factors of dysmenorrhea. Data from 
countries not included in the previous systematic review, particularly developing countries, 
were identified and thus enhance our overall knowledge base on dysmenorrhea which has 
been mainly based on literature from developed countries. Most studies were rated as 
moderate-quality only (quality rating included in Appendix A), mainly related to potential 
biases introduced by the design or conduct of the study. The main concerns with most 
studies were 1) study design, as cross-sectional studies were often used to identify risk 
factors; 2) questionable validity of measurement, as retrospective self-reporting of 
symptom was used by most studies; 3) representativeness of the sample, as insufficient 
information on the characteristics of non-responders or drop-outs was provided; 4) no 
justification of power of the study provided, given the sample size; and/or 5) no quality 
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control method reported for the data collection. In addition, six studies omitted key 
exposure variables such as parity or OCP use from the analysis, which may cause 
potential biases due to possible confounding. Due to the substantial heterogeneity among 
the studies, in terms of the study population, definition of dysmenorrhea, symptom 
reporting methods, length of recall or investigation, and various measurements used for 
the risk factors studied, a meta-analysis was not performed. Instead, a narrative review 
and qualitative summation on the associations of the risk factors and dysmenorrhea was 
undertaken.  
Prevalence and/or incidence 
A total of 14 individual studies [3, 4, 11, 64-74] and two systematic reviews [10, 45] 
presented data on the prevalence and/or incidence rates of dysmenorrhea.  
Primary studies. The results from the 15 primary studies, 14 of which reported on the 
prevalence and/or incidence of dysmenorrhea, are summarised in Table 3-1. The reported 
prevalence of dysmenorrhea of any severity varies between 16% and 91% in women of 
reproductive age. The lowest prevalence of 16% was reported in a random sample of 
Japanese women aged 17 to 51 years through daily diary recording for one month [69]. 
Although an incidence of 16% (defined as proportion of participants who developed 
dysmenorrhea during the study period) was reported in the study, no baseline 
dysmenorrhea status was determined for the participating women. Therefore, the reported 
rate was more appropriately interpreted as one-month prevalence rate. The highest 
prevalence of 91% was reported in a random sample of Iranian women aged 16 to 56 
years, with most under 30 years of age without children, through self-reporting [72]. 
Primary dysmenorrhea was specified in three studies, occurring in 60%to 91% of the 
women.  
Most studies relied on subjective level of pain reported by the participants (generally mild, 
moderate or severe), with only three studies using some type of criteria to define severe 
pain. Whilst Weissman et al [11] and Tavallaee et al [72] used similar definitions as pain 
requiring bed rest and missing work or cutting back on activities, the other study defined it 
as having a score of 8 to 10 on a 10-point visual analogue scale [74]. According to these 
criteria, severe pain was reported in 2% to 29% of women. In addition, dysmenorrhea 
limiting activities was reported in four studies varying from 16% to 29% of women.
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Table 3-1: Characteristics of primary studies (published between 2002–2011) and reported rates for dysmenorrhea 
First Author,  
Year 
(Reference no.) 
Study Quality Country N Age Group 
(Years) 
Reporting 
Method 
Length of 
Investigation 
/Recall 
Hormonal 
Contraception 
Type of 
Dysmenorrhea 
Definition of 
Dysmenorrhea 
Rate (Prevalence/Incidence)  
of Dysmenorrhea 
Overalla Mild Moderate Severe 
Longitudinal study 
Ohde, 2008 [69] Moderate Japan 823 18–51 Daily diary 1 month Not specified Not specified Any pain 15.8%    
Wang, 2004 [73] Moderate-
good 
China 388 20–34 Daily diary 12 months or 
until pregnancy 
No Not specified Any pain Incidence 28.0% 
Prevalence 44.4% 
  
Weissman, 2004 
[11] 
Moderate-
good 
USA 404 19–46 Self-reporting Past 12 months Yes Primary Any pain 76.0%  53.0% 21.0% 2.0% 
Cross-sectional study 
Abenhaim, 2006 
[64] 
Moderate USA 904 36-44 Self-reporting Not specified No Not specified Moderate-severe 36.7%    
Burnett, 2005 [65] Moderate Canada 1,546 ≥18 Interview Not specified Yes Primary Any pain 
Limiting activity 
60.4% 
20.6% 
24.0% 
 
36.4% 
 
Harlow, 2002 [75] Moderate USA 976 36–44 Interview Varied (up to 5 
years after 
menarche) 
Yes Not specified Any pain NR    
Laszlo, 2008 [66] Moderate Hungary 2,722 <55 Interview Not specified Not specified Not specified Limiting activity 15.5%    
Laszlo, 2009 [67] Moderate Hungary 821 37.16 
(9.37)b 
Interview Not specified Not specified Not specified Limiting activity 20.1%    
Nohara, 2011 [68] Poor-
moderatec 
Japan 2,166 NR Self-reporting Not specified Not specified Not specified Severe 76.5% Tolerable 47.9% 28.6% 
Patel, 2006 [3] Moderate-
good 
India 2,262 18–45 Interview Last 12 months Yes Not specified Any pain 
Limiting activity 
54.6% 
28.7% 
21.3% 15.0% 18.3% 
Pawlowski, 2004 
[70] 
Moderate Mexico 177 18–45 Interview Not specified No Not specified Any pain 28.0%    
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First Author,  
Year 
(Reference no.) 
Study Quality Country N Age Group 
(Years) 
Reporting 
Method 
Length of 
Investigation 
/Recall 
Hormonal 
Contraception 
Type of 
Dysmenorrhea 
Definition of 
Dysmenorrhea 
Rate (Prevalence/Incidence)  
of Dysmenorrhea 
Overalla Mild Moderate Severe 
Pitts, 2008 [71] Poord Australia 1,983 16–49 Interview Last 12 months Yes Not specified Any pain 71.7%   15.0% 
Santer, 2005 [4] Moderate-
good 
UK 2,833 25–44 Self-reporting Last 6 months Yes Not specified Severe 15.0%   15.0% 
Tavallaee, 2011 
[72] 
Poor-
moderatee 
Iran 276 16–56 Self-reporting Last 12 months Yes Primary Any pain 91.0% 41.0% 28.0% 22.0% 
Unsal, 2010 [74] Moderate Turkey 729 15–49 Interview Not specified Yes Not specified Any pain 63.6%    
N, number of participants. 
a. Reported as prevalence unless otherwise specified. Note although Nohara (2011) define dysmenorrhea as severe pain, the overall prevalence was reported for any pain. 
b. Age as mean (SD) for women with pain limiting activity. 
c. A cross-sectional study, with a high non-respondent rate (73%) but no information on their characteristics, and analyses were not controlled for OCP use.  
d. A cross-sectional study, with a moderate survey response rate of 57%, no information on non-responders, the final models only adjusted for age, and important confounders such as both parity and OCP use were not 
controlled for.  
e. A cross-sectional study, with a small sample size, and the analyses were not adjusted for important risk factors such as parity. 
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In a prospective cohort study using daily diary recording, the incidence of dysmenorrhea 
was reported in 28% of women during a follow-up of 12 months [73]. The study 
ascertained the past history of dysmenorrhea according to whether the women 
experienced dysmenorrhea during the past 12 months at baseline; however, it did not 
provide explicit definition of incidence. Weissman et al, in another prospective longitudinal 
study of 404 women with primary dysmenorrhea, studied the change of the symptom over 
six years follow-up [11]. Although 88% of women with primary dysmenorrhea at baseline 
still reported the condition at follow-up, it was not consistent over time. Among women with 
the condition at baseline, 26% experienced improvement and 27% experienced worsening 
of the condition over six years.  
Systematic reviews. A systematic review conducted by WHO [45] assessed the worldwide 
prevalence of three different types of chronic pelvic pain, including dysmenorrhea. It 
included 106 cross-sectional studies on 124,259 non-pregnant women with or without 
endometriosis, mainly published from 1980 onwards. The prevalence varied from 8.8% in 
hospitalised women aged 19 to 41 years to 94% in girls aged 10 to 20 years. Studies from 
the United Kingdom reported a prevalence range between 45% and 97% for any 
dysmenorrhea in community-based studies, and between 41% and 62% in hospital-based 
studies. In 20 high-quality studies with representative samples, the prevalence of 
dysmenorrhea was reported as being between 17% and 81%. Severe dysmenorrhea, 
however, was reported in 12% to 14% of women in community-based studies in the United 
Kingdom. The review explored the source of variation in prevalence estimates and found 
the validated measurement tool to be a significant factor in explaining the heterogeneity.  
Another systematic review [10], which included 25 studies from developing countries 
between 1970 to mid-2002, reported on the prevalence of a range of menstrual disorders 
for women of reproductive age. The number of studies reporting on the prevalence of 
dysmenorrhea is not clear. Despite a limited evidence base and the imprecise definition of 
menstrual disorders, the review summarised that between 25% and 50% of adult women 
reported menstrual pain. Severe pain or pain that prevents a woman from work or daily 
activities ranged from 5% to 20%. The review authors concluded that the findings are 
comparable to those reported in studies from developed countries and menstrual disorders 
constitute an important area of unmet need for reproductive health services for women in 
developing countries. 
Risk factors 
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Fifteen individual studies [3, 4, 11, 64-75] and a systematic review [76] reported on the 
associations between at least one risk factor and dysmenorrhea. Table 3-2 to Table 3-4 
present qualitative summations on the association between dysmenorrhea and the main 
risk factors reported in the studies. All the associations reported in the tables were based 
on multivariable analyses although the extent of adjustment made varies among the 
studies, with one study adjusting for age only in the analyses [71]. Three studies did not 
control for the important effect of parity when examining the association between age and 
dysmenorrhea. In addition, six studies [66-69, 71, 75] did not collect the information on 
OCP use and thus its effect was not accounted for in their analyses. Only one study [75] is 
duplicated in the current review and the earlier systematic review identified [76]. More 
detailed information including the effect size reported for significant risk factors can be 
found in Appendix B. 
Demographic and lifestyle factors. The association of age and dysmenorrhea was reported 
in nine studies, with two longitudinal [11, 69] and five cross-sectional [3, 65, 68, 71, 72] 
studies consistently demonstrating a significant inverse relationship between age and the 
risk of dysmenorrhea (Table 3-2). Among the seven studies reporting an inverse 
association, four conducted the analyses adjusted for parity/live birth, whereas the other 
three failed to do so [69, 71, 72]. In the study by Weissman et al [11], the univariate 
analysis revealed that women younger than 25 years were at more than twice the risk 
(odds ratio (OR) 2.24, 95% confidence interval (CI): 1.24, 4.05) of reporting moderate to 
severe pain compared with those aged 25 to 34 years. In their multivariable analysis 
model, including live birth, a one-year increase in age was associated with an OR of 0.92 
(95% CI: 0.86, 0.98) for developing moderate to severe dysmenorrhea. The other two 
cross-sectional studies [4, 70] did not detect a significant association in the adjusted 
analysis, although the large study from Scotland showed a reduced risk of severe pain 
with every 5-year increment in age (OR 0.93, 95% CI: 0.82, 1.05). The reported odds 
ratios were between one and three for younger women to have more severe 
dysmenorrhea. The pooled effect size (OR 1.89) from three studies in the systematic 
review for women younger than 30 years of age is in line with these estimates [76]. 
Family history of dysmenorrhea demonstrated a strong effect on reporting of menstrual 
pain by the women in two cross-sectional studies. An odds ratio of 3.8 (95% CI: 2.2, 6.9) 
was reported in a sample of 276 Iranian women with primary dysmenorrhea [72] and an 
even stronger effect with an OR of 20.7 (95% CI: 11.5, 37.4) was observed in a study of 
729 Turkish women [74].  
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Fruit and vegetable intake, on the other hand, was shown to reduce the risk of 
dysmenorrhea in a cross-sectional study with the ORs of 0.4 (95% CI: 0.2, 0.6) and 0.2 (95% 
CI: 0.08, 0.50) for high and very high fruit and vegetable intake respectively for risk of 
dysmenorrhea [72]. 
No significant associations were detected between years of education [3, 65, 69, 71], 
marital status [3, 71], area of residence [69] and dysmenorrhea. Similarly, alcohol 
consumption was not associated with dysmenorrhea [68, 74]. 
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Table 3-2: Adjusted associationa between dysmenorrhea and reported main demographic and lifestyle factors in the included studiesb 
First author, year 
(Reference no.) 
Age 
(younger) 
Education Employed Married BMI (higher) Residence Income/SES 
(lower) 
Smoking Alcohol use Fruit & vegetable 
intake (higher) 
Family history of 
dysmenorrhea 
Longitudinal study 
Ohde, 2008 [69] ↑ ↔ ↑  ↔ ↔ ↔     
Weissman, 2004 [11] ↑       ↔    
Cross-sectional study 
Burnett, 2005 [65] ↑ ↔     ↔ ↑    
Nohara, 2011 [68] ↑    ↑   ↔ ↔   
Patel, 2006 [3] ↑ ↔ ↔ ↔   ↔     
Pawlowski, 2004 [70] ↔    ↔       
Pitts, 2008 [71] ↑ ↔ ↔ ↔        
Santer, 2005 [4] ↔      ↑     
Tavallaee, 2011 [72] ↑    ↔  ↑   ↓ ↑ 
Unsal, 2010 [74]   ↔    ↔ ↔ ↔  ↑ 
Systematic review 
Lathe, 2006 [76] ↑ ↔ ↔ ↔ ↔  ↑ ↑ ↔   
a. Associations based on multivariable analyses although the extent of adjustment made varies among the studies: Pitts (2008) only adjusted for age, parity was not adjusted for in three studies: Ohde (2008), Pitts (2008), 
Tavallaee (2011), OCP was not adjusted for in three studies: Ohde (2008), Nohara (2011), Pitts (2008). 
b. ↑ = significant risk factors for dysmenorrhea; ↓ = significant protective factors against dysmenorrhea; ↔ = no significant association detected. 
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Table 3-3: Adjusted associationa between dysmenorrhea and reported main reproductive factors in the included studiesb 
First Author, Year 
(Reference No.) 
Age at Menarche 
(later) 
Parity/Live Birth 
(higher) 
Age First Giving 
Birth (later) 
OCP/Hormonal 
Contraception 
IUCD Tubal Ligation Caesarean Section Heavy Menses Irregular Menses 
Longitudinal study 
Weissman, 2004 [11]  ↓        
Cross-sectional study 
Abenhaim, 2006 [64]  ↓     ↔   
Burnett, 2005 [65] ↔ ↔  ↓ ↔     
Harlow, 2002 [75]      ↔    
Nohara, 2011 [68]  ↓        
Patel, 2006 [3] ↓ ↓  ↔ ↔ ↔  ↑  
Pawlowski, 2004 [70] ↔ ↔ ↑       
Pitts, 2008 [71]  ↓        
Santer, 2005 [4]  ↓  ↓      
Unsal, 2010 [74] ↔ ↓       ↑ 
Systematic review 
Lathe, 2006 [76] ↓ ↓ ↑ ↓ ↔ ↑  ↑ ↑ 
a. Associations based on multivariable analyses; although, the extent of adjustment made varies among the studies: Pitts (2008) only adjusted for age, whereas parity was not adjusted for, OCP was not adjusted for in two 
studies: Nohara (2011), Pitts (2008). 
b. ↑ = significant risk factors for dysmenorrhea; ↓ = significant protective factors against dysmenorrhea; ↔ = no significant association detected.
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The association between cigarette smoking and dysmenorrhea was reported in four 
studies and mixed results were seen. One longitudinal [11] and two cross-sectional studies 
[68, 74] did not detect any significant association, whereas another cross-sectional study 
reported an increased risk of dysmenorrhea for smokers [65]. Similarly, conflicting results 
were observed among the studies for a range of other sociodemographic and lifestyle 
factors, such as employment, socioeconomic status and BMI. However, there is only a 
limited number of studies, and no longitudinal studies, have reported on these associations.  
Reproductive factors. The association between parity and/or number of live births and 
dysmenorrhea was reported in nine studies (Table 3-3). Despite different categorisation 
used for parity, results were consistent from one longitudinal study [11] and six cross-
sectional studies [3, 4, 64, 68, 71, 74] demonstrating a significant negative association 
between increased parity or number of live births and the risk of dysmenorrhea. Weissman 
et al [11], in their multivariable analysis model including age, demonstrated a significant 
cross-sectional association between parity and moderate to severe dysmenorrhea (OR 
0.70, 95% CI: 0.54, 0.91 for an increment of one birth) at baseline. Furthermore, the 
authors examined the effect of live birth after baseline on the severity of dysmenorrhea at 
follow-up and showed that live birth was associated with an OR of 0.20 (95% CI: 0.08, 
0.53) for reporting moderate to severe dysmenorrhea. The remaining two cross-sectional 
studies failed to find a significant relationship between dysmenorrhea and parity [65, 70]. 
The observed ORs ranged from 0.3 to 0.74 for parity of one or more compared with 
nulliparity, whereas an OR of 7.83 (95% CI: 4.21, 14.57) for dysmenorrhea was observed 
for never giving birth (compared with three or more number of births) in a cross–sectional 
study with 729 Turkish women [74]. 
The association of OCP or hormonal contraception use with dysmenorrhea was only 
reported in three cross-sectional studies, two of which observed a protective effect of OCP 
or hormonal contraception use [4, 65]. The third study failed to show a significant 
association between moderate to severe pain and different types of contraceptives, 
including OCP use, in a large sample of Indian women [3]. In the two studies reporting a 
protective association, a relative effect size of two to four was detected. The use of an 
intrauterine contraceptive device (type not specified) was reported in two cross-sectional 
studies that found no relation with dysmenorrhea [3, 65]. Similarly, no significant 
association between tubal ligation and dysmenorrhea was found in two cross-sectional 
studies [3, 75]. 
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The presence of heavy menses or irregular menses was associated with increased risk for 
dysmenorrhea in two cross-sectional studies, with an OR of 1.9 (95% CI: 1.4, 2.6) [3] and 
1.9 (95% CI: 1.22, 32.95) [74] respectively. In addition, giving birth to first child at an earlier 
age (at mean age of 19.4 versus 21.1 years) was related to a reduced risk of 
dysmenorrhea in a cross-sectional study of 177 women, not using hormonal 
contraceptives, from a traditional Mayan society [70].  
Inconsistent results for the association between age at menarche and menstrual pain were 
found in four cross-sectional studies. Three studies did not observe any significant effect 
for age at menarche [65, 70, 74], whereas the other study [3] reported a significantly 
reduced risk of dysmenorrhea in women with age at menarche later than 12 years (OR 
0.75, 95% CI: 0.6, 0.9). No significant association was observed between the number of 
caesarean sections and dysmenorrhea after adjusting for a range of sociodemographic 
and lifestyle factors in a sub-study of the Harvard Study of Moods and Cycles [64].  
Psychological factors. Stress has been reported in five studies (Table 3-4). The results are 
consistent among one prospective longitudinal study of nulliparous Chinese women [73] 
and three cross-sectional studies [66-68]. All four studies reported a positive association 
between stress and the risk of dysmenorrhea among female workers, whereas the other 
cross-sectional study among a random sample of Iranian women did not reveal a 
significant relationship after adjusting for age, socioeconomic status, BMI, fruit and 
vegetable intake, smoking, alcohol consumption and family history of dysmenorrhea. The 
study did, however, show an increased OR of having severe pain in women who were 
extremely stressed in the unadjusted analysis [72]. Among the studies reporting a 
significant association, various methods were used to measure different types of stress. In 
the longitudinal study [73], self-perceived stress, either work-related or generated from 
other source, in the proceeding menstrual cycle was recorded in a daily diary. Work-
related stress, measured by a range of variables including control at workplace, co-worker 
support, job security, effort-reward imbalance and over-commitment, was obtained through 
interview [66, 67], whereas self-reported stress was reported among a group of Japanese 
workers [68]. In general, a modest effect (ORs of 1 to 2.5) was observed for the reported 
high level of stress and increased risk of dysmenorrhea. However, Wang et al [73] 
detected a combined effect of more than a 10-fold (OR 10.4, 95% CI: 4.9, 22.3) risk of 
reporting dysmenorrhea in the subsequent cycle among women with both high stress in 
the preceding cycle and a history of dysmenorrhea compared with women with low stress 
and no history of dysmenorrhea. 
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One cross-sectional study observed a strong effect of being depressed most of the time 
and the risk of menstrual pain with an OR of 13.3 (95% CI: 2.0, 86.0) in a random sample 
of Iranian women with primary dysmenorrhea [72]. A higher somatoform symptom score 
(>7), indicating poor mental health, was also significantly associated with moderate to 
severe menstrual pain in a random sample of 2,262 Indian women, with an OR of 3.67 (95% 
CI: 2.7, 4.9) [3]. The same study also observed a significant association between violence 
from others and the risk of moderate to severe dysmenorrhea (OR 2.23, 95% CI: 1.5, 3.4) 
[3]. These associations, however, are only shown in a very limited number of cross-
sectional studies, and no longitudinal data have yet lent their support for these. 
Table 3-4: Adjusted associationa between dysmenorrhea and reported main psychological and other factors in the included studiesb 
First author, year 
(Reference no.) 
Psychological factors  Others 
 Depressed Stress 
(higher) 
Somatoform 
Symptom Scorec 
(higher) 
Violence from 
others 
 Long-standing 
illness 
Lower abdominal pain 
Longitudinal study 
Wang, 2004 [73]  ↑      
Cross-sectional study 
Laszlo, 2008 [66]  ↑      
Laszlo, 2009 [67]  ↑      
Nohara, 2011 [68]  ↑      
Patel, 2006 [3]   ↑ ↑   ↑ 
Santer, 2005 [4]      ↑  
Tavallaee, 2011 [72] ↑ ↔      
Systematic review 
Lathe, 2006 [76] ↔  ↑     
a Associations based on multivariable analyses; although, the extent of adjustment made varies among the studies: parity was not adjusted for in 
Tavallaee (2011), OCP was not adjusted for in three studies: Laszlo (2008 & 2009), Nohara (2011). 
b ↑ = significant risk factors for dysmenorrhea; ↓ = significant protective factors against dysmenorrhea; ↔ = no significant association detected. 
c A score used for indicating mental health by measuring somatic symptoms (higher score indicates increasing severity). 
Other factors. Several other general health problems have been studied in a limited 
number of cross-sectional studies (Table 3-4), showing significant association between 
long-standing illness and an increased risk of severe menstrual pain (OR 1.73, 95% CI: 
1.33, 2.23) [4], and between lower abdominal pain (not related to menstrual periods) and 
an increased risk of moderate to severe pain (OR 1.8, 95% CI: 1.3, 2.3) [3]. 
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In addition, a systematic review evaluated factors predisposing women to chronic and 
recurrent pelvic pain of three different types: dysmenorrhea, dyspareunia and non-cyclical 
pelvic pain [76]. A total of 63, mainly case-control, studies were included for dysmenorrhea. 
Twenty-nine of these studies satisfied three or more quality criteria used. Detailed 
characteristics for the patients in the included studies were not reported. The review 
conducted a series of meta-analyses across the studies. Among the range of risk factors 
evaluated in at least two of the included studies, presence of dysmenorrhea was found to 
be associated with age <30 years (OR 1.89, 99% CI: 1.36, 2.63), BMI <20 kg/m2 (OR 1.42, 
99% CI: 1.26, 1.59), smoking (OR 1.37, 99% CI: 1.19, 1.57), high socioeconomic status 
(OR 1.25, 99% CI: 1.04, 1.50), age at menarche <12 years (OR 1.54, 99% CI: 1.17, 2.04), 
longer cycles (OR 1.46, 99% CI: 1.01, 2.11), irregular cycles (OR 2.02, 99% CI: 1.19, 3.44), 
heavy menstrual flow (OR 4.73, 99% CI: 2.95, 7.58), presence of premenstrual symptoms 
(OR 2.42, 99% CI: 1.84, 3.18), clinically suspected pelvic inflammatory disease (OR 1.58, 
99% CI: 1.09, 2.30), sterilisation (OR 1.35, 99% CI: 1.04, 1.75), history of sexual abuse 
(OR 1.60, 99% CI: 1.29, 2.00), and somatisation (OR 3.04, 99% CI: 1.42, 6.53). On the 
other hand, use of oral contraceptives (OR 0.65, 99% CI: 0.60, 0.71) and higher parity (OR 
0.64, 99% CI: 0.57, 0.72) were associated with reduced risk of dysmenorrhea. 
Heterogeneity was present in all analyses with multiple studies.  
3.1.4 Discussion	
This review has highlighted that recent data on the rates and risk factors for dysmenorrhea 
in women of reproductive age from longitudinal studies or community-based samples are 
sparse. Among the limited studies identified, the prevalence of dysmenorrhea varies 
substantially from 16% to 91%. The lowest prevalence of 16% reported in a random 
sample of Japanese women aged 17to 51 years was attributed to the short study period 
(one month) and potential under-reporting of mild menstrual pain [69]. In addition, the 
prospective daily diary recording may also be a reason for the reported lower rate. 
Disregarding this lowest rate and that of 28% reported in women with a mean age of giving 
birth at 19.9 years from a traditional society in Mexico, the prevalence of 37% to 91% 
reported in other studies is very similar to the range of 45% to 97% reported from 
community-based studies in the WHO review [45] and the range of 43% to 90% reported 
in earlier literature [51]. The variation in prevalence rates may be attributed to the lack of 
standard methods for assessing the severity of dysmenorrhea and the use of different 
definitions, ranging from the occurrence of occasional menstrual cramps to pain severe 
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enough to interfere with daily activities and/or to require prescribed medication. In addition, 
the difference in the study populations, medication use including OCPs, various reporting 
methods, and length of recall of symptoms may also partially explain the variation in the 
prevalence reported.  
Most studies show that dysmenorrhea is a common problem affecting the majority of 
women in the community. Severe pain or pain limiting women’s daily activities, however, 
occurred only in 2% to 28% of adult women. The lowest rate of 2% reported in a 
longitudinal study was possibly due to potential under-reporting as 74% of the included 
women were employed and thus were less likely to stay in bed and miss work, which is 
used to define severe pain in the study [11]. The prevalence of severe pain reported in this 
review appears to be higher than the 12% to 14% reported in community-based studies in 
the WHO review [45] but comparable with 5% to 20% reported in another review of the 
condition in developing countries [10]. Weissman et al [11] found that dysmenorrhea 
persisted over the six-year follow-up among the majority of women reporting it at baseline, 
and improvement or worsening of the condition were equally likely. In their multivariable 
analysis, presence of dysmenorrhea at baseline (excluding women with severe 
dysmenorrhea) was a strong predictor of reporting moderate or severe dysmenorrhea at 
follow-up (OR 7.48, 95% CI: 3.09, 18.15). More studies are needed to explore the natural 
history of the condition.  
Despite some disagreement, the majority of the previous literature generally demonstrates 
an inverse association between both age and parity with dysmenorrhea [50, 53-55, 77]. 
This association was confirmed by the vast majority of studies included in this review, 
consistent across different types of study; although, three studies failed to adjust for parity 
in their analysis on the association between age and dysmenorrhea [69, 71, 72]. The 
systematic review [76] also supported the association. Interestingly, Burnett and 
colleagues found that the effect of age remained in the adjusted model including nulliparity, 
whereas the association between nulliparity and primary dysmenorrhea was no longer 
significant when controlled for age and smoking (β = 0.93, p = 0.582) [65]. It is unclear 
though what the proportion of nulliparous women was in the study. Furthermore, the study 
did find that the women most debilitated by pain were significantly more likely to be 
nulliparous. Nevertheless, the longitudinal study by Weissman et al [11] provides stronger 
support for the inverse association between both age (OR 0.92, 95% CI: 0.86, 0.98) and 
live birth (OR 0.20, 95% CI: 0.08, 0.53) and the severity of dysmenorrhea after controlling 
for each other; however, parity clearly had a much stronger effect in their analysis. In 
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addition, the study also found that gravidity was less influential than live birth, consistent 
with other studies showing no effect from pregnancies ending in miscarriage or abortion 
[55, 77].  
Different mechanisms have been proposed for the relation between live birth and 
dysmenorrhea. One is related to the pathogenesis of primary dysmenorrhea of the close 
association with elevated prostaglandin levels in the secretory endometrium which triggers 
pain [23, 78]. After a term delivery, the endometrium may release a lower level of 
prostaglandins, resulting in decreased pain [77]. Another hypothesis is that neuronal 
degeneration in the uterus following term pregnancy, due to disappearance of uterine 
adrenergic nerves and a decrease in uterine noradrenaline in the third trimester of 
pregnancy, may explain the disappearance or reduction of menstrual pain after childbirth 
[55]. 
A strong effect of family history of dysmenorrhea and risk of dysmenorrhea was shown in 
two studies, which is in line with some previous studies reporting similar association, 
suggesting genetic susceptibility to dysmenorrhea among women with variant genotypes 
in a number of metabolic gene polymorphisms [59, 79]. However, other possible 
explanations are that the association could be related to conditioned behaviour that is 
learned from mother or sisters or possibility of societal reward or control if pain exists [23]. 
Alternatively, it could be simply due to similar living patterns and lifestyles in the families 
[72]. 
Among the range of lifestyle and other demographic factors studied, such as smoking, BMI, 
and socioeconomic status, conflicting results were shown. Previous studies on the 
association between smoking and dysmenorrhea are mixed; although most cross-sectional 
studies show an increased risk among smokers [53, 54, 56], a negative effect was also 
seen [80]. Inconsistent results have also been observed for smoking and the incidence or 
the severity of dysmenorrhea in longitudinal studies [43, 55]. Sundell et al [55] found that 
the prevalence and severity of dysmenorrhoea was increased in smokers and the severity 
increased with the number of cigarettes smoked per day. On the other hand, Harlow and 
Park [43] found that smoking was not associated with the probability of having pain or 
severe cramps; but among those with pain, smokers were more likely to have pain lasting 
longer than two days. Similarly, in one longitudinal study [43], being overweight was found 
to be an important risk factor for the probability of experiencing pain and for increasing 
duration of pain, while the severity of dysmenorrhoea was not associated with either height 
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or weight in another [55]. The systematic review also failed to detect a significant 
association between obesity and dysmenorrhea in the pooled analysis of five studies [76]. 
No association was shown between women’s education, marital status, alcohol use and 
the risk of dysmenorrhea in the current review, which is supported by the recent 
systematic review identified [76] and previous studies [43, 53, 57]. However, caution 
should apply when interpreting the systematic review results, as heterogeneity was 
present in all analyses with multiple studies and the review is based largely on case-
control studies which are subject to recall bias. 
A protective effect of OCPs or other forms of hormonal contraceptive for dysmenorrhea is 
evident in the majority of previous studies [50, 53-55, 60], consistent across different study 
types. This is largely confirmed by the current review; although, one of the studies on a 
large sample of Indian women did not show any significant association between different 
methods of contraception, including OCPs, and moderate to severe dysmenorrhea [3]. The 
reason for this discrepancy may be due to the small number of women using OCPs (n = 
43) in the study. There is evidence suggesting an early age at menarche and increased 
risk of dysmenorrhea [43, 55, 58], which is supported by the systematic review [76]. 
However, most of the studies reporting it in this review failed to show an association [65, 
70, 74] with the exception of the Indian study [3]. The reason for the discrepancy is not 
readily apparent and the association may be confounded or mediated by other factors. 
Furthermore, although there is suggestion of some associations of other reproductive 
factors such as age at first birth, caesarean section, heavy and irregular menses [43, 53, 
77], this review is unable to reach any firm conclusion due to the limited number of studies 
reporting these effects.  
Among the psychological factors studied, a positive association between perceived stress, 
related to work or general life events, and the risk of dysmenorrhea was shown in most 
included studies (one longitudinal and three cross-sectional). Similar results have been 
reported by previous studies [61, 81]. The biological mechanism for association between 
work stress and dysmenorrhea is not well understood, potentially it is through a cascade of 
neuroendocrine responses [73]. Stress inhibits the release of follicle stimulating hormone 
and luteinising hormone, leading to impaired follicular development. This can alter 
progesterone synthesis and release, which may influence the activity of prostaglandin. 
Besides progesterone, stress related hormones, including adrenaline and cortisol, also 
appear to influence prostaglandin synthesis and/or binding in the myometrium [73]. 
Furthermore, mental health may act as a mediator in the relationship between stress and 
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dysmenorrhea, with high job stress increasing the risk of mental health morbidity, which in 
turn is positively related to painful menses [67].  
Of note is that these studies were generally conducted on groups of employed women, 
whereas another cross-sectional study of a random sample of Iranian women did not 
observe a significant association between stress level and the severity of pain in the 
adjusted analysis [72]. One possible explanation for the discrepancy is that this random 
sample of Iranian women—most of whom are younger than 30 years with no children, 
have a college or higher education, and are from a higher socioeconomic class—may be 
quite different from those employed women included in most other studies. The other 
explanation may be that this study has a relatively small sample size (n = 276), coupled 
with ordinal logistic regression analyses used to examine the association between multiple 
levels of stress and severity of pain; thus, the study may be under-powered to detect a 
difference. Consistent with other studies [49, 82], positive associations were suggested for 
depression and somatisation with dysmenorrhea in this review; however, no meaningful 
conclusion can be made due to the limited number of studies reporting associations. 
There are number of limitations in this review. As it is not a systematic review, there is 
potential to miss some relevant studies. By adopting a comprehensive approach through 
literature search and reference lists scan, we hope to limit the impact of this. A narrative 
approach was used for this review, instead of a meta-analysis, because of profound 
heterogeneity in study populations, definitions of dysmenorrhea, and measurements of risk 
factors among the included studies. Only a limited number of studies were included in this 
review due to restrictions on study design and year of publishing, which may in turn limit 
the ability to detect a true association between the risk factors and dysmenorrhea. 
However, given that the 2006 systematic review by Latthe [76] covered the studies 
published up to 2002, it is unlikely that any important study addressing our research 
purpose has been missed. As the main objective of the study is to get a true picture of 
dysmenorrhea in the community, only a representative community sample may give 
accurate estimates of the problem.  
Through conducting this review, a few issues are highlighted and deserve further research 
effort: better quality population-based longitudinal studies on the natural history of 
dysmenorrhea and on the effect of its risk factors across the reproductive life course; 
epidemiological studies of age-specific incidence and prevalence of dysmenorrhea; more 
standardised measurement of common risk factors useful for potential meta-analysis to 
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estimate the true effect size; more comprehensive reporting of study results (can be 
supplementary material due to space limit).  
In conclusion, this review shows that dysmenorrhea is a significant problem for a large 
proportion of women throughout the reproductive age. Severe dysmenorrhea limiting daily 
activities is much less common. Improvement of the condition over time has been 
observed; however, many women also experience an unchanged or worse condition. From 
longitudinal or population data, this review has confirmed the following: 
 Dysmenorrhea is inversely related to age, parity or number of live births, and oral 
contraception use 
 Dysmenorrhea is positively associated with stress related to both work and general 
life, and family history of dysmenorrhea. 
However, uncertainty still remains for a number of lifestyle factors, such as smoking, 
obesity, diet, psychological factors, and some environmental factors. Furthermore, there is 
a lack of longitudinal data to study the natural history of dysmenorrhea and the effects of a 
range of modifiable risk factors over time. More research on these from population-based 
prospective longitudinal studies to generate robust evidence will help support targeted 
preventive interventions. 
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3.1.5 Literature	update	after	publication	of	Paper	1	
Since the publication of the review, two population-based studies have been identified that 
examined the risk factors for dysmenorrhea. A longitudinal study from Sweden 
investigated the influence of different methods of contraception on the prevalence and 
severity of dysmenorrhea [83]. The study sampled every third or fourth female resident in 
the city of Gothenburg who were aged 19 years in 1981 (n = 656), 1991 (n = 780) and 
2001 (n = 666). The participants were followed up at 5-year intervals until they were aged 
44, 34, and 24 years respectively. The severity of dysmenorrhea was assessed at each 
follow-up using a verbal multidimensional scoring system (VMS) and a visual analog scale 
(VAS). In the analysis with the combined population by age, the study found that the 
severity of dysmenorrhea decreased between 19 to 44 years of age. Compared with other 
contraceptive methods or no contraception, levonorgestrel-releasing intrauterine system 
(Lng-IUS) and combined oral contraceptives were associated with significantly reduced 
dysmenorrhea severity, with a mean difference of -0.4 units in VMS and -13 mm in VAS 
(both p <0.01) for Lng-IUS and -0.4 units in VMS and -11 mm in VAS (both p <0.01) for 
combined oral contraceptives. Childbirth also reduced dysmenorrhea severity by -0.3 units 
(p <0.05) in VMS and -16 mm in VAS (p <0.001). The copper intrauterine device, on the 
other hand, did not influence the severity of dysmenorrhea.  
Another cross-sectional study investigated the factors related to dysmenorrhea among 
3,017 Vietnamese women from three different regions: 1,026 living in northern Vietnam, 
998 living in southern Vietnam and 993 migrant Vietnamese women living in South Korea 
[84]. The women included in the study were aged between 17 to 42 years. Dysmenorrhea 
was reported in 59% of the participants. The adjusted logistic regression analysis showed 
that a younger age (OR 0.97, 95% CI: 0.95, 0.99), earlier menarche (OR not reported), 
and heavy menstrual volume (OR 1.84, 95% CI: 1.35, 2.50) were related to increased 
odds of dysmenorrhea, whereas pregnancy (OR 0.55, 95% CI: 0.45,0.72) and women 
residing in either northern (OR 0.41, 95% CI: 0.34, 0.50) or southern (OR 0.59, 95% CI: 
0.46, 0.76) Vietnam reduced the risk of dysmenorrhea. No association was found between 
dysmenorrhea and BMI, income, or duration of residency in Korea. 
The findings from these additional studies are in line with those in the main body of the 
literature review. OCPs or hormonal contraception was shown to reduce the severity of 
dysmenorrhea; however, intrauterine contraceptive device use did not show any effect on 
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the presence of dysmenorrhea. Similarly, younger age, earlier menarche, and heavy 
menstrual volume were related to increased odds of dysmenorrhea, whereas no 
association was found between BMI and dysmenorrhea.  
3.2 Prevalence and risk factors of PMS 
3.2.1 Introduction	
PMS is defined as a broad group of recurrent psychological, behavioural and physical 
symptoms occurring during the last week of the luteal phase (day 15 to 28) of the 
menstrual cycle which resolve in the follicular phase (day one to 14), generally no later 
than the end of menstruation [8, 85]. Typically, symptoms peak around the time of the 
onset of menses, with most symptoms presenting three to four days prior to menstruation 
and continue through the first two to three days of menstruation. Different terms have been 
used to describe the condition, with premenstrual tension (PMT) first described by Frank in 
the 1930s [86]. Due to its apparent emphasis on the mental component of the syndrome, 
PMT was replaced by PMS in the 1950s which remains widely used today [87]. In addition, 
the term ‘premenstrual tension syndrome’ is also used by the WHO International 
Classification of Disease [12]. PMDD, on the other hand, represents a more severe form of 
PMS, predominantly the psychological end of the PMS spectrum with marked behavioural 
and emotional symptoms and substantial impairment in functioning [5, 8]. In total, over 150 
symptoms have been attributed to the syndrome although fewer than 20 are most 
commonly reported [88, 89]. Among these, depressed mood, anxiety, affective lability, 
anger or irritability, and feeling out of control are core psychological symptoms; whereas 
bloating, breast tenderness and headache are typical physical symptoms of PMS [88].  
Symptoms of PMS are non-specific, thus the essential component of PMS diagnosis 
includes the timing and severity of the symptoms, the degree of disruption in functioning, 
and the differentiation of the condition from other physical or mental disorders [5, 8]. There 
are no objective tests, either physiological or endocrine, for the diagnosis of PMS. 
Currently, different criteria are used for the diagnosis of PMS: three of which are more 
commonly adopted, especially in research settings. The most relaxed criteria is the WHO 
criteria in the Tenth Revision of the International Classification of Disease (ICD-10) which 
requires the presence of one recurrent distressing symptom from a range of physical and 
emotional symptoms [90]. It makes no reference to symptom severity and functional 
impairment for the women and, as a result, a large proportion of reproductive-age women 
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who have mild symptoms may be classified as having PMS. It is, therefore, considered as 
being too liberal to be of practical use, especially in clinical settings [5, 8].  
Contrary to this, the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) from the American Psychiatric Association [91] includes a very stringent set of 
criteria for PMDD in the appendix, indicating further research is required before it can be 
qualified as full criteria. As presented in Table 3-5, DSM-IV requires that women with 
PMDD must have at least one severe affective symptom—including markedly depressed 
mood or hopelessness, anxiety or tension, affective lability, and persistent anger—which 
occurs regularly during the last week of the luteal phase in most menstrual cycles. The 
symptoms must be severe enough to impair functioning. Due to its restrictive approach, it 
may under-recognise women who are debilitated by the condition [8]. 
Table 3-5: DSM-IV diagnostic criteria for premenstrual disphoric disorder [91] 
A In most menstrual cycles during the past year, at least five of the following symptoms should present, with at least one of the 
symptoms being either 1, 2, 3, or 4 
 1 Marked depressed mood, feelings of hopelessness or self-deprecating thoughts 
 2 Marked anxiety, tension, feeling of being ‘keyed up’ or ‘on edge’ 
 3 Marked affective lability (e.g. feeling suddenly sad or tearful or increased sensitivity to rejection) 
 4 Persistent or marked anger or irritability or increased interpersonal conflicts 
 5 Subjective sense of difficulty in concentrating 
 6 Decreased interest in usual activities (e.g. work, school, friends, hobbies) 
 7 Lethargy, easy fatigability or marked lack of energy 
 8 Marked change in appetite, overeating or special food cravings 
 9 Hypersomnia or insomnia 
 10 A sense of being overwhelmed or out-of-control 
 11 Other physical symptoms, such as breast tenderness or swelling, headaches, joint or muscle pain, a sensation of bloating, weight gain 
B Symptoms must be present for most of the time during the last week of luteal phase and absent during the week after menses 
C Symptoms interfere with work, school or social activities or relationships 
D Symptoms are not merely an exacerbation of the symptoms of another disorder 
E Confirmation of the previous criteria by prospective daily ratings for at least two consecutive menstrual cycles 
Given the limitations of these two sets of criteria for PMS, there is a lack of more practical 
diagnostic criteria to capture the moderate to severe form of PMS. Recognising this 
shortage, the American College of Obstetricians and Gynecologists (ACOG) developed a 
definition which requires that at least one emotional and one physical symptom must be 
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present during the five days before menses in at least two to three consecutive menstrual 
cycles (Table 3-6) [92]. It requires that the symptoms be verified using daily prospective 
charting and that some identifiable functional impairment be present.  
Table 3-6: ACOG diagnostic criteria for premenstrual syndrome [92] 
1 Patients have to report at least one of the following affective AND somatic symptoms during five days before menses in each of the three 
prior menstrual cycles: 
 Affective Depression, angry outbursts, irritability, anxiety, confusion, social withdrawal 
 Somatic Breast tenderness, abdominal bloating, headache, swelling of extremities. 
2 These symptoms are relieved within four days of the onset of menses, without recurrence until at least cycle day 13. 
3 The symptoms are presented in the absence of any pharmacological therapy, hormonal ingestion, or drug or alcohol use. 
4 The symptoms occur reproducibly during two cycles of prospective recording. 
5 The patient suffers from identifiable dysfunction in social or economic performance. 
In 2014, following thorough literature review and detailed discussion, the American 
Psychiatric Association included PMDD as a full category in the newly-released 
DSM-V [93], rather than a criteria set in the appendix as in DSM-IV. The changes 
are relatively minor and serve to refine the language of DSM-IV research criteria, as 
shown in Table 3-7, with the major changes being highlighted in italics. In summary, 
the timing of symptom onset and offset has been altered to be more explicit with 
respect to menstruation. Likewise, symptoms do not necessarily remit, but begin to 
improve, within a few days after onset of menstruation and are minimal in the week 
post menses. In addition, marked affective lability and irritability or anger have been 
moved to the top of the symptom list as they have been suggested as the most 
prominent psychological symptoms in recent literature. In criterion C, clinical 
significant distress has been added in addition to interference, as many distressed 
women summon coping skills to manage the impact of their symptoms. Finally, the 
distinction between PMDD and an ongoing medical disorder or substance-induced 
conditions has been highlighted in criterion G [94]. Due to its recent release, the 
studies included in this review used DSM-IV criteria for defining PMDD. 
Table 3-7: DSM-V diagnostic criteria for premenstrual disphoric disorder [93] 
A In the majority of menstrual cycles, at least five symptoms must be present in the final week before the onset of menses, start to 
improve within a few days after the onset of menses, and become minimal or absent in the week post menses. 
B One (or more) of the following symptoms must be present:: 
 1 marked affective lability (e.g., mood swings; feeling suddenly sad or tearful, or increased sensitivity to rejection) 
43 
 2 marked irritability or anger or increased interpersonal conflicts 
 3 marked depressed mood, feelings of hopelessness, or self-deprecating thoughts 
 4 marked anxiety, tension, and/or feelings of being keyed up or on edge 
C One (or more) of the following symptoms must additionally be present, to reach a total of five symptoms when combined with 
symptoms from Criterion B above: 
 1 decreased interest in usual activities (e.g. work, school, friends, hobbies) 
 2 subjective difficulty in concentration 
 3 lethargy, easy fatigability, or marked lack of energy 
 4 marked change in appetite; overeating; or specific food cravings 
 5 hypersomnia or insomnia 
 6 a sense of being overwhelmed or out-of-control 
 7 physical symptoms such as breast tenderness or swelling, joint or muscle pain, a sensation of ‘bloating’ or weight gain. 
Note: The symptoms in Criteria A–C must have been met for most menstrual cycles that occurred in the preceding year. 
D The symptoms are associated with clinically significant distress or interference with work, school, usual social activities, or relationships 
with others (e.g. avoidance of social activities; decreased productivity and efficiency at work, school, or home). 
E The disturbance is not merely an exacerbation of the symptoms of another disorder, such as major depressive disorder, panic disorder, 
persistent depressive disorder (dysthymia), or a personality disorder (although it may co-occur with any of these disorders). 
F Criterion A should be confirmed by prospective daily ratings during at least two symptomatic cycles. (Note: The diagnosis may be 
made provisionally prior to this confirmation.) 
G The symptoms are not attributable to the physiological effects of a substance (e.g. a drug of abuse, a medication, other treatment) or 
another medical condition (e.g. hyperthyroidism). 
Daily prospective symptom ratings by the woman for at least two cycles to confirm the 
symptoms are considered the most useful diagnostic tool for PMS. They are currently 
regarded as the gold standard and are required by both ACOG and DSM criteria for 
diagnosis of PMS/PMDD [5, 8, 93]. Various self-assessment instruments are available for 
daily symptom rating, such as daily recording of severity of problems (DRSP), 
premenstrual symptom diary (PMSD), calendar of premenstrual experiences (COPE), 
menstrual distress questionnaire (MDQ), VAS, to name a few [5, 95-97]. However, these 
instruments vary considerably in their scope—in terms of the range of symptoms included, 
the rating scales adopted and scoring methods used—which may affect the comparability 
of the estimated rates of PMS among studies adopting different tools [5]. Further, due to 
the extended evaluation period of two to three months required, these assessment 
instruments are not widely adopted especially in clinical settings [5, 8]. In addition to daily 
symptom reports, other standardised measurement instruments to assess psychiatric 
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disorders, impairment of functioning and quality-of-life are suggested as important 
supplements for the diagnosis of PMS [5]. 
The aetiology of PMS is not well understood, with different theories proposed. On the one 
hand, ovulation is almost certainly the trigger of the symptoms; thus, the hypothesis that 
ovarian steroids, particularly ovulatory progesterone, play an important role in the 
pathophysiology of the syndrome appears to be intuitive [8]. However, research indicates 
that circulating ovarian steroids levels (progesterone, oestrogen and testosterone) are 
normal in women with PMS, suggesting that women with PMS are more vulnerable to the 
normal fluctuations of one or more of these hormones [13, 98]. On the other hand, the 
interactions of fluctuating levels of ovarian steroids or their metabolites with a number of 
neurotransmitters have been proposed to be involved in the pathogenesis of PMS. 
Serotonin dysregulation is currently the most plausible hypothesis [8, 12]. This is 
supported by the observations that 1) ovarian steroids modulate serotonergic transmission 
as the levels of serotonin receptor, transport and reuptake vary according to changes in 
oestrogen and progesterone concentrations [98, 99]; 2) the role of the serotonergic system 
in regulating mood and behaviour is well-known [13]; 3) selective serotonin-reuptake 
inhibitors (SSRIs) and other serotonin-enhancing treatments such as serotonin-releasing 
agents and serotonin precursors have been used as the effective first-line therapy for 
severe PMS/PMDD [100]; and 4) various indices of serotonergic transmission are reported 
to be abnormal in women with PMS [12].  
Another neurotransmitter that has been linked to PMS is the main inhibitory 
neurotransmitter gamma-aminobutyric acid (GABA), an important regulator of stress, 
anxiety, vigilance and alertness [101]. The hypothesis is based on the observations that 1) 
some progesterone metabolites interact with GABAA receptor (the site of action of 
endogenous agents such as neuroactive steroids and exogenous agents such as 
progestogens) by binding to its neurosteroid-binding site, changing its configuration, 
making it resistant to further activation and likely contributing to the negative mood 
symptoms associated with PMS; and 2) women with PMS seem to differ from control 
women with respect to the responsiveness of GABAA receptor [12, 101]. However, 
although women with PMDD have low plasma GABA, low GABA has not been proven as a 
marker for mood state [102], and currently there are many unanswered questions and 
controversy regarding the theory [12]. Note that this theory does not conflict with the 
serotonin hypothesis as there are important interactions between GABA-ergic and 
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serotonin neurons, and that several SSRIs have profound effects on enzymes involved in 
the production of progesterone metabolites that modulate GABAA receptors [12, 13]. 
In addition, there is some evidence supporting the cognitive behavioural perspective of 
premenstrual symptoms. It is proposed that the core of PMDD is the negative attributions 
made by women about their symptoms, with  these women tending to frame their 
premenstrual changes as being out of control and not coping, further triggering negative 
thoughts [87]. Furthermore, various other factors—including genetic predisposition (with a 
30% to 80% heritability), neurotransmitters other than serotonin and GABA such as beta-
endorphin, and dietary and vitamin deficiency—are also suggested to be involved in the 
causal pathways of this complex disorder; however, none of these are well established [23, 
103-105]. Therefore, current knowledge on the aetiology of PMS suggests that a 
multifaceted approach which encompasses biological and psychosocial perspectives 
needs to be reflected in the diagnosis and management of PMS/PMDD [87, 106]. 
Recently, it has been emphasised that the extent to which PMS impact on women's life, 
work and their families is under-recognised by the majority of health professionals, lay 
people, government and health organisations [19]. Differences in the interpretation of 
significant PMS have led to considerable variations in estimated prevalence; thus, a 
precise, universal classification was called for by the International Society for Premenstrual 
Disorders (ISPMD) to enhance our understanding of PMS and its impact, to facilitate 
diagnosis, and to enable appropriate management [19]. As a result, a unified diagnosis, 
with classification of premenstrual disorders (PMD) along with their quantification and 
guidelines on clinical trial design was reached in the ISPMD Montreal consensus meeting 
in 2008 [107]. According to the consensus, PMD are divided into two categories: Core and 
Variant PMD (Table 3-8). Core PMD are typical, reference disorders associated with 
spontaneous ovulatory menstrual cycles and both the ACOG definition of PMS and DSM 
definition of PMDD meet the criteria for Core PMD. Variant PMD, on the other hand, exists 
where more complex features are present and encompass primarily four different types, 
namely premenstrual exacerbation (of underlying medical or psychiatric condition), PMD 
with anovulatory ovarian activity, PMD with absent menstruation, and progestogen-
induced PMD [107]. It is anticipated that the ISPMD classification will be considered by the 
various authoritative bodies in updating their classification criteria in due course [19]. 
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Table 3-8: ISPMD classification of premenstrual disorders [107] 
Core PMD 
Ovulation dependent 
Symptoms non-specific 
Number of symptoms not proscribed 
Symptoms prospectively rated 
Psychological and somatic equally important 
Symptom-free in follicular phase 
Burden (impairment and distress) on 
Absence of underlying psychiatric disorder 
Variant PMD 
Premenstrual exacerbation (of underlying medical or psychiatric condition) 
PMD with absent menstruation (hysterectomy, endometrial ablation, levenorgestrel intrauterine system) 
Progestogen-induced PMD (typically cyclical hormone replacement therapy; combined oral contraception) 
PMD with non-ovulatory activity 
3.2.2 Methodology	
The methodology used for the review in terms of search strategies and study selection 
criteria are similar to that used for dysmenorrhea. It has been described in the beginning of 
the chapter. The specific search terms related to PMS used were ((‘premenstrual 
syndrome’[MeSH Terms] OR (‘premenstrual’[tiab] AND ‘syndrome’[tiab]) OR ‘premenstrual 
syndrome’[tiab]) OR PMS[tiab] OR (‘premenstrual’[tiab] AND ‘tension’[tiab]) OR 
‘premenstrual tension’[tiab])) OR (premenstrual[tiab] AND dysphoric[tiab] AND 
(‘disease’[MeSH Terms] OR ‘disease’[tiab] OR ‘disorder’[tiab]) OR PMDD[tiab]). Quality 
assessment on the included studies was not conducted. However, in the absence of a 
formal quality assessment, this review only included studies that are of better designs, 
such as longitudinal study, case-control studies, or cross-sectional studies with large 
community-based samples, which are less likely to introduce certain biases pertaining to 
study design issues and more likely to provide more accurate estimates on study 
outcomes. 
The reference lists of included studies were scanned to check for any additional studies 
not captured by the electronic database search. Data from included studies were extracted 
into a standard form including the key characteristics and main findings of the studies, 
including their limitations. The definition of PMS, diagnostic criteria used (e.g. ICD-10, 
ACOG, DSM or other), symptom reporting method (e.g. interview or self-reporting instead 
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of prospective daily symptom ratings), length of symptom recall, and the severity of 
PMS/PMDD were noted if the studies clearly reported them. Meta-analyses of the included 
studies were not performed due to the substantial heterogeneity among the studies in 
study design, population included, and measurement of both outcomes and risk factors 
used. Instead, a qualitative synthesis of the most up-to-date and better-designed studies 
was provided. 
3.2.3 Results	and	discussion	
The initial literature search retrieved 2,978 articles. After applying the selection criteria 
described above and scanning the reference lists of included studies, a total of 28 primary 
studies were included: 8 longitudinal studies, 5 case-control studies and 15 population 
based cross-sectional studies. During the course of this project, literature update was 
performed regularly and a further 9 studies were subsequently included (2 longitudinal, 5 
case-control and 2 cross-sectional studies).  
3.2.3.1 Prevalence and incidence of PMS/PMDD 
This review highlighted that recent data on the rates and risk factors for PMS/PMDD from 
longitudinal studies or large community-based samples were limited. Five longitudinal [22, 
25, 26, 108, 109] and 17 community-based cross-sectional studies [110-126] reported on 
the prevalence and/or incidence rates of PMS/PMDD. The results from the studies are 
summarised in Table 3-9. 
Most studies applied one of the commonly used diagnostic criteria, namely ICD-10 or 
ACOG for PMS and DSM-IV for PMDD, albeit different degrees of modification were made. 
Very few studies applied the full set of ACOG or DSM-IV criteria, especially the 
requirement for prospective daily symptom rating, which was used in only five studies [110, 
114, 121, 123, 126]. Different classification systems and cut-off points were applied in 
defining the severity of the symptoms in the studies despite similar symptom rating scales, 
either a 4- or 6-point scale, being used.  
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Table 3-9: Characteristics of studies reporting on the rates of PMS/PMDD 
Study ID Country N Age group 
(years) 
Reporting 
method 
Length of symptom 
recall 
Daily 
symptom 
rating 
Symptom severity 
score 
Criteria used PMS/PMDD Rate of PMS/PMDD 
Prevalence Incidence 
Longitudinal study 
Mustaniemi (2011) 
[108] 
Finland 170 Mean 22 Self-report Last 3 months No 6-point scale 
(minimal – 
extreme) 
ACOG 
DSM-IV 
PMS 
PMDD 
11.8%  
5.9%  
 
Perkonigg (2004) 
[22] 
Germany 1,251 Baseline 14–24 Interview Last 12 months 
(follow-up: 42 mons) 
No Not reported M-CIDI DSM-IVa PMDD Baseline: 4.5% 
Follow-up: 7.5% 
3% 
Potter (2009)b [25] France 3,027 18–44 Interview Last 12 months 
(follow-up: 12 
months) 
No Not reported Study-specific PMS 12.2% 
Moderate: 8.1% 
Severe: 4.1% 
 
Silva (2008) [109] Brazil 2,082 Mean 23 Interview Not specified No 4-point scale 
(none – severe) 
Study-specific PMS 62.2 
Moderate: 13.4% 
Severe: 5.8% 
 
Wittchen (2002) 
[26] 
Germany 1,251 Baseline 14–24 Interview Last 12 months 
(follow-up: 42 
months) 
No Not reported M-CIDI DSM-IVa PMDD 5.8% 2.5% 
7.4% (cum) 
Cross-sectional study 
Cohen (2002) [110] USA 513 36–44 Daily 
record 
1 cycle Yes 
(DRSP) 
6-point scale 
(none – extreme) 
Study-specific 
(based on Moos 
Inventory) 
PMDD 6.4%  
Dennerstein 
(2009)c [111] 
8 countries 4,085 14–49 Interview Last 12 months No 4-point scale 
(none – severe) 
Modified DSM-IV PMS Mild: 40.8% 
Moderate: 21.9% (P) – 28.7% (M) 
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Study ID Country N Age group 
(years) 
Reporting 
method 
Length of symptom 
recall 
Daily 
symptom 
rating 
Symptom severity 
score 
Criteria used PMS/PMDD Rate of PMS/PMDD 
Prevalence Incidence 
Severe: 8.6% 
Duenas (2011) 
[112] 
Spain 2,108 15–49 Interview Last 12 months No Mild/ moderate/ 
severe 
PSST PMS 
PMDD 
73.7% (moderate-severe: 6.6%) 
1.1% 
Forrester-Knauss 
(2011) [113] 
Switzerland 3,522 Mean 35 Self-report Not specified No 4-point scale PSST PMS 13.5% 
Gehlert (2009) 
[114] 
USA 1,246 13–55 Daily 
record 
2 cycles Yes 6-point scale 
(none – severe) 
DSM-IV PMDD 1.3% 
54% (self-report) 
Masho (2005) [115] USA 874 18–44 Interview Not specified No 6-point scale 
(none – extreme) 
SPAF PMS 10% 
Pal (2011) [116] Pakistan 402 15–49 Interview Last 12 months No 4-point scale 
(none – severe) 
ICD-10 
ACOG 
DSM-IV 
PMS 
 
PMDD 
79.9% (ICD-10) 
12.7% (ACOG) 
5.5% (DSM-IV) 
Pilver (2011) [117] USA 2,718 18–40 Interview Last 12 months No Not reported WMH-CIDI DSM-IV PMS 
PMDD 
38.3% 
3.0% 
Pilver (2011) [118] USA 3,856 18–40 Interview Last 12 months No Not reported WMH-CIDI DSM-IV PMDD 3.3% 
Pilver (2011) [119] USA 2,590 18–40 Interview Last 12 months No Not reported WMH-CIDI DSM-IV PMDD 4.1% 
Pilver (2011) [120] USA 3,698 18–40 Interview Last 12 months No Not reported WMH-CIDI DSM-IV PMDD 3.9% 
Qiao (2012) [121] China 4,480 18–45 Daily 
record 
2 cycles Yes 
(DRSP) 
6-point scale ACOG PMS 21.1% 
Moderate: 4.6% 
Severe: 2.1% 
 
Sadler (2010) [126] UK 974 20–34 Daily 
record 
6 weeks Yes Not reported M-MMDQ PMS 24% 
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Study ID Country N Age group 
(years) 
Reporting 
method 
Length of symptom 
recall 
Daily 
symptom 
rating 
Symptom severity 
score 
Criteria used PMS/PMDD Rate of PMS/PMDD 
Prevalence Incidence 
Silva (2006) [122] Brazil 1,096 15–49 Interview Last 3 months No Not reported Modified DSM-IV PMS 25.2% 
60.3% (self-report) 
Skrzypulec-Plinta 
(2010) [123] 
Poland 1,540 18–45 Daily 
record 
2 cycles Yes 4-point scale 
(none – severe) 
DSM-IV PMDD 2.1% 
Takeda (2006) 
[124] 
Japan 1,187 20–49 Self-report Last 3 months No 4-point scale 
(none – severe) 
PSQ PMS 
PMDD 
Moderate-severe: 5.3% 
1.2% 
Tschudin (2010) 
[125] 
Switzerland 3,913 15–54 Self-report Not specified No Not specified PSST PMS 
PMDD 
Moderate-severe: 10.3% 
3.1% 
a. Criterion C (differential diagnosis) and D (prospective rating) were not used. 
b. A combined dataset from the two study years (2003–04) was used in the analysis with a total N = 3,027 (n = 1,587 in 2003 and n = 1,440 in 2004), with women contributing either one or two observations. 
c. In their series of studies, individual premenstrual symptoms experienced were the outcomes: M = moderately severe symptom dominated by mental symptoms, P = moderately severe profile but a marked tendency 
towards physical symptoms. 
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PMS. Among the studies identified, the prevalence of PMS of any severity varied 
substantially from 10% to 80%. As expected, the highest prevalence was reported in a 
cross-sectional study of a group of Pakistan women aged 15 to 49 years of age [116], 
since ICD-10 is the only diagnostic criteria used which requires only one of the defined 
symptoms. This is consistent with previous reviews reporting a prevalence of PMS of up to 
80% to 90% among ovulatory women [13, 127]. An earlier longitudinal community-based 
study (the Zurich Study) also reported that approximately 50% of women participants 
suffered from at least one somatic symptom and 35% from at least one emotional 
symptom [128]. Applying the stricter ACOG criteria, this review found the prevalence of 
PMS varied between 12% and 21%. This is lower than that of 21% to 29% reported in a 
recent review, which included studies adopting the same criteria [9]. However, the studies 
providing data on prevalence in that review used convenience sampling which is more 
likely to report a higher prevalence [114].  
Regardless of the different cut-offs used to classify symptom severity, this review found 
that 5% to 29% of women were classified as having moderate to severe PMS with 
significant functional impairment. This is comparable with moderate PMS reported by 14% 
in the Zurich cohort when classified according to the severity of distress—identified as the 
best indicator of severity of PMS in terms of functional impairment and treatment seeking 
[20]. However, the rate appears to be in the lower range of the prevalence of moderate to 
severe PMS of 20% to 40% in a previous review [127]. The lowest prevalence of 5% was 
reported in two studies of Asian populations [121, 124], in line with previous evidence 
supporting cultural influence on the experience and expression of psychiatric disorders 
[129]. However, Dennerstein et al [21] found no regional difference in either the duration or 
the severity of symptoms reported in a global study on the variation of premenstrual 
symptoms among women from 14 countries in Europe, Latin America and Asian.  
PMDD. According to the more rigorous criteria from DSM-IV, 1% to 9% of women met the 
criteria for PMDD in the included studies. This confirms the prevalence of 3% to 8% 
consistently reported in population-based epidemiological studies with prospective daily 
symptom charting [9, 127]. Although prospective daily symptom ratings are currently 
considered as the gold standard, a recent review on the epidemiology of PMS noted that 
studies defining PMDD by retrospective evaluation of symptoms yielded comparable 
prevalence rates, 2% to 6%, as those using prospective ratings [9]. The current review 
appears to support this notion in that, applying similar diagnostic criteria, lower prevalence 
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for PMDD was reported in both studies using daily symptom ratings [114] and 
retrospective reporting [112, 124]. Nevertheless, noting the restrictive approach of DSM-IV 
in the diagnosis of PMDD, some researchers have suggested that the true prevalence of 
clinically significant PMDD may vary from 13% to 19% in the population [127]. A less 
arbitrary and more consistent diagnostic protocol that balances rigor with feasibility is 
needed so that women will not be labelled with a serious condition unnecessarily, whereas 
women with PMDD can be properly diagnosed and receive appropriate management and 
benefits [114]. 
Variability of PMS/PMDD. The stability of the PMS/PMDD status over time was evaluated 
in two longitudinal studies [25, 26], indicating that the symptoms fluctuated over time in the 
majority of women reporting them at baseline. However, more severe PMS or PMDD was 
relatively stable. In a study of a group of young German women [26], only 5% of PMDD 
cases were fully remitted and 78% were still symptomatic over a follow-up of 42 months—
even though some of them no long met the DSM-IV criteria. Potter et al [25], in a study on 
French women, supported these findings and showed that 65% of women having severe 
PMS at baseline still had PMS at the end of one-year follow-up. On the other hand, only a 
small proportion of women developed the disorder over time. An incidence rate of 3% was 
reported for PMDD over 42 months in a group of young German women [22, 26]. A recent 
global study revealed a bell-shaped effect of age on the prevalence of some, but not all, 
premenstrual symptoms with the peak effect observed at around 35 years of age [21]. Due 
to the limited evidence base, longitudinal studies which follow women over a sufficient 
period of time are needed to fully elucidate the course of the disorder. 
3.2.3.2 Risk factors of PMS/PMDD 
Eight reports from seven longitudinal studies [22, 25, 26, 108, 109, 130-132], 10 case-
control studies [104, 105, 133-140], and 14 community-based studies [110, 111, 113, 115, 
117-120, 122, 123, 125, 126, 141, 142] investigated the associations between a range of 
risk factors and PMS/PMDD. Among the longitudinal studies, only four [22, 108, 109, 130] 
examined the associations of the risk factors and PMS/PMDD, taking into consideration 
the temporal relationship, whereas the others [25, 26, 131, 132] examined the associations 
in a cross-sectional fashion. In addition, three reports [22, 26, 132] included largely 
overlapping study populations, varying slightly in the total sample size; so caution should 
apply to avoid double counting the evidence. The reported effects from the included 
studies are based on adjusted analyses of varying degrees, with the minimum adjusting for 
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age. No recent review was identified which provides comprehensive assessment on the 
risk factors for PMS/PMDD. 
3.2.3.2.1 Demographics 
Most of the associations between the demographic characteristics and the risk of 
PMS/PMDD are reported from cross-sectional studies (Table 3-10).  
Age. Mixed results were produced from 13 studies investigating the association between 
age and PMS/PMDD. Four studies [22, 115, 122, 142] suggested that younger age was 
related to a higher risk of PMS with an odds ratio of up to two, whilst eight studies failed to 
detect a significant association [25, 110, 113, 118, 120, 123, 125, 126]. The other two 
multi-country studies among women from Europe and Latin America [111] and Asia [141], 
revealed a inverse U-shaped effect of age on the intensity of PMS (using a total duration 
and severity index), with the peak prevalence around age 35 years. Previous longitudinal 
and large community-based studies [128, 143, 144] and an earlier review [145] also 
reported inconsistent findings on the association; however, there appears to be some 
agreement that PMS was more common among women younger than 34 to 44 years [143, 
146, 147].  
The inconsistency in the reported relationship may be partly due to the different age 
groups of women and different symptom profiles included in the studies. On the one hand, 
it is plausible that a higher prevalence may occur among women in their peak reproductive 
age (mid-20s to 30s) who are most likely to have regular ovulatory cycles, since ovulation 
is important for the occurrence of PMS/PMDD, and the likelihood of anovulatory cycles 
decreases with age among adolescents and increase among premenopausal women [12, 
106]. On the other hand, the diverse symptoms included in the diagnostic criteria for 
PMS/PMDD and the studies may have different aetiology and thus show different 
associations with age [21]. In a combined analysis of the data from the two multi-country 
studies [21], the 23 individual symptoms of PMS were classified into three groups 
according to their observed relationships with age (from 15 to 49 years); namely, no effect 
of age, an inverse U-shaped relation with age, and decreasing intensity with age. 
Therefore, only evidence from longitudinal studies which follow women as they age are 
likely to resolve this discrepancy [147]. 
BMI. Inconsistent results on the association between BMI and PMS/PMDD were 
demonstrated among the eight studies reporting it. Five studies [25, 120, 123, 125, 126] 
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did not show a significant association, whereas increased BMI (overweight or obese) was 
associated with an increased risk of PMS in three studies [115, 135, 142]; however, Gold 
et al only reported the relationship of BMI with specific premenstrual symptoms such as 
craving and bloating [142]. The strongest evidence is from a case-control study nested 
within the prospective Nurse’s Health Study II (NHS2), including 1,057 nurses aged 27 to 
44 years at baseline [135]. The study observed a significant linear relationship between 
BMI at baseline and risk of incident PMS, with each 1 kg/m2 increase in BMI associated 
with a 3% increase in the risk of developing PMS (RR 1.03, 95%CI: 1.01, 1.05). The study 
performed a range of other analyses on the relationship between PMS and adiposity as 
measured by waist circumstance, waist/hip ratio, weight change and weight cycling. After 
controlling for BMI, no consistent effects were detected for most of these variables except 
weight gain of ≥20 kg between age 18 years and baseline (compared with women 
maintaining stable weight), which showed a significantly higher risk of developing PMS 
during follow-up (RR 1.59, 95% CI: 1.04, 2.42).  
The findings from earlier population-based studies generally yielded inconsistent results 
with either positive or non-significant associations demonstrated [143, 146, 147]. The 
proposed mechanisms for the relationship between BMI and PMS are mainly through 
interaction of hormonal and neurotransmitters as higher BMI has been related to lower 
oestradiol and progesterone levels, which might in turn lead to impaired serotonin function 
[12, 148]. In addition, ovarian hormone change related to BMI may also contribute to water 
retention in PMS through dysregulation of the renin-angiotensin-aldosterone system 
leading to sodium and fluid retention [149]. Therefore, longitudinal studies would be helpful 
to further examine the relationship between obesity and PMS/PMDD. 
Education. Education was inconsistently related to the risk of PMS/PMDD in the included 
studies, with contradictory results. Six studies reported no association between education 
and PMS/PMDD [25, 111, 115, 118, 125, 142], four reported a positive associations [113, 
120, 122, 150] and three reported a negative associations) [110, 123, 126]. The findings 
are supported by previous population-based studies [143, 144] and reviews [145] showing 
mixed results. 
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Table 3-10: Adjusted association between PMS/PMDD and reported main demographic and lifestyle factors in the included studiesa 
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Longitudinal study 
Perkonigg (2004) [22] ↓ 
       
↔ 
   
 
 
 
 
  
 
Potter (2009) [25] ↔ ↔ ↔ ↔ ↔ 
       
 
 
 
 
  
 
Wittchen (2002) & (2003)b 
[26, 132] 
        ↑ ↔ ↔         
Case-control study 
Bertone-Johnson (2005) [104]            ↓  ↓      
Bertone-Johnson (2008) [133]         ↑           
Bertone-Johnson (2009) [134]          ↔          
Bertone-Johnson (2010) [135]     ↑ ↔              
Bertone-Johnson (2014) [136]             ↔  ↔     
Chocano-Bedoya (2011) 
[105] 
         ↔      ↓    
Chocano-Bedoya (2013) 
[137] 
                ↓ ↑  
Cross-sectional study 
Cohen (2002) [110] ↔ ↓ ↑ ↔ 
  
↔ 
 
↑ 
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Dennerstein (2009)c [111] ∩ ↔ ↔ ↔ 
   
↔ ↑ 
   
 
 
 
 
  ↔ 
Dennerstein (2010)c [150] ∩ ↑ ↔ ↔ 
    
↔ 
   
 
 
 
 
  ↔ 
Forrester-Knauss (2011) 
[113] 
↔ ↑   ↔ 
  
↔ 
  
↓ 
  
 
 
 
 
  ↔ 
Gold (2007) [142] ↓ ↔ 
  
↑ 
   
↑ ↓ 
 
↔  
 
 
 
  ↔ 
Masho (2005) [115] ↓ ↔ ↔ ↔ ↑ 
 
↔ ↔ ↑ 
   
 
 
 
 
  ↔ 
Pilver (2011) [118] ↔ ↔ ↔ 
    
↔ ↑ 
   
 
 
 
 
  
 
Pilver (2011) [119] 
      
↓ 
     
 
 
 
 
  
 
Pilver (2011) [120] ↔ ↑ ↔ ↔ ↔ 
 
↓ ↔ ↔ 
   
 
 
 
 
  
 
Sadler (2010) [126] ↔ ↓   ↔    ↔ ↔         ↔ 
Silva (2006) [122] ↓ ↑ ↔ ↔   ↓  ↔          ↔ 
Skrzypulec-Plinta (2010) 
[123] 
↔ ↓ ↔ ↔ ↔ 
   
↔ ↔ 
  
 
 
 
 
  ↔ 
Tschudin (2010) [125] ↔ ↔ ↔ ↔ ↔    ↑ ↔         ↔ 
a. ↑= significant risk factors for PMS/PMDD; ↓= significant protective factors against PMS/PMDD; ↔ = no significant association detected; ∩ = inverse -shaped relationship (with age around 35 years having the maximum 
intensity of symptoms). 
b. Regression analyses controlled for age only. 
c. In their series of studies, a total duration severity index (DSI) of all individual premenstrual symptoms experienced was the outcome. 
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Ethnicity. A significantly lower risk of PMS/PMDD was related with non-white ethnicity in 
three cross-sectional studies [118, 119, 122], whereas three other studies did not report 
any association between ethnicity and PMS/PMDD [110, 113, 115]. These findings are, 
once again, largely in agreement with previous literature reporting mixed results for 
ethnicity [143, 144]. Overall, premenstrual symptoms appeared to be reported by a 
substantial proportion of women in all cultures, however there might be a difference in 
symptom profiles reported among different study populations [21, 144, 145].  
Other demographic characteristics. Similarly, studies included in this review generally 
confirmed the findings from earlier longitudinal and population-based studies [128, 143, 
144, 147], demonstrating no association between PMS/PMDD and employment [25, 111, 
115, 118, 120, 122, 123, 125, 150], marriage status [25, 110, 111, 113, 115, 120, 122, 123, 
125, 150], and socioeconomic status or income [111, 115, 118, 120].  
3.2.3.2.2 Lifestyle factors 
Most evidence on the relationship between PMS/PMDD and common lifestyle factors are 
based on cross-sectional analyses (Table 3-10).  
Smoking. The association between smoking and PMS/PMDD was reported in two 
longitudinal, one nested case-control, and 11 cross-sectional studies, producing mixed 
results. An increased risk of PMS/PMDD was shown for current and former smokers in 
eight studies [26, 110, 111, 115, 118, 125, 133, 142]; however, the other six studies failed 
to detect a significant association [22, 120, 122, 123, 126, 150]. In the case-control study 
nested within the prospective NHS2 [133], researchers performed a series of analyses 
using different smoking-related variables. They found a significant association between 
smoking status two years prior to diagnosis and the risk of developing PMS, with a relative 
risk of 2.10 (95% CI: 1.56, 2.83) for current smokers and 1.66 (95% CI: 1.35, 2.05) for 
former smokers. Increased risk of PMS was also significantly related to increased total 
pack-year of smoking with a dose-response relationship demonstrated, with the relative 
risks varying from 1.39 to 2.41 (p = 0.03 for trend). Furthermore, early initiation of smoking 
(before symptoms developed) also significantly increased the risk of PMS (RR 1.73, 95% 
CI: 1.28, 2.32); however, no linear relationship was detected for years of smoking 
cessation and PMS.  
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A longitudinal study looking at nicotine dependence at baseline and the risk of incident 
PMDD failed to show a significant association, despite an increased risk of PMDD (OR 1.7, 
95% CI: 0.6, 4.5) for nicotine dependence [22]. Due to the small number of women having 
PMDD, the study may lack power to detect a significant difference. Furthermore, the two 
multi-country studies by Dennerstein and colleagues also showed mixed results, with a 
significant association shown for smoking and PMS in the study on European and Latin 
American women [111] and no association shown among Asian women [150]. The authors 
speculated that the overall low prevalence of smoking among Asian women might be one 
of the contributing factors for this discrepancy [150].  
The findings appear to be in line with earlier longitudinal and population studies showing 
inconsistent results, with some demonstrating a positive association for smoking and 
menstrual disorders including PMS [56, 147] and others showing no significant association 
when looking specifically at PMS [128, 143, 144]. The rationales for the observed 
association may be mainly related to the fact that cigarette smoking affects sex steroid and 
gonadotropin levels as evidenced by the observation that heavier smoking was associated 
with higher oestrogen, progesterone and follicle-stimulating hormone metabolite levels 
during the follicular phase, and with lower progesterone levels during the luteal phase. 
This altered endocrine function is proposed to contribute to the reported associations of 
smoking with adverse reproductive outcomes, including menstrual dysfunction [12, 151]. 
However, due to the overall inconsistent results, additional research is needed to confirm 
and better understand this association. 
Alcohol consumption. No significant association was shown between alcohol use and 
PMS/PMDD in six [26, 105, 123, 125, 126, 132, 134] of the eight studies reporting them, 
with the best evidence from another case-control study nested within the NHS2 [134]. This 
study examined the risk of developing PMS/PMDD at follow-up with a range of variables 
related with alcohol consumption including total amount of alcohol intake, various time 
periods of alcohol intake and total drinking-years. After controlling for potential 
confounders, including smoking, no consistent relationship between alcohol use and risk of 
developing PMS and PMDD was observed; although there may be a minimally increased 
risk with long-term alcohol use [134]. The findings generally agree with the results from 
earlier longitudinal and population studies showing no significant association between 
drinking and PMS [128, 143]. 
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Physical activity. Similarly, results were consistent from nine cross-sectional studies 
showing no significant association between physical activity and PMS/PMDD [111, 113, 
115, 122, 123, 125, 126, 142, 150]. Earlier population-based studies produced mixed 
results on the associations between physical activity and PMS/PMDD [143, 144]; however, 
it was not clear whether exercise was used therapeutically to minimise premenstrual 
symptoms in the study reporting an association [143]. 
Dietary factors. Dietary factors were sparsely reported in the included studies. There was 
some evidence from three case-control studies nested within the NHS2 [104, 105, 137] 
which reported a reduced risk of developing PMS with increased dietary calcium, vitamin 
B1 (thiamine), vitamin B2 (riboflavin), total vitamin D and iron intake; and an increased risk 
of PMS with higher total intake of potassium. However, in another NHS2 nested case-
control study with a similar population base, no relationship was found between both 
plasma 25-hydroxyvitamin D (25-OHD) and total calcium levels with the risk of PMS [136]. 
Due to the limited evidence base, no meaningful conclusion could be reached. 
Drug use. Only one study was identified which reported on the association of drug use and 
risk of PMDD [26]. Although being part of a longitudinal study, it examined the association 
in a cross-sectional nature. The study showed an increased, but not statistically significant, 
association between drug abuse or dependence and PMDD (OR 2.2); however, lack of 
power due to the small number of PMDD cases (n = 74) included in the study may be one 
of the potential explanations for the non-significant finding. Further analysis revealed a 
significant association (OR 3.3, p <0.05) between drug abuse or dependence and 
subthreshold PMDD, defined as cases short of just one diagnostic criteria for PMDD— 
according to DSM-IV— with most subthreshold cases showing a lack of persistent 
impairment associated with premenstrual symptoms. 
3.2.3.2.3 Reproductive factors 
Once again, most of the included studies reporting on the association of reproductive 
factors and PMS/PMDD are based on cross-sectional data analyses (Table 3-11).  
Age at menarche. Results were consistent from all six studies [25, 109, 110, 115, 118, 
123], including one birth cohort study from Brazil, that reported on age at menarche and 
the risk of PMS/PMDD, with no significant association detected [109]. Although the 
Brazilian study observed a higher risk of PMS in women whose age at menarche was less 
than 11 years, this was not statistically significant. The findings among previous 
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population-based studies are generally supportive of the result of this review showing no 
significant association [143, 146], although a non-significant higher risk of PMS among 
women with an earlier age at menarche was reported in one study [143].  
Hormonal contraception use. Results from the nine studies that reported on the 
association of hormonal contraceptive and the risk of PMS/PMDD were by and large 
consistent. Six of nine studies failed to detect a significant association [25, 113, 115, 118, 
122, 150], whereas the other three studies yielded conflicting results with one showing a 
positive association [120] and the other two a negative association [125, 126]. The findings 
accord with the inconclusive results from earlier studies with some showing an inverse 
relationship between OCP use and PMS [128, 144] and others detecting no significant 
association [152, 153].  
Despite being commonly prescribed as the treatment for PMS, evidence on the 
effectiveness of OCPs on PMS appears to be controversial [152, 154-156]. ACOG has 
recommended OCP use if physical symptoms of PMS were predominant [92]. Globally, 
OCP use was shown to minimally affect or slightly reduce the incidence or severity of 
premenstrual symptoms [157]. However, the variability among different types of oral 
contraceptive preparations—such as monophasic, biphasic and triphasic preparations—
may be an important factor influencing the results [106]. There is some evidence that the 
therapeutic effect of triphasic preparations with varying doses of the progestin component, 
imitating the natural cycle, is minimal due to the increased sensitivity to fluctuating 
hormone and neurosteroid levels in women with PMS [155]. Further research is needed to 
examine the relationship between the types of OCPs use and PMS. Furthermore, studies 
to investigate whether fluctuations in neurosteroid level are responsible for the effects of 
OCPs on premenstrual mood symptoms are also called for [155].  
Parity. Results were generally consistent from seven studies reporting on the association 
between parity and the risk of PMS/PMDD. Five studies failed to detect a significant 
association [25, 111, 115, 123, 142] and the other two reported conflicting results [122, 
141]. Findings from earlier population-based studies also yielded mixed results with some 
reporting an inverse relationship between parity and PMS [128], and others showing no 
association [143, 146] 
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Table 3-11: Adjusted association between PMS/PMDD and reported main reproductive factors in the included studiesa 
First author  
(year) 
Age at 
menarche 
(later) 
Very low birth 
weight 
Parity/live birth 
(higher) 
OCP/hormonal 
contraception 
Dysmenorrhea 
Heavy 
menses 
Long/Irregular 
cycle 
Longitudinal study 
Mustaniemi (2011) 
[108]  
↔ 
     
Potter (2009) [25] ↔ 
 
↔ ↔ ↑ ↔ ↑ 
Silva (2008) [109] ↔   
     
Cross-sectional study 
Cohen (2002) [110] ↔      ↔ 
Dennerstein (2009)b 
[111] 
  ↔     
Dennerstein (2010)b 
[150] 
  ↓ ↔    
Forrester-Knauss 
(2011) [113] 
   ↔    
Gold (2007) [142]   ↔     
Masho (2005) [115] ↔  ↔ ↔   ↔ 
Pilver (2011) [118] ↔   ↔    
Pilver (2011) [120]    ↑    
Sadler (2010) [126]    ↓    
Silva (2006) [122]   ↑ ↔    
Skrzypulec-Plinta 
(2010 [123] 
↔  ↔     
Tschudin (2010) 
[125] 
   ↓    
a. ↑= significant risk factors for PMS/PMDD; ↓= significant protective factors against PMS/PMDD; ↔ = no significant association detected. 
b. In their series of studies, a total duration severity index (DSI) of all individual premenstrual symptoms experienced was the outcome. 
Other menstrual problems. As shown in Table 3-11, a limited number of studies also 
reported on the relationship between other menstrual problems and PMS/PMDD. A 
positive relationship between PMS/PMDD and dysmenorrhea but not heavy menses was 
reported in one study [25]; however, the relationship between PMS/PMDD and long cycles 
or irregular periods remained unclear [25, 110, 115]. In line with this, an earlier review also 
reported conflicting results on the correlation of PMS and other menstrual cycle 
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characteristics [145]. No conclusion on the associations can be drawn due to the limited 
evidence base.  
3.2.3.2.4 Psychosocial factors  
A wide range of psychosocial risk factors were investigated in the included studies; 
however, only a limited number of studies reported on any particular factor (Table 3-12). It 
should be noted that evidence on a number of risk factors are from two studies (in three 
reports) which included similar groups of German women [22, 26, 132]. 
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Table 3-12: Adjusted association between PMS/PMDD and reported main psychological and other factors in the included studiesa 
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Longitudinal study 
Gollenberg (2010) [130]   ↑                    
Koci (2007) [131]       ↑                
Perkonigg (2004) [22] ↔   ↑ ↔ 
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↔ ↔ ↔ ↔ ↑ ↑ ↔  
  
    
Potter (2009) [25] 
 
 ↑  
        
    
  
    
Wittchen (2002) & (2003)b [26, 
132] 
↑   ↑ ↑ 
    
↔ ↑ ↑ ↑    
  
   ↑ 
Case-control study 
Bertone-Johnson (2014) [138]      ↑  ↑               
Soyda Akyol (2013) [139]                ↑       
Soydas l (2014) [140]      ↑ ↑ ↑               
Cross-sectional study 
Cohen (2002) [110] 
 
↑  
  
 
       
  
   
    
Forrester-Knauss (2011) [113] 
 
↑  
  
 
       
  
 
↓ ↑    ↔ 
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 Psychological factors  Other 
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Pilver (2011) [117]                     ↑  
Pilver (2011) [118] ↑   
          
  
   
 ↑  ↔ 
Pilver (2011) [120] ↑   ↑ ↑ 
       
   
   
    
Sadler (2010) [126] ↑                      
Silva (2006) [122]                      ↔ 
Tschudin (2010) [125] 
  
↑ 
          
  
   
    
a. ↑= significant risk factors for PMS/PMDD; ↓= significant protective factors against PMS/PMDD; ↔ = no significant association detected. 
b. Regression analyses controlled for age only. 
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Stress. A higher stress was associated with increased risk of PMS/PMDD consistently in 
all three studies reporting it [25, 125, 130]. The only study examining the longitudinal 
relation between perceived stress in the previous month and premenstrual symptom 
severity across two cycles was among 259 American women aged 18 to 44 years [130]. 
The study found that, compared with low stress, high stress was associated with an 
increased risk of reporting eight or more symptoms of PMS as moderate or severe (OR 7.2, 
95% CI: 3.3, 15.8). Stress scores were positively related with increased symptom severity 
scores for total, psychological and physical symptoms (p <0.0001). In addition, changing 
stress levels across the cycles were also associated with a corresponding pattern of 
symptom severity, with more moderate or severe symptoms reported during the cycle that 
was preceded by higher stress levels. 
The relationship between psychological stress or stressful life events and PMS has been 
widely investigated in the literature, and the consensus was that women reporting 
significant life stresses were more likely to report severe PMS [128, 143, 146]. The exact 
mechanism of how stress contributes to increased premenstrual symptom severity is not 
clear, but stress-induced changes in ovarian hormone levels through hypothalamic-
pituitary-ovarian axis may be involved, which may render a woman more susceptible to 
menstrual disorders [130, 158]. In addition, there is suggestion that PMS was related to 
activation of the hypothalamic-pituitary-adrenal axis or a heightened sensitivity to its 
function as women with PMS are more sensitive to increased cortisol levels (related to 
fluid retention and associated symptoms) [159]. Alternatively, stress levels may impact on 
the neurotransmitters epinephrine, norepinephrine and serotonin, which are related to 
anxiety and mood-related symptoms [159]. Severe or prolonged exposure to stress in 
susceptible individuals may result in dysregulation of the generalised stress response, 
which would increase their vulnerability to subsequent life stressors since both hyper- and 
hypo-activation of the stress response would reduce the sense of well-being and 
performance [158].  
Trauma and post-traumatic stress disorder (PTSD). Three studies [22, 120, 132] examined 
the association between both trauma and PTSD with PMDD, producing mixed results. It 
should be noted that two of the studies were based on a similar population of a community 
sample of 1,251 young German women [22, 132]. All studies were consistent in showing a 
positive association between trauma and PMDD, with the longitudinal data analysis 
demonstrating that traumatic events greatly increased the odds of developing PMDD (OR 
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4.2, 95% CI: 1.2, 12.0) [22]. Although cross-sectional data demonstrated a positive 
association between PTSD and PMDD [120, 132], no significant association between 
baseline PSTD and incident PMDD at follow-up was observed in a longitudinal study (OR 
0.7, 95% CI: 0.1, 2.8) [22]. The authors indicated that the non-significant result for PTSD 
might be due to the small number of women with both PTSD and PMDD (n = 10). When 
data were analysed cross-sectionally at follow-up, PTSD was significantly related to PMDD 
(OR 3.7, 95% CI: 2.1, 6.5). In addition, Wittchen and colleagues performed a case-by-case 
review of the ten cases with PTSD and PMDD at baseline and first follow-up, and found 
that the majority of triggering traumatic events (e.g. abuse in childhood, life-threatening 
event or witnessing traumatic events experienced by others) leading to PTSD occurred 
before menstruation [132]. This supported their hypothesis of a causal effect of traumatic 
events on PMDD.  
In the cross-sectional study using data from the Collaborative Psychiatric Epidemiology 
Surveys, Pilver et al extended the findings of the German studies to a more diverse 
sample of 3,698 American women and included a three-level variable to characterise 
exposure as no trauma, trauma only, and trauma plus PTSD [120]. They found a graded 
association between trauma, PTSD and PMDD. Compared with women without history of 
trauma, women with trauma but not PTSD were more likely to report PMDD (OR 2.8, 95% 
CI: 1.3, 6.4); however, the highest risk of reporting PMDD was seen among women with 
both trauma and PTSD (OR 8.1, 95% CI: 3.6, 18.6). Among trauma survivors, PTSD was 
still significantly associated with PMDD (OR 2.6 95% CI: 1.4, 5.1) after further adjusting for 
trauma characteristics (number and severity of traumatic events). Few previous studies 
examined the association between either traumatic events or PTSD and PMDD, with a 
secondary analysis of a longitudinal data reporting history of both adolescent physical and 
sexual abuse being significantly associated with severe premenstrual symptoms in 
adulthood [131]. 
The specific pathway linking trauma and PTSD to PMDD is unclear. However, as 
mentioned previously, a non-specific dysregulation of the stress response in association 
with traumatic events was suggested to also influence menstruation due to its co-existence 
with other mental and physical disorders [132, 160]. This is supported by evidence 
suggesting that women with PMDD and a history of trauma showed abnormal 
neuroendocrine functioning compared with women with PMDD but no history of trauma 
[161]. 
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Abuse. Two longitudinal studies [22, 131] and two case-control studies [138, 140] 
examined the relationship between childhood and/or adolescent abuse and PMS/PMDD. 
Childhood or adolescent physical and emotional abuse was shown to be positively 
associated with the presence of PMS/PMDD consistently in all studies. However, mixed 
results were shown for the association between sexual abuse during childhood and/or 
adolescence and PMS. Both adolescent and childhood sexual abuse was found to be 
correlated with the presence or risk or severity of PMS/PMDD in three studies [22, 131, 
140]; however, the case-control study nested in NHS2 [138] failed to detect a significant 
association between sexual abuse and the incidence of PMS after controlling for potential 
confounders. The authors of the later study further performed a range of analyses 
considering the combination of different type, severity and chronicity of abuse, and found 
that severe-chronic abuse of multiple types was associated with significantly elevated risk 
of PMS. For example, forced sex and severe physical abuse during both childhood and 
adolescence had an OR of 2.8 (95% CI: 1.5, 5.3) to develop PMS compared with those 
without any exposure to abuse. In addition, the study also detected a 2.5-fold (95% CI: 1.6, 
3.8) increased risk of developing PMS for women who experienced childhood emotional 
abuse [138]. It is not clear why emotional and physical abuse was more consistently 
associated with the risk of PMS than sexual abuse, but the authors stated that their 
findings were consistent with literature on the relationship between abuse and other 
affective disorders [162, 163].  
A potential explanation of the effect of early life exposure to abuse is that it is associated 
with persistent alterations in neurobiological systems which are known to be stress 
responsive. This persistent dysregulation demonstrated in both the hypothalamic-pituitary-
adrenal axis and the sympathetic nervous system may result in dysregulation in stress 
responsiveness to even mild stressors later in life, and suggest a persistence of mood 
disturbance even in the absence of current psychiatric illness [164]. In addition, evidence 
also suggests that abuse history may contribute to the persistent dysfunction of the 
hypothalamus-pituitary-thyroid axis, which is responsive to severe traumatic stress such as 
sexual abuse, in women with PMDD [165]. The elevated free and total triiodothyronine (T3) 
concentrations, the most biologically active thyroid hormone, in women with menstrual-
related mood disorder and history of sexual abuse may contribute to the 
pathophysiological mechanism of PMS/PMDD, as decreased T3 concentrations was found 
in women with a history of sexual abuse but without menstrual-related mood disorder [165]. 
Furthermore, there is suggestion that a common serotonin transporter gene-linked 
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polymorphism (5-HTTLPR), which appears to be more prevalent in women with PMDD, is 
related to the more severe consequences of abuse. Thus women with this underlying 
genetic vulnerability may be more susceptible to the development of PMS/PMDD [166]. 
Mood disorders. Four studies examined the associations between PMS/PMDD and a 
number of mood disorders. Three cross-sectional studies consistently showed that any 
mood disorder was associated with an increased risk of PMS/PMDD [118, 120, 132]; 
however, one longitudinal study examined the association between mood disorder at 
baseline and the risk of incident PMDD and did not find any significant association [22]. 
This contrasts with a previous longitudinal study (the Zurich Study) that supported an 
association between PMS and affective disorders [128]. In addition, previous longitudinal 
studies also reported a significant association between both anxiety and major depression 
and an increased risk of PMS [103, 128]. This result is replicated by the results from two 
studies from the current review on anxiety, including a longitudinal study showing a history 
of anxiety disorder had an odds of 2.5 (95% CI: 1.1, 5.5) of developing PMDD at follow-up 
[22]. Supporting previous findings, two cross-sectional studies [110, 142] from the current 
review also detected a relationship between depression and PMS/PMDD. 
Other psychological factors. The associations between PMS/PMDD and a range of other 
psychological factors, such as eating disorder, somatoform disorder, substance 
dependence, were investigated in a very small number of studies as shown in Table 3-12. 
No meaningful conclusions can be made on any of the results based on the limited 
evidence base. 
3.2.3.2.5 Other risk factors 
A limited number of studies reported on the association between a number of other 
variables and PMS/PMDD (Table 3-12). Among the four studies reporting on the 
relationship between health perception and PMS/PMDD, three cross-sectional studies 
showed consistent results indicating no association [113, 118, 122], whereas the 
longitudinal study reported that poor and very bad health perception was related to 
increased risk of PMDD or subthreshold PMDD [26]. A previous longitudinal study showed 
that general well-being and premenstrual symptoms were highly correlated at each follow-
up time point [167]. This was also supported by population-based studies showing that 
self-perceived poor health was related to more severe premenstrual symptoms [144, 146]. 
It is suggested that comorbid conditions may exacerbate premenstrual symptoms through 
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unknown mechanisms and that there were subgroups of the population with greater than 
average sensitivity to symptoms and pain [144].  
3.2.4 Conclusion	
The current review confirms the previous finding that PMS of any severity is prevalent, 
affecting up to 80% of menstruating women. Moderate to severe PMS with significant 
functional impairments is less common, occurring in 5% to 29% of women. Only 1% to 9% 
of women of reproductive age meet the strict DSM-IV criteria for PMDD, which is a 
relatively stable condition over time. However, limited data showed that more fluctuation in 
symptom status was observed for less severe PMS over time. 
Consistent with previous literature, recent community studies failed to show any consistent 
association between PMS/PMDD and any demographic factors, including age and BMI. 
Despite mixed evidence from previous literature, this review suggests that:  
 Smoking may increase the risk of PMS but there is uncertainty due to discrepancy 
in the literature. 
 Alcohol use, physical activity and parity are unlikely to be associated with risk of 
PMS/PMDD. 
 Stress, abuse, mood disorder, trauma and PTSD are associated with increased risk 
of PMS/PMDD; although, the body of evidence is relatively small.  
More research from population-based, prospective, longitudinal studies will be essential to 
elucidate individual level change of PMS status over time (age effect) and to further test 
the associations between PMS and some potentially modifiable risk factors including 
smoking, obesity, drug and OCP use. In addition, future studies can also help to confirm 
the associations between PMS/PMDD and the psychological factors identified in the 
current review. The evidence generated may in turn support effective preventative and 
management strategies. 
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Chapter 4. Dysmenorrhea and PMS in young 
Australian women 
As demonstrated in Chapter 3, the reported prevalence of dysmenorrhea or PMS varies 
widely in the literature; highlighting the uncertainties of their magnitude in the community. 
Few studies have examined the variability and the trend over time of either condition in the 
same group of women. Therefore, the ALSWH provides an ideal opportunity to address 
these uncertainties.  
This chapter mainly presents the results from a study examining the prevalence and the 
trajectories of dysmenorrhea and PMS over time. Other than that, literature also suggests 
that it is important to assess the impairment of functioning and quality-of-life of affected 
women as supplements for the diagnosis of these menstrual conditions, especially PMS 
[5]. Therefore, although not the main objective of this project, the association between self-
reported quality-of-life using the SF-36 and the respective menstrual conditions was 
explored to illustrate the burden and the significance of dysmenorrhea and PMS in a 
representative sample of Australian women.  
4.1 The prevalence and long‐term trend of dysmenorrhea and PMS 
(Paper 2) 
This section presents a study examining the prevalence and the trajectories of 
dysmenorrhea and PMS over time, using ALSWH 1973–78 cohort data. The paper was 
published in the peer-reviewed journal Maturitas as following: 
Ju H, Jones M, Mishra GD. Premenstrual syndrome and dysmenorrhea: symptom 
trajectories over 13 years in young adults. Maturitas. 2014 Jun;78(2):99-105. 
Website: http://www.sciencedirect.com/science/article/pii/S0378512214000942 
Reproduced with permission of ELSEVIER IRELAND LTD in the format Republish in a 
thesis/dissertation. Permission is covered by the rights as an Elsevier journal author as 
outlined at http://www.elsevier.com/about/policies/author-agreement/lightbox_scholarly-
purposes. 
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Abstract 
Objectives: To ascertain the prevalence of PMS and dysmenorrhea in Australian women 
and to examine whether there is population subgroups with distinct symptom trajectories. 
Study design: A prospective cohort study, including 9,671 young women random sampled 
from the national Medicare database and followed up for 13 years, examined the 
prevalence, the long-term trend and the trajectories of the conditions. 
Main outcome measures: Prevalence of PMS and dysmenorrhea over time, the symptom 
trajectories, and the probability of reporting the condition at follow-up. 
Results: The prevalence of PMS varied between 33% and 41% and that of dysmenorrhea 
between 21% and 26%. The probabilities of reporting PMS and dysmenorrhea were 0.75 
(95% CI: 0.73, 0.76) and 0.70 (95% CI: 0.68, 0.72), respectively, among women who 
reported them in three previous consecutive surveys. Four unique trajectories were 
identified for both conditions. PMS was experienced by 80% of women during the study 
period, with normative (22.1%), late onset (21.9%), recovering (26.5%) and chronic (29.5%) 
groups revealed. Dysmenorrhea occurred in 60% of women with normative (38.3%), low 
(28.0%), recovering (17.2%) and chronic (16.5%) groups identified.  
Conclusions: PMS and dysmenorrhea are common among young women. Both have 
relatively stable prevalence over time, but exhibit considerable variation at the individual 
level. Four subgroups of women who followed similar symptom trajectories were identified. 
PMS was experienced by 80% of women during the study period and it tended to be a 
long-lasting problem in many. Although 60% of women experienced dysmenorrhea, only a 
small group consistently reported it. Smoking and illicit drugs use, and smoking and 
obesity were more common among women with persistent PMS and dysmenorrhea 
respectively.  
Key words: premenstrual syndrome, PMS, dysmenorrhea, menstrual pain, painful 
menstruation, prevalence 
Abbreviations: BMI, body mass index; CI, confidence interval; OCP, oral contraceptive pill; 
PMS, premenstrual syndrome.  
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4.1.1 Introduction	
Overall a large number of menstruating women suffer from one or more menstrual 
symptoms [8]. Among these symptoms, PMS (previously known as premenstrual tension) 
and dysmenorrhea are the two most prevalent [3, 4]. The majority of these conditions, 
however, are mild to moderate in nature and more severe forms each affect up to 20% of 
women [9, 10]. 
Moderate and severe menstrual conditions can significantly impact on quality-of-life for 
affected women, interfering with study, employment, inter-personal relationships and 
family and social life [13, 16]. Compared with women without menstrual symptoms, 
decreased work productivity, increased work absenteeism and healthcare use have been 
reported in symptomatic women, resulting in considerable economic losses [16, 17].  
The reported prevalence of both conditions in the literature varies substantially, with that of 
PMS ranging from 10% to 90% [13], regardless of diagnostic criteria used, and 
dysmenorrhea of any severity from 17% to 81% [45]. The high variation in reported 
prevalence has been attributed to a range of factors, among which are study design and 
population studied. The majority of current literature is based on cross-sectional studies 
mostly using convenience samples and there is a paucity of studies which have followed 
the same group of women to examine the trend of the conditions [5, 6].  
Therefore, this longitudinal population-based study aimed to ascertain the prevalence and 
long-term trend of PMS and dysmenorrhea in young Australian women and to examine 
whether there are population subgroups with distinct trajectories of the conditions.  
4.1.2 Methods	
This study used data from the 1973-78 cohort of the ALSWH, a prospective cohort study. 
Specifically, the study population was women registered with the national Medicare 
database, which includes almost all Australian citizen and permanent residents. Women 
were randomly selected from all parts of Australia, with deliberate oversampling from rural 
and remote areas. The 1973–78 cohort included 14,247 women aged 18 to 23 years at 
baseline (1996) who, when compared with the national census, were found to be broadly 
representative of Australian women of this age group in country of birth, education, marital 
status and housing situation; although, there is slight differences in that more women 
included in the survey were Australian-born, had a diploma or university degree and were 
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not in the labour force [29]. Questionnaires were sent to participants every three to four 
years, with the most recent survey being conducted in 2012. Further details of the study 
methods have been reported elsewhere [28]. ALSWH was approved by the Human 
Research Ethics Committees of the University of Newcastle and the University of 
Queensland. Permission to use the data was granted for this study from the Publications, 
Analyses and Substudies Committee of the ALSWH in August 2012. 
For this study, Survey 1 was not included due to evidence of substantial over-reporting of 
both PMS and dysmenorrhea among the cohort, which is known as ‘telescoping’ effect 
common in self-reported data [41, 42]. Therefore, data from five waves of the survey over 
13 years (Survey 2 in 2000 to survey 6 in 2012) were included and baseline refers to 
Survey 2 hereafter. We included women who had a hysterectomy, as the number in this 
group of young women was minimal and PMS can still occur among women who have had 
a hysterectomy [19]. Women who used OCPs, were pregnant or gave birth in the last 12 
months were included since they were a large group and some provided valid data on their 
menstrual symptoms.  
All data were collected through self-report. The outcomes of interest were based on 
questions regarding specific menstrual symptoms (In the last 12 months have you had: 
premenstrual tension, severe period pain?). Women were considered to have had a recent 
history of each symptom if their response was ‘sometimes’ or ‘often’, and to be symptom-
free if their response was ‘never’ or ‘rarely’.  
Baseline sociodemographic characteristics of the women included age, highest level of 
education, marital status, employment, area of residence, BMI, current smoking status, 
alcohol consumption, illicit drug use and physical activity. These variables were 
categorised as shown in Table 1. In addition, the following reproductive characteristics 
were included: contraception use, number of births (live and still), and age at menarche. 
Statistical analyses were performed using SAS version 9.3 for Windows (SAS Institute Inc., 
Cary, NC). Prevalence was calculated weighting for area of residence to account for 
oversampling of women in rural and remote areas. For PMS and dysmenorrhea, patterns 
of variability in symptom status at the individual level over time was displayed for women 
providing data at each survey using plots for longitudinal categorical variables. The 
probability of reporting the conditions at the latest survey was predicted using nominal 
logistic models with explanatory variables based on the woman’s previous symptom status.  
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Group-based trajectory analyses (latent class analysis) were performed separately for 
PMS and dysmenorrhea using SAS PROC TRAJ [38], with the aim of identifying 
population subgroups with similar trajectories. Model fit was assessed using the Bayesian 
Information Criterion and the model with the lowest score was selected [168, 169]. Three 
sets of trajectory analyses were performed and compared using data from i) all women 
included in the study, ii) women who provided at least three outcome measures and iii) all 
complete cases. As a result, trajectories in women with at least three outcome measures 
were considered the most appropriate and are reported here as this population balances 
the trade-offs between adequate sample size and missing data. Group characteristics 
were compared at baseline. The impact of OCP use and pregnancy and/or giving birth in 
the last 12 months was controlled for in the trajectory analyses by adding the variables as 
time-varying covariates.  
4.1.3 Results	
There were 9,688 women who responded to the questionnaire in 2000 (Survey 2), 9,081 in 
2003, 9,145 in 2006, 8,200 in 2009, and 8,008 in 2012. Sociodemographic and 
reproductive characteristics for 9,671 women at baseline, excluding 17 women with 
missing values for both PMS and dysmenorrhea, are presented in Table 4-1. There were 
some differences in the characteristics of women with and without the conditions. Women 
who reported PMS or dysmenorrhea were more likely to be single, unemployed, current 
smokers, nulliparous or have an early menarche age. In addition, women reporting PMS 
were more likely to have a diploma or higher education, be risky alcohol drinkers and illicit 
drug users, reside in urban areas, and use other contraceptive methods. Women who 
reported dysmenorrhea were less likely to be in the older age group and to use OCPs.  
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Table 4-1. Baseline sociodemographic and reproductive characteristics of the women aged 22–27 years by PMS and dysmenorrhea 
status in 2000, Australia 
 Sample PMS  Dysmenorrhea 
 N* % 95% CI  % 95% CI 
Total 9671 33.1 32.2, 34.1  25.2 24.3, 26.0 
Age (years)       
 22–23 3616 33.2 31.7, 34.8  27.3 25.9, 28.8 
 24–25 3858 33.1 31.6, 34.6  25.1 23.8, 26.5 
 26–27 2197 33.0 31.0, 34.9  21.6 19.9, 23.3 
Highest education       
 Less than high school 1050 27.8 25.1, 30.5  26.5 23.8, 29.2 
 High school/trade certificate 2541 30.9 29.1, 32.7  27.0 25.3, 28.7 
 Diploma or higher 5734 35.1 33.9, 36.4  24.0 22.9, 25.1 
Marital status       
 Single 5132 35.2 33.9, 36.5  27.4 26.2, 28.6 
 Married/defacto 4346 30.7 29.3, 32.0  22.7 21.4, 23.9 
 Separate/divorced/widowed 145 31.7 24.2, 39.3  20.7 14.1, 27.3 
Employment status       
 Unemployed 5627 35.1 33.8, 36.3  27.3 26.1, 28.5 
 Employed 3914 30.7 29.2, 32.1  22.0 20.7, 23.3 
BMI (kg/m2)       
 Underweight (<18.5) 585 36.6 32.7, 40.5  30.4 26.7, 34.2 
 Normal weight (18.5 to <25) 5469 35.3 34.0, 36.6  24.3 23.2, 25.5 
 Overweight (25 to <30) 1719 32.5 30.3, 34.7  26.5 24.4, 28.6 
 Obese (≥30) 926 32.8 29.8, 35.9  28.1 25.2, 31.0 
Smoking status       
 Never-smoker 5510 31.4 30.5, 32.6  23.0 21.9, 24.1 
 Ex-smoker 1386 33.9 31.4, 36.4  25.3 23.0, 27.6 
 Smoker <10 cigarettes/day  1388 37.7 35.1, 40.2  27.2 24.8, 29.5 
 Smoker 10–19 cigarettes/day 855 35.1 31.9, 38.3  31.6 28.5, 34.7 
 Smoker ≥20 cigarettes/day 452 34.3 29.9, 38.7  32.7 28.4, 37.1 
Alcohol consumption       
 None/rarely 3650 29.7 28.2, 31.2  25.8 24.3, 27.2 
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 Sample PMS  Dysmenorrhea 
 N* % 95% CI  % 95% CI 
 Low-risk drinking 5593 34.9 33.7, 36.2  24.4 23.3, 25.5 
 Risky/high-risk drinking 363 38.6 33.6, 43.6  29.8 25.1, 34.5 
Illicit drug use       
 Never 3404 28.0 26.5, 29.5  23.6 22.2, 25.0 
 Yes, not in last 12 months 2092 32.5 30.5, 34.5  23.6 21.7, 25.4 
 Used in last 12 months 4006 38.0 36.5, 39.5  27.1 25.8, 28.5 
Physical activity       
 Sedentary 989 30.1 27.3, 33.0  25.8 23.1, 28.5 
 Low 4129 33.6 32.2, 35.1  24.5 23.2, 25.8 
 Moderate 2202 34.7 32.7, 36.7  25.2 23.4, 27.0 
 High 2101 32.5 30.5, 34.5  26.3 24.4, 28.2 
Area of residence       
 Urban 5301 36.4 35.1, 37.7  26.1 24.9, 27.3 
 Rural 3962 29.1 27.7, 30.5  24.1 22.8, 25.5 
 Remote 366 30.3 25.6, 35.0  22.7 18.4, 27.0 
Contraception use       
 Not use 2231 31.7 29.8, 33.6  29.5 27.6, 31.3 
 OCPs 5347 32.2 31.0, 33.5  20.8 19.7, 21.9 
 Others 1954 37.6 35.5, 39.8  31.7 29.6, 33.7 
Number of births       
 0 7933 35.4 34.4, 36.5  26.2 25.2, 27.1 
 1 1047 23.0 20.5, 25.6  21.8 19.3, 24.3 
 2 or more 670 20.9 17.8, 24.0  17.9 15.0, 20.8 
Age at menarche (years)       
 8–11 252 37.0 34.4, 39.7  30.5 27.0, 33.0 
 12–14 8152 33.1 32.0, 34.2  24.4 23.4, 25.4 
 ≥15 1166 30.2 27.6, 32.8  24.1 21.6, 26.6 
* N varies for each characteristic due to missing value. 
The weighted prevalence for both conditions across surveys was relatively stable among 
this group of young women (Figure 4-1). Approximately 35% of the women reported PMS 
at age 22 to 27 years. The prevalence remained fairly constant over the first four surveys, 
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before a noticeable increase to 41% was seen when they were 34 to 39 years of age. The 
prevalence of dysmenorrhea decreased modestly over time from 26% at age 22 to 27 
years to 21% at age 31 to 36 years, before increasing to 23% at the time of last survey. 
Analysis excluding women who used OCPs, were pregnant or gave birth in the last 12 
months showed almost identical patterns in both outcomes, albeit a slightly higher 
prevalence, especially for dysmenorrhea when excluding OCP use in the earlier surveys, 
but the difference diminished as the women aged. 
 
Figure 4-1: Weighted prevalence of dysmenorrhea and PMS over time among the cohort of Australian women aged between 22 to 27 
years in 2000  
At the individual level, substantial variation in symptom status was observed for both PMS 
(Figure 4-2) and dysmenorrhea (Figure 4-3) over time among women with data from all 
five surveys. Overall 30% and 50% of the women were free from PMS and dysmenorrhea, 
respectively. Among women reporting the conditions, similar patterns of change were seen 
for both PMS and dysmenorrhea. A small group of women reported the respective 
conditions consistently in all five surveys, approximately 7% (19% among baseline cases) 
for PMS and 3% (13% among baseline cases) for dysmenorrhea. A second group of 
women who experienced the conditions at baseline achieved full remission in the 
subsequent surveys, accounting for 5% of the women with PMS and 6% with 
dysmenorrhea. However, a larger group of women reported the conditions intermittently, 
compromising 23% of women with PMS and 16% with dysmenorrhea. New cases 
occurred in each subsequent survey among women who did not previously report the 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
2000
 Age    22‐27y
PMS    n=9671
Dysm  n=9671
2003
25‐30y
9056
9056
2006
28‐33y
9043
9056
2009
31‐36y
8084
8077
2012
34‐39y
7949
7958
Dysmenorrhea
PMS
78 
respective conditions, varying from 6% to15% for PMS and 4% to10% for dysmenorrhea. 
Likewise, these new cases displayed similar patterns of variation in the follow-up surveys. 
The probability of reporting PMS or dysmenorrhea at Survey 6, given prior symptom status 
in the three previous surveys, are presented in Table 4-2. For PMS, the probability of 
reporting the condition at Survey 6 was 0.18 if the women did not experience PMS 
previously. It increased substantially among women who experienced PMS in any of the 
three previous surveys, with the highest being 0.75 among women reporting it in all three 
previous surveys. Similar patterns were seen for the probability of reporting dysmenorrhea 
at Survey 6; although, overall lower probabilities were observed. The probability was 0.10 
among women who did not report dysmenorrhea previously, with the highest being 0.70 
among women presenting dysmenorrhea in all three previous surveys.  
Table 4-2. Probability of reporting dysmenorrhea and PMS status in Survey 6 in 2012 by the presence of the respective conditions in 
previous survey(s) 
Survey(s) with women 
presenting condition 
PMS  Dysmenorrhea 
Probability 95% CI  Probability 95% CI 
None 0.179 0.169, 0.189  0.097 0.091, 0.104 
3 0.279 0.260, 0.299  0.168 0.151, 0.186 
4 0.326 0.304, 0.349  0.217 0.196, 0.240 
5 0.428 0.405,0.451  0.325 0.300, 0.352 
3 & 4 0.462 0.438, 0.487  0.342 0.314, 0.372 
3 & 5 0.571 0.543, 0.597  0.475 0.439, 0.511 
4 & 5 0.625 0.600, 0.649  0.554 0.521, 0.586 
3, 4 & 5 0.747 0.729, 0.764  0.700 0.676, 0.723 
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Figure 4-2: Changes of PMS status among the cohort of Australian women in the five surveys from 2000 to 2012. Each stacked bar 
represents a single survey, and green represents absence of symptom and purple represents presence of symptom in the past 12 
months. 
 
Figure 4-3: Changes of dysmenorrhea status among the cohort of Australian women in the five surveys from 2000 to 2012. Each stacked 
bar represents a single survey, and green represents absence of symptom and purple represents presence of symptom in the past 12 
months.  
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Applying latent class analysis to predict symptom trajectories, a four-group model was 
found to best fit the data for both PMS and dysmenorrhea. Trajectories of PMS are 
presented in Figure 4-4, with probability of reporting PMS by age displayed. OCP use, 
pregnancy and/or giving birth in the past 12 months showed minimum impact on group 
assignment. Overall, nearly 80% of women reported PMS at some point during the survey 
period. The ‘normative’ group, consisting of 22% of women, was characterised by 
negligible symptom throughout the period. A similar proportion (22%) of women formed the 
‘late onset’ group, defined by an increasing probability over time. When the women were 
aged 22 to 27 years, only about 10% reported PMS and the probability steadily increased 
approaching 60% when they were 34 to 37 years of age. The ‘recovering’ group included 
27% of women defined by a steadily declining probability over time, with approximately 45% 
of them at age 22 to 27 years and just over 10% at age 34 to 39 years having PMS. Lastly, 
approximately 30% of women comprised the ‘chronic’ group with a high probability of 70% 
to 80% for PMS observed throughout the survey period. 
Similarly, four-group trajectories were found for dysmenorrhea (Figure 4-5). The model 
including OCP use, pregnancy and/or giving birth in the past 12 months as time-varying 
covariates was chosen due to their impact on the trajectory. Overall, approximately 60% of 
women reported dysmenorrhea some time during the study period. The ‘normative’ group 
included 38% of women defined by no or few symptoms throughout the study period. The 
‘low’ group comprised of 28% of women characterised by a moderately increasing 
probability of reporting dysmenorrhea over time, from approximately 10% to nearly 40%. 
The ‘recovering’ group consisted of 17% of women who were defined by a decreasing 
probability of dysmenorrhea from approximately 50% at age 22 to 27 years to only 10% at 
age 34 to 39 years. Finally, a ‘chronic’ group consisted of 17% of women characterised by 
a high probability of dysmenorrhea of between 70% to 80% throughout the study period.  
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Figure 4-4: Trajectories of PMS for the cohort of Australian women from year 2000 (Survey 2) to 2012 (Survey 6)  
 
Figure 4-5: Trajectories of dysmenorrhea for the cohort of Australian women from year 2000 (Survey 2) to 2012 (Survey 6)  
When comparing trajectory group characteristics at baseline (Table 4-3), women in the 
chronic group for both PMS and dysmenorrhea were more likely to be unemployed and 
smoking, to start smoking earlier and to have an early menarche age; whereas women in 
the normative group were more likely to be married and use OCPs. For PMS, women in 
the chronic group were more likely to use illicit drugs in the last 12 months and, for 
dysmenorrhea, were more likely to be obese and have less education. 
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Table 4-3. Group characteristics among the women at baseline in year 2000, Australiaa 
 Nb PMS  Dysmenorrhea 
  Normative 
(22.1%) 
Late onset 
(21.9%) 
Recovering 
(26.5%) 
Chronic 
(29.5%) 
 Normative 
(38.3%) 
Low 
(28.0%) 
Recovering 
(17.2%) 
Chronic 
(16.5%) 
Age (years)           
 <24 2,974 32.6 15.1 23.3 29.1  51.2 17.8 15.5 15.5 
 24–25 3,220 33.1 15.8 20.4 30.7  53.1 18.9 13.3 14.7 
 ≥26 1,837 30.2 16.8 21.0 32.1  53.6 19.5 11.9 15.0 
Highest education           
 Less than high school 749 34.6 15.5 20.0 29.9  47.7 20.2 14.6 17.6 
 High school/trade certificate 2,039 32.6 15.4 20.8 31.3  48.6 19.0 15.6 16.8 
 Diploma or higher 4,992 31.7 15.8 22.3 30.1  55.1 18.1 12.9 13.9 
Marital status           
 Single 4,243 32.1 14.7 22.4 30.8  51.4 18.1 14.7 15.7 
 Married/defacto 3,649 32.6 17.0 20.4 30.0  53.9 19.2 12.8 14.1 
 Separate/divorced/widowed 104 24.3 16.5 31.1 28.2  48.1 22.1 13.5 16.4 
Employment status           
 Unemployed 3,345 34.2 16.6 21.9 27.2  56.7 17.9 13.0 12.4 
 Employed 4,610 30.7 15.1 21.5 32.8  49.1 19.3 14.6 17.0 
BMI (kg/m2)           
 Underweight (<18.5) 481 34.0 12.9 21.7 31.5  51.8 17.7 16.4 18.1 
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 Nb PMS  Dysmenorrhea 
  Normative 
(22.1%) 
Late onset 
(21.9%) 
Recovering 
(26.5%) 
Chronic 
(29.5%) 
 Normative 
(38.3%) 
Low 
(28.0%) 
Recovering 
(17.2%) 
Chronic 
(16.5%) 
 Normal weight (18.5 to <25) 4,662 31.9 15.5 22.4 30.2  54.4 18.0 13.9 13.8 
 Overweight (25 to <30) 1,463 30.4 16.6 22.1 30.9  49.4 20.0 14.8 15.8 
 Obese (≥30) 768 31.6 13.4 21.2 33.7  47.9 20.6 12.4 19.1 
Smoking status           
 Never-smoker 4,728 34.5 16.1 21.5 27.9  56.0 17.5 13.2 13.4 
 Ex-smoker 1,135 29.5 14.6 21.1 34.9  48.2 21.7 13.5 16.7 
 Smoker <10 cigarettes/day  1,131 27.7 16.2 21.8 34.4  48.7 20.0 13.5 17.8 
 Smoker 10–19 cigarettes/day 653 30.7 14.7 22.0 32.6  45.3 19.5 16.1 19.1 
 Smoker ≥20 cigarettes/day 323 28.5 16.1 22.3 33.1  45.8 17.3 21.1 15.8 
Age started smoking           
 Non-smoker 4,901 34.7 15.7 21.0 28.6  56.3 17.3 12.7 13.8 
 Age started smoking ≤15 years 1,816 29.0 16.2 19.2 35.6  46.5 19.9 15.0 18.6 
 Age started smoking >15 years 1,871 31.7 15.3 21.8 31.2  50.8 19.0 13.0 17.2 
Alcohol consumption           
 None/rarely 2,919 33.3 15.8 20.2 30.8  50.9 19.4 14.0 15.7 
 Low-risk drinking 4,783 32.1 15.9 22.2 29.9  54.1 17.9 13.6 14.5 
 Risky/high-risk drinking 282 25.2 14.5 26.6 33.7  44.3 24.1 15.6 16.0 
Illicit drug use           
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 Nb PMS  Dysmenorrhea 
  Normative 
(22.1%) 
Late onset 
(21.9%) 
Recovering 
(26.5%) 
Chronic 
(29.5%) 
 Normative 
(38.3%) 
Low 
(28.0%) 
Recovering 
(17.2%) 
Chronic 
(16.5%) 
 Never 2,850 37.7 15.6 20.1 26.7  54.7 18.0 13.9 13.3 
 Yes, not in last 12 months 1,738 31.0 18.0 21.2 29.8  53.2 18.4 13.8 14.7 
 Used in last 12 months 3,327 28.0 14.6 23.3 34.1  49.6 16.7 14.0 16.8 
OCPs           
 No 3,368 28.8 14.9 21.3 35.0  46.7 20.1 15.8 17.4 
 Yes  4,562 34.6 16.3 21.9 27.2  55.8 17.9 12.6 13.6 
Number of births           
 0 6,665 31.9 15.5 22.3 30.3  52.9 18.2 14.0 14.9 
 1 825 33.9 17.6 18.7 29.8  51.4 20.5 11.8 16.4 
 ≥2 535 33.9 16.9 17.0 32.2  49.7 20.8 14.8 14.8 
Age at menarche (years)           
 8–11 1,061 32.3 15.5 21.7 30.6  44.6 20.4 16.1 18.9 
 12–14 5,961 27.0 16.3 22.2 34.5  53.6 18.5 13.3 14.6 
 ≥15 950 36.5 16.8 20.5 26.2  55.0 17.1 14.5 13.5 
a The percentage may not added up to 100% due to rounding. 
b Total number of women varies due to missing values. 
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4.1.4 Discussion	
This descriptive population-based study showed that a considerable proportion of women 
reported PMS and dysmenorrhea throughout their reproductive years, with over a third 
suffering from PMS and approximately a quarter suffering from dysmenorrhea at any 
survey point. The prevalence of dysmenorrhea confirms the findings from a recent review 
of longitudinal and community-based studies reporting 2% to 28% severe pain in adult 
women [6], but is higher than the 12% to 14% reported from an earlier review of 
community-based United Kingdom studies including women of any age [45]. The reported 
prevalence of PMS in the literature varies widely due to different diagnostic criteria used [9, 
13]. As premenstrual tension is the clustering of more severe premenstrual symptoms [86], 
our findings of 33% to 41% are in line with the range of 20% to 40% of moderate-severe 
cases reported in a previous review [6] and findings from other longitudinal studies [26, 
128]. 
The findings from earlier cross-sectional studies on the association between age and PMS 
are inconsistent, despite some agreement that the prevalence of PMS peaks around 35 
years of age [21, 143]. This was not supported by our findings, which shows the 
prevalence increased after 33 years of age from a combined data analysis according to 
women’s age (results in Appendix C). The observed pattern of change for dysmenorrhea 
found in this study confirms those from limited earlier longitudinal studies, indicating that 
dysmenorrhea is a symptom during reproductive years with a declining prevalence with 
age [11, 55].  
Contrary to the stable prevalence at the population level, considerable variation in the 
presence of both conditions at an individual level was exhibited. Among women who 
presented with the respective conditions either at baseline or developed them over time, 
only a small group consistently reported them at follow-up while the majority reported them 
intermittently. The findings support a previous longitudinal study [11] demonstrating that 
improvement in dysmenorrhea with age (or parity) is not universal, with many women 
experiencing unchanged or worse symptoms over time. Consistent with our finding, 
previous studies also reported intra-individual variation in PMS status over time, with the 
vast majority of women experiencing fluctuation in the presence and/or severity of the 
condition [25, 26]. 
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This study took a unique approach to investigate the trajectories of PMS and 
dysmenorrhea, revealing four distinct subgroups of women for both conditions. With 
replication in further longitudinal studies, the results may inform and enable clinicians and 
women alike to anticipate the likelihood of the course of these conditions over time. Overall, 
80% of women in our study experienced PMS at some stage during their reproductive life 
with one-third likely to report PMS over time, but nearly 40% of women were symptom-free 
from dysmenorrhea throughout the study period. This implies a greater disease burden 
can be anticipated from PMS, which in turn can inform healthcare providers caring for 
these women in their service planning. Clinicians consulting women with menstrual 
problems who repeatedly present with PMS should be aware that there is an over 70% 
probability that these women will experience the condition at follow-up visits, resulting in 
long-lasting complaints. For women who present with dysmenorrhea, however, some 
assurance can be given that only a small group will continuously experience the symptom 
in the following years. Comparison of profiles for different trajectory groups revealed that 
smoking and illicit drug use were more common among women with persistent PMS, and 
smoking and obesity in persistent dysmenorrhea. Further evidence from longitudinal 
studies to ascertain and quantify the associations of these risk factors would be beneficial 
for healthcare professionals to accurately advise women on their most likely trajectories. 
Strengths and limitations  
This prospective longitudinal study followed the same women over 13 years, providing a 
unique opportunity to study the trend of PMS and dysmenorrhea as women age and to 
elucidate within–women variability. Most importantly, through trajectory analyses, this 
study identified symptom profiles for both PMS and dysmenorrhea which provides 
potentially valuable information on subgroups of women who followed similar courses of 
the conditions, thus may facilitate better identification of risk factors. Furthermore, results 
from this large study with a nationally representative sample are likely to reflect the true 
estimate of the symptoms in the population.  
Despite these strengths, there are a number of limitations of this study. First, all the data 
are self-reported, which may be subject to reporting bias. Given the lack of well-defined 
objective diagnostic tools and models for assessing most menstrual conditions, primary 
care professionals rely on individual subjective working models in practice, even for the 
better defined menstrual disorders such as menorrhagia [170]. Coupled with the 
longitudinal nature and large size of the study, self-report may be reasonable and is the 
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most feasible means of data collection. Second, prospective daily symptom ratings were 
not obtained, and data over the past 12 months were collected retrospectively at each 
survey wave. This may subject the data to recall bias. However, daily symptom reporting 
over an extended evaluation period is not widely adopted even in clinical practice [5, 8] 
and would be less practical in this population setting. The long period of observation and 
repeated measures may also offset the disadvantage of the absence of daily rating. Third, 
no specific diagnostic criteria for PMS and dysmenorrhea were used apart from the survey 
question, which may raise the question of the reliability of the data and limit the ability to 
compare our results with those of others. However, premenstrual tension is a widely used 
term in both clinical settings and in the media in Australia (personal communication with 
local specialist); therefore, using the questionnaire to ascertain PMS and dysmenorrhea 
status is unlikely to impact substantially on the reliability of our data. Furthermore, currently 
there is no single universally accepted criterion adopted for either condition, especially in 
clinical practice, resulting in the variation of prevalence reported in the literature. 
In addition, a high attrition (32%) occurred at Survey 2 among this young cohort, with the 
sample size remaining relatively stable thereafter. Comparison between responders and 
non-responders of the prevalence of PMS (39.8% vs 41.4%) and dysmenorrhea (44.6% vs 
42.8%) at Survey 1 showed no evidence of differential drop-out, indicating the random 
nature of attrition for the outcomes of interest. Previous study has also investigated the 
nature of this attrition and its impact, revealing that this attrition is more likely to be 
temporary with almost half of the women being consistent respondents [40]. Despite this 
attrition being related to smoking and poorer general and mental health, no serious bias 
was introduced to preclude meaningful longitudinal analyses of the data. 
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4.2 Impact of dysmenorrhea and PMS on quality‐of‐life 
As indicated previously, this exploratory analysis aims to provide some indication of the 
burden of the conditions on affected women as measured by self-reported SF-36 
responses. Using ALSWH data from Surveys 2 to 6, SF-36 physical health component 
summary scores (PCS) and mental health component summary scores (MCS) were 
compared using paired t-test between the women with and without the conditions. 
Following this, regression analysis was performed to investigate the longitudinal 
association between SF-36 scores and dysmenorrhea or PMS, separately, over time using 
GEE to account for the repeated measures of variables. Univariate analysis was first 
conducted to examine the crude association. Multivariable-adjusted analysis was then 
performed to control for known predictors of SF-36 scores, such as age, education, area of 
residence, BMI, smoking status, and physical activity. 
The analyses revealed that, compared with women without dysmenorrhea, women who 
reported dysmenorrhea had significantly lower scores in both PCS and MCS as measured 
by SF-36 (p <0.0001) consistently across all five surveys (Table 4-4). However, a larger 
difference of three to four points in MCS between women with and without dysmenorrhea 
was reported as compared with one to two points in PCS. Among women who reported 
PMS, significantly lower scores of around four to five points was reported for MCS only, 
and no difference in PCS was found. 
Table 4-4: Summary physical and mental component summary scores* based on SF-36 by symptom status 
Condition Survey 2 Survey 3 Survey 4 Survey 5 Survey 6 
Physical health_Physical Component Summary score (PCS) 
Dysmenorrhea p <0.0001 p <0.0001 p <0.0001 p <0.0001 p <0.0001 
 No 53.3 ± 7.5 53.0 ± 7.8 52.8 ± 7.7 52.4 ± 8.0 52.2 ± 8.0 
 Yes 51.5 ± 8.3 51.2 ± 8.5 50.8 ± 8.8 50.8 ± 9.1 50.5 ±9 .0 
PMS p = 0.56 p = 0.07 p = 0.47 p = 0.81 p = 0.54 
 No 52.9 ± 7.8 52.5 ± 8.0 52.3 ± 8.0 52.1 ± 8.2 51.8 ± 8.3 
 Yes 52.8 ± 7.8 52.8 ± 7.9 52.2 ± 8.1 52.1 ± 8.4 51.9 ± 8.3 
Mental health_Mental Component Summary score (MCS) 
Dysmenorrhea p <0.0001 p <0.0001 p <0.0001 p <0.0001 p <0.0001 
 No 44.8 ± 11.0 45.8 ± 10.9 47.0 ± 10.4 47.1 ± 10.4 47.5 ± 10.3 
 Yes 40.8 ± 12.0 42.1 ± 12.0 42.9 ± 11.9 43.1 ± 12.1 43.5 ± 11.6 
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Condition Survey 2 Survey 3 Survey 4 Survey 5 Survey 6 
PMS p <0.0001 p <0.0001 p <0.0001 p <0.0001 p <0.0001 
 No 45.3 ± 11.0 46.5 ± 10.7 47.6 ± 10.2 47.7 ± 103 48.3 ± 9.9 
 Yes 40.8 ± 11.7 41.8 ± 11.8 43.0 ± 11.6 43.4 ± 11.5 44.0 ± 11.3 
* The scores are standardised against the entire Australian adult population. 
The results from the longitudinal regression analysis are presented in Table 4-5. The 
univariate analysis showed an inverse association between dysmenorrhea and both 
physical and mental health among this group of women, whereas PMS was significantly 
associated with mental health only. Adjusting for known predictors of SF-36 scores had 
minimum impact on the estimates. Women with dysmenorrhea had a 1-point lower mean 
PCS compared with women without dysmenorrhea, whilst a bigger difference of 2.2 in 
MCS was revealed, favouring women without dysmenorrhea. Similarly, a significantly 
lower MCS was detected among women reporting PMS compared with women without 
PMS, with a mean difference of 2.9. However, a slightly higher, albeit statistically 
significant, PCS was revealed for women with PMS.  
Table 4-5: Univariate and multivariable-adjusted association from GEE between dysmenorrhea or PMS and summary SF-36 scores from 
2000 to 2012 among the 1973–78 cohort of the ALSWH (N = 9,207) 
SF-36 Univariate Multivariable-adjusted 
 Mean difference 95% CI Mean difference 95% CI 
PCS     
Dysmenorrhea -1.03 -1.25, -0.81 -1.00 -1.21, -0.79 
PMS 0.34 0.16, 0.52 0.29 0.11, 0.46 
MCS     
Dysmenorrhea -2.29 -2.58, -2.00 -2.16 -2.45, -1.87 
PMS -2.94 -3.18, -2.69 -2.90 -3.15, -2.66 
Multivariable-adjusted includes known predictors of SF-36 scores such as age, education, area of residence, BMI, smoking status, physical activity 
The findings from this research generally support previous literature that shows menstrual 
disorders impact on women’s quality-of-life [1, 141, 171, 172], with some discrepancies 
revealed. Significantly worse physical and mental health was consistently reported by 
women with dysmenorrhea over the five surveys after adjusting for known predictors of 
SF-36 scores, contrasting with previous studies which failed to show worse mental health 
for women with dysmenorrhea [172, 173]. On the other hand, these findings are consistent 
with previous literature that reported a stronger association between PMS and mental 
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health. However, a smaller mean difference of about three points was detected between 
women with and without PMS compared with a difference of 5 to 12 points previously 
reported. Although there is no clear discussion on the cut-offs for clinically meaningful 
differences in the scores, these differences have been shown to be comparable to those 
for other chronic diseases such as asthma, congestive heart failure, chronic lung disease, 
irritable bowel syndrome, and other mood disorders [171, 174]. It is not clear if any known 
predictors of SF-36 scores or comorbidities have been adjusted for in the previous studies 
and that the women included in the previous studies might be a group who reported more 
symptoms of or more frequent cycles with PMS [171, 174]. Nevertheless, the differences 
detected among this cohort of ALSWH women appear to be smaller than some of those 
reported in the literature. Despite the statistical significance of these differences, their 
clinical meaningfulness would need to be further discussed.  
Unlike previous findings which show worse mental and physical health for women with 
PMS [1, 141, 171], only worse mental health was detected for women with PMS in this 
research, whereas no meaningful difference in physical health was obvious between 
women with and without PMS. Some potential explanations for the discrepancies between 
this research and previous findings might be the design of the survey questionnaire. For 
example, the question for PMS asked about premenstrual tension, which has an apparent 
emphasis on the mental component of the syndrome [87]. This may explain the more 
profound difference detected in the mental health summary score. For dysmenorrhea, on 
the other hand, the question regarding dysmenorrhea asked about severe period pain: the 
cyclical occurrence of the severe pain might have a psychological impact on women apart 
from physical impairment. Alternatively, the observed associations might be confounded 
by other comorbidities which may also impact on their HRQoL.  
In summary, a considerable proportion of young Australian women reported dysmenorrhea 
and PMS throughout their reproductive years. Both dysmenorrhea and PMS impact on 
women’s quality-of-life as measured by the SF-36 in this group of women. Dysmenorrhea 
had a moderate impact on both physical and mental health of the women affected, 
whereas PMS predominantly influenced women’s mental health. More in-depth 
comparison of the impairment of the conditions on women’s daily activities is needed, 
taking into account the frequency of symptoms and other comorbidities, which is an 
interesting area for future studies. Furthermore, future research should focus on the 
individual domains of SF-36 and try to establish clinical meaningful differences in the 
scores among women with or without the menstrual conditions investigated. 
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Chapter 5. Population-level risk factors identification 
in ALSWH 
5.1 Introduction 
As highlighted in the literature reviews in Chapter 3, the evidence about the relationship 
between most lifestyle risk factors and dysmenorrhea or PMS is largely mixed or limited, 
especially from longitudinal studies. Given the large population-based sample and the 
longitudinal nature, ALSWH provides a unique opportunity to study the associations 
between a range of modifiable lifestyle risk factors, particularly time-varying risk factors, 
and the presence of dysmenorrhea or PMS over time. A target group of lifestyle risk 
factors has been previously identified that are of public health significance in Australia 
(Chapter 1) and that have showed uncertain associations with either dysmenorrhea or 
PMS (Chapter 3). The main aim of this exploratory analysis is to select significant risk 
factors, from the target lifestyle risks, in the ALSWH population for further in-depth 
analyses in the following chapters.  
5.2 Methods 
As described in Chapter 1, two sources were used in identifying target modifiable lifestyle 
factors to be investigated in this thesis ─ literature reviews and the Australian burden of 
disease and injury study [27]. There appeared to be a high concordance from the two 
sources in identifying a group of modifiable lifestyle factors, namely BMI, smoking, alcohol 
consumption, illicit drug use, and dietary factors, which are leading contributors to health 
loss at the population level in Australia. In addition, there is limited number of longitudinal 
studies which have examined their associations with both dysmenorrhea and PMS/PMDD. 
As a result, with the exception of dietary factors (reason specified in Chapter 1.2), the 
other lifestyle factors were identified as main exposure of interests in this thesis. 
In this exploratory analysis, a longitudinal logistic regression method was applied, taking 
into account the repeated measures of variables using GEE. The associations between 
modifiable lifestyle risk factors, as exposure variables, and dysmenorrhea or PMS were 
investigated separately, at population level. The associations of interest were examined 
after taking into account the effect of a range of other sociodemographic, lifestyle, 
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reproductive and psychological factors, sequentially entered into the models as blocks of 
variables. First, univariate analysis was conducted to identify exposure variables that were 
statistically significantly associated with dysmenorrhea or PMS. Then those significant 
exposure variables identified were entered into multivariable-adjusted models. Statistical 
significance was set at p <0.05. 
As stated in Chapter 2, due to significant over-reporting of both dysmenorrhea and PMS, 
Survey 1 was not included in this analysis. Baseline data were sourced from Survey 2. The 
details of categorisation of both outcome and exposure variables have been reported in 
Chapter 2 and are not repeated here.  
5.3 Results 
The results are presented in Table 5-1.  
Dysmenorrhea. All exposure variables, except area of residence and physical activity, 
were significantly related to the odds of reporting dysmenorrhea and, therefore, were 
included in the multivariable-adjusted analysis. The final model showed that, compared 
with those who had less than high school education, women who had diploma or higher 
education were significantly less likely to report dysmenorrhea (OR 0.79, 95% CI: 0.70, 
0.89). Both OCP use and parity of one or more, compared with no OCP use and nulliparity 
respectively, showed significantly protective effects for dysmenorrhea with the odds 
varying between 0.49 to 0.63, after controlling for each other, as well as age. Compared 
with normal weight women, women who were underweight or obese had approximately 25% 
higher risk (ORs of 1.25 for underweight and 1.24 for obese) of reporting dysmenorrhea. 
Comparing women who had never smoked with those who smoked, a dose–response 
relationship was observed between smoking and dysmenorrhea, with the corresponding 
ORs of 1.21, 1.39, 1.47 and 1.68 for ex- and current smokers who smoked <10, 10 to 19 
and ≥20 cigarettes/day, respectively. Compared with age at menarche of 12 to 14 years, 
early menarche was significantly associated with an OR of 1.26 (95% CI: 1.14, 1.40) for 
reporting dysmenorrhea. Women who spoke a European language other than English, 
compared with those who spoke English, also showed a higher odds of reporting 
dysmenorrhea (OR 1.33, 95% CI: 1.13, 1.56). No associations were observed between 
dysmenorrhea and unemployment, illicit drug use or alcohol consumption after adjusting 
for other potential confounders. 
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Table 5-1: Univariate and multivariable-adjusted association (OR, 95% CI) between potential risk factors and dysmenorrhea or PMS from 
2000 to 2012 among the 1973–78 cohort from ALSWH from GEE* 
 Dysmenorrhea (N = 9,036) PMS (N = 8,921) 
 Univariate Multivariable-
adjusted 
Univariate Multivariable-
adjusted 
Age  0.97 (0.95, 0.99) 0.99 (0.96, 1.01) 1.02 (1.00, 1.04) 1.04 (1.01, 1.06) 
Highest education  p <0.0001 p <0.0001 p = 0.32 p = 0.92 
 Less than high school 1 1 1 1 
 High school/trade certificate 0.98 (0.86, 1.11) 0.96 (0.84, 1.09) 1.02 (0.91, 1.15) 1.01 (0.89, 1.14) 
 Diploma or higher 0.83 (0.74, 0.93) 0.80 (0.70, 0.90) 1.06 (0.95, 1.19) 1.02 (0.91, 1.14) 
Employment status p = 0.007 p = 0.37 ─ ─ 
 Employed 1 1   
 Unemployed 1.11 (1.03, 1.20) 1.04 (0.96, 1.12)   
Marital status  p <.0001 p = 0.28 p <0.0001 p = 0.21 
 Single 1 1 1 1 
 Married/defacto 0.80 (0.74, 0.84) 0.95 (0.88, 1.01) 0.86 (0.81, 0.92) 1.06 (0.99, 1.13) 
 Separate/divorced/widowed 0.83 (0.72, 0.96) 0.93 (0.81, 1.09) 0.93 (0.82, 1.05) 1.03 (0.90, 1.17) 
Coping with income  p <0.0001 p <0.0001 p = 0.003 p = 0.0001 
 Impossible 1.20 (0.98, 1.47) 1.23 (1.00, 1.51) 1.01 (0.84, 1.21) 0.99 (0.82, 1.20) 
 Difficult all the time 1.33 (1.21, 1.46) 1.39 (1.26, 1.54) 1.17 (1.07, 1.27) 1.18 (1.07, 1.28) 
 Difficult sometimes 1.15 (1.07, 1.24) 1.25 (1.15, 1.35) 1.10 (1.02, 1.17) 1.17 (1.09, 1.26) 
 Not too bad 1.01 (0.94, 1.08) 1.06 (0.99, 1.14) 1.03 (0.97, 1.10) 1.09 (1.02, 1.16) 
 Easy 1  1 1 
Area of residencea p  0.74 ─ p <.0001 p = 0.03 
 Urban 1  1 1 
 Rural 0.98 (0.91, 1.04)  0.87 (0.82, 0.92) 0.92 (0.87, 0.98) 
 Remote 0.97 (0.83, 1.14)  0.87 (0.75, 1.00) 0.93 (0.81, 1.08) 
Language spoken at home p = 0.0005 p = 0.003 p <0.0001 p = 0.001 
 English 1 1 1 1 
 European other than English 1.41 (1.20, 1.66) 1.33 (1.13, 1.56) 1.39 (1.21, 1.61) 1.31 (1.13, 1.52) 
 Asian 0.85 (0.62, 1.16) 0.80 (0.59, 1.10) 0.78 (0.58, 1.04) 0.79 (0.59, 1.06) 
 Other 1.28 (0.91, 1.81) 1.18 (0.81, 1.70) 0.91 (0.61, 1.34) 0.87 (0.58, 1.29) 
BMI (kg/m2) p <0.0001 p <0.0001 p = 0.0002 p = 0.001 
 Underweight (<18.5) 1.27 (1.11, 1.44) 1.25 (1.09, 1.43) 1.21 (1.07, 1.36) 1.18 (1.04, 1.34) 
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 Dysmenorrhea (N = 9,036) PMS (N = 8,921) 
 Univariate Multivariable-
adjusted 
Univariate Multivariable-
adjusted 
 Normal weight (18.5 to <25) 1 1 1 1 
 Overweight (25 to <30) 0.99 (0.93, 1.07) 0.97 (0.90, 1.04) 0.92 (0.87, 0.98) 0.91 (0.86, 0.97) 
 Obese (≥30) 1.29 (1.19, 1.41) 1.20 (1.10, 1.31) 1.01 (0.93, 1.09) 0.97 (0.89, 1.47) 
Smoking status p <0.0001 p <0.0001 p <0.0001 p = 0.09 
 Never-smoker 1 1 1 1 
 Ex-smoker 1.19 (1.10, 1.29) 1.20 (1.10, 1.30) 1.14 (1.07, 1.23) 1.06 (0.99, 1.15) 
 Smoker <10 cigarettes/day  1.46 (1.33, 1.61) 1.37 (1.24, 1.52) 1.30 (1.25, 1.49) 1.13 (1.03, 1.24) 
 Smoker 10–19 cigarettes/day 1.57 (1.40, 1.75) 1.43 (1.26, 1.61) 1.25 (1.12, 1.39) 1.03 (0.92, 1.16) 
 Smoker ≥20 cigarettes/da 1.74 (1.51, 2.01) 1.61 (1.38, 1.88) 1.20 (1.04, 1.39) 0.98 (0.84, 1.14) 
Physical activityb p = 0.26 ─ p = 0.08 ─ 
 Sedentary 1  1  
 Low 0.96 (0.89, 1.04)  0.98 (0.91, 1.05)  
 Moderate 0.99 (0.91, 1.09)  1.02 (0.95, 1.11)  
 High 1.03 (0.94, 1.13)  1.06 (0.97, 1.15)  
Alcohol consumption p = 0.006 p = 0.34 p <0.0001 p = 0.004 
 None/rarely 1 1 1 1 
 Low-risk drinking 1.00 (0.94, 1.06) 0.98 (0.92, 1.04) 1.17 (1.11, 1.23) 1.10 (1.03, 1.16) 
 Risky/high-risk drinking 1.24 (1.09, 1.42) 1.07 (0.93, 1.24) 1.40 (1.24, 1.59) 1.14 (1.00, 1.30) 
Illicit drug use (n = 8921) p <0.0001 p = 0.52 p <0.0001 p <0.0001 
 Never 1 1 1 1 
 Not in last 12 months 1.03 (0.96, 1.10) 0.97 (0.90, 1.04) 1.13 (1.06, 1.20) 1.06 (1.00, 1.14) 
 Used in last 12 months 1.21 (1.12, 1.31) 1.01 (0.92, 1.10) 1.49 (1.39, 1.60) 1.28 (1.18, 1.38) 
OCPs (n = 7,930) p <0.0001 p <0.0001 p <0.0001 p <0.0001 
 Not use 1 1 1 1 
 Used 0.68 (0.64, 0.72) 0.63 (0.60, 0.67) 0.87 (0.83, 0.91) 0.82 (0.78, 0.86) 
Number of births p <0.0001 p <0.0001 p <0.0001 p <0.0001 
 0 1 1 1 1 
 1 0.54 (0.50, 0.59) 0.48 (0.44, 0.52) 0.48 (0.45, 0.52) 0.46 (0.42, 0.49) 
 ≥2 0.62 (0.57, 0.66) 0.55 (0.51, 0.60) 0.70 (0.65, 0.75) 0.67 (0.62, 0.72) 
Age at menarche (years) p <0.0001 p <0.0001 p <0.0001 p <0.0001 
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 Dysmenorrhea (N = 9,036) PMS (N = 8,921) 
 Univariate Multivariable-
adjusted 
Univariate Multivariable-
adjusted 
 8–11 1.32 (1.20, 1.46) 1.25 (1.13, 1.39) 1.20 (1.10, 1.31) 1.19 (1.09, 1.31) 
 12–14 1 1 1 1 
 ≥15 0.91 (0.81, 1.02) 0.90 (0.80, 1.01) 0.87 (0.79, 0.96) 0.85 (0.77, 0.94) 
Endometriosis  p <0.0001 p <0.0001 ─ ─ 
 No 1 1   
 Yes 3.04 (2.67, 3.46) 3.13 (2.74, 3.57)   
History of abuse  ─ ─ p <0.0001 p <0.0001 
 Yes   1.44 (1.35, 1.53) 1.31 (1.23, 1.41) 
 No   1 1 
 Don’t want to answer   1.04 (0.83, 1.29) 0.97 (0.78, 1.22) 
Depressed  ─ ─ p <0.0001 p <0.0001 
 No   1 1 
 Yes   1.54 (1.46, 1.62) 1.47 (1.39, 1.56) 
a n = 9,029 for dysmenorrhea 
b n = 9,000 for dysmenorrhea and 8,885 for PMS  
PMS. The univariate analysis did not show any significant association between education 
and physical activity with PMS. However, education was included in the multivariable-
adjusted models as it has been shown as a risk factor in previous literature [113, 120, 141]. 
The final model revealed that education and marital status were not associated with the 
presence of PMS. However, compared with women who spoke English, women who 
spoke a European language other than English at home had an OR of 1.31 for reporting 
PMS. The relationship between smoking and PMS was not consistent, with current 
smokers who smoked <10 cigarettes per day showing a slightly higher odds of reporting 
PMS (OR 1.13, 95% CI: 1.03, 1.24), whereas heavier smokers (≥10 cigarettes) did not 
show significant association with PMS. Similarly, an inconsistent relationship was shown 
between BMI and PMS. Compared with women who had a normal BMI, women who were 
underweight were 1.18 times as likely to report PMS (OR 1.18, 95% CI: 1.04, 1.34), 
whereas women who were overweight had a slightly lower odds of reporting PMS (OR 
0.91, 95% CI: 0.86, 0.97).Obesity, on the other hand, was not associated with PMS (OR 
0.97, 95% CI: 0.89, 1.47). Compared with women who had never used illicit drugs, women 
who currently used drugs demonstrated higher odds of reporting PMS (OR 1.28, 95% CI: 
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1.18, 1.38), whilst women who no longer used drugs did not show significant association. 
Women with a history of any type of abuse and who felt depressed were approximately 30% 
and 50% more likely to report PMS respectively. OCP use, parity of one or more, and late 
menarche all showed a protective effect on PMS; however, women with early age at 
menarche were more likely to report PMS. Although statistically significant, the 
associations between PMS and age and between PMS and area of residence were weak.  
5.4 Discussion 
The aim of this exploratory analysis was to identify potential modifiable lifestyle risks for 
dysmenorrhea or PMS in ALSWH population for further analysis. During this process, the 
Australian Burden of Disease and Injury Study [27] was consulted in prioritising potential 
risk factors. As discussed in Chapter 1, high body mass, physical inactivity, tobacco use, 
alcohol and illicit drug use were identified as leading contributors to health loss related to a 
range of causes in that study. Given the significance of these risk factors at the population 
level, they were targeted as the potential exposure variables in this current research.  
The results from this exploratory analysis showed that, among the identified targeted 
lifestyle risk factors attributable to a large proportion of health loss in Australia in 2003 [27], 
both smoking and high body mass were strongly associated with dysmenorrhea, whereas 
only illicit drug use showed a strong relationship with PMS in the ALSWH population. 
Physical activity was not significantly associated with either dysmenorrhea or PMS. The 
unadjusted association between alcohol consumption and both dysmenorrhea and PMS 
largely disappeared after controlling for other variables including smoking and illicit drug 
use, suggesting their potential confounding effect given the tendency for their combined 
use as a cluster. In addition, smoking and high body mass did not show consistent 
association with PMS in the adjusted analysis among this group of women. These results 
are generally in line with the findings from the literature reviews reported in Chapter 3, 
which showed that physical activity and alcohol consumption have no significant 
relationship with dysmenorrhea, but uncertainties surround the association between 
dysmenorrhea and smoking, obesity and diet [6]. No study was identified that investigated 
the association between illicit drug use and dysmenorrhea. Furthermore, most previous 
studies also failed to demonstrate a significant association between PMS and physical 
activity or alcohol consumption [123, 125, 126], whereas mixed results were yielded for the 
association between PMS and smoking [22, 26, 118, 126, 133, 150] or BMI [25, 120, 135, 
142]. Sparse evidence was identified for the relationship between illicit drug use and PMS. 
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Therefore, the associations between dysmenorrhea and smoking (Chapter 6) and BMI 
(Chapter 8), and the association between PMS and illicit drug use (Chapter 7) were further 
investigated as presented over the next three chapters. 
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Chapter 6. Cigarette smoking and trajectories of 
dysmenorrhea (Paper 3) 
As cigarette smoking was shown to be one of the significant lifestyle risk factors 
associated with dysmenorrhea in the ALSWH population, the relationship is investigated in 
more detail. In this chapter a paper is presented that shows how baseline smoking status 
and the age at initiation of smoking influences trajectories of dysmenorrhea over time. The 
paper was published in the peer-reviewed journal Tobacco Control in 2014.  
Prior to publication, the paper was chosen by BMJ for a press release to over 5000 
recipients worldwide under embargo (details in Appendix D). Following the publication, a 
media release was also issued by The University of Queensland (Appendix E). These 
have generated great interest from numerous print and internet journalists. Response to 
the publication has been very positive. According to Altmetric score, which is one measure 
of the quality and quantity of online attention that an article receives, this article has done 
particularly well and is in the 97th percentile compared with over three million articles 
across all journals ever tracked by Altmetric, putting it in the top 5% of all articles. 
Ju H, Jones M, Mishra GD. Smoking and trajectories of dysmenorrhoea among young 
Australian women. Tobacco Control. 2016;25:195-202 Published Online First:  17 Nov 
2014. doi:10.1136/tobaccocontrol-2014-051920. 
Website: http://tobaccocontrol.bmj.com/content/early/2014/10/28/tobaccocontrol-2014-
051920.abstract?sid=55c0bb75-c846-40aa-a0c3-97c8ec6afdeb 
Reproduced with permission of BMJ PUBLISHING GROUP LTD in the format Republish in 
a thesis/dissertation via Copyright Clearance Centre. 
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Abstract 
Objective: To investigate the association of cigarette smoking at baseline and trajectories 
of dysmenorrhea in a large sample of Australian women. 
Design: A prospective cohort study. 
Setting: Australian (population-based survey). 
Participants: A total of 9,067 young women, with at least three measures of dysmenorrhea, 
randomly sampled from the national Medicare database and followed up from 2000 to 
2012. 
Main outcome measures: Trajectories of dysmenorrhea.  
Results: At baseline, approximately 25% reported dysmenorrhea and 26% were current 
smokers. Four trajectory groups were identified for dysmenorrhea: normative (42%), late 
onset (11%), recovering (33%) and chronic (14%), with the chronic group showing high 
probabilities of reporting dysmenorrhea over time. Compared with never smokers, a 
significantly higher odds of being in the chronic group was detected for smokers, with ORs 
being 1.33 (95% CI: 1.05, 1.68) for ex-smokers and 1.41 (95% CI: 1.17, 1.70) for current 
smokers, after adjusting for socio-demographic, lifestyle and reproductive factors. An 
inverse relationship was identified for earlier age of smoking initiation, with the respective 
ORs of 1.59 (95% CI: 1.18, 2.15), 1.50 (95% CI: 1.18, 1.90) and 1.26 (95% CI: 1.03, 1.55) 
for initiation of smoking ≤13, 14 to 15 or ≥ 16 years. No consistent relationship was evident 
between smoking behaviour and the odds of being in the other trajectory groups.  
Conclusions: Smoking and early initiation of smoking are associated with increased risk of 
chronic dysmenorrhea. The immediate adverse health effects of smoking provide further 
support for smoking prevention programs to target young women especially teenagers. 
Key words: dysmenorrhea, menstrual pain, painful period, smoking, trajectory 
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6.1 Introduction 
Dysmenorrhea is a common gynaecological complaint, affecting up to 91% of women of 
reproductive age with 2% to 29% having severe pain [6]. As a debilitating condition, it has 
a major impact on health-related quality-of-life and social and occupational roles, resulting 
in significant work and school absences [1, 24]. Considerable economic losses due to 
dysmenorrhea were estimated resulting from costs of medications, medical care and 
decreased productivity [23]. 
Among the range of risk factors identified for dysmenorrhea in the literature, smoking was 
found to produce mixed results. There is some evidence that smoking increased the risk of 
dysmenorrhea [55, 175]. A dose-response relation was also observed for the risk of 
dysmenorrhea and the number of cigarettes smoked per day (smoking 10 to 30 cigarettes 
per day doubled the risk) and the duration of smoking (relative risk of 2.8 for duration of 10 
to 20 years) [57, 62]. Furthermore, women who smoked were shown to be more likely to 
have severe dysmenorrhea, and the severity increased with the number of cigarettes 
smoked per day [55]. However, some longitudinal evidence suggests that smoking was not 
associated with the probability of having pain, but among those with pain, smokers were 
1.5 times as likely to have pain lasting longer than two days [43]. This inconsistency is 
confirmed in a review that mainly examined findings from recent population-based cross-
sectional studies [6]. 
To date, few large longitudinal studies have investigated the association between smoking 
and patterns of dysmenorrhea over time. Most previous studies have examined the cross-
sectional association and treated the women as homogeneous groups either with or 
without the symptom at one time point, ignoring there may be subgroups of women with 
differing symptom patterns over time. This study investigates the association of cigarette 
smoking at baseline and trajectories of dysmenorrhea in a large sample of Australian 
women, focusing on population subgroups who share common courses of the condition 
over 13 years. 
6.2 Methods 
Population 
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The study population was from the 1973–78 cohort of the ALSWH, a prospective cohort 
study. ALSWH randomly sampled women registered on the national Medicare database, 
which includes almost all people resident in Australia. The 1973–78 cohort included 
14,247 women aged 18 to 23 years at baseline (1996) who were found to be reasonably 
representative of Australian women of this age group from the national census in country 
of birth, marital status and housing situation, although women included in the survey were 
more likely to have tertiary education and less likely to be in the labour force [28]. 
Questionnaires were sent to participants every three years, with the most recent survey 
being conducted in 2012. The detailed study methods have been reported elsewhere [29]. 
ALSWH was approved by the Human Research Ethics Committees of The University of 
Newcastle and The University of Queensland. Permission to use the data was granted for 
this study from the Publications, Analyses and Substudies Committee of the ALSWH in 
August 2012. 
As discussed in a previous study [176], Survey 1 was not included due to evidence of 
considerable over-reporting of dysmenorrhea, known as ‘telescoping’ effect [42]. Therefore 
data from five waves of the survey over 13 years (from Survey 2 in 2000 to Survey 6 in 
2012) were included in this study. Hereafter, baseline refers to Survey 2. To enable 
reliable trajectory analysis, only those women who reported their dysmenorrhea status in 
at least three surveys (N = 9,067) were included in this study.  
Measurements 
All data were collected through self-report at each survey. Dysmenorrhea was based on 
the question: ‘In the last 12 months have you had severe period pain?’. Women were 
considered to have had a recent history of dysmenorrhea if their response was ‘sometimes’ 
or ‘often’, and to be symptom-free if their response was ‘never’ or ‘rarely’.  
The main exposure of interest was smoking behaviour which was measured by three 
variables: 1) smoking status was categorised as never smoker, ex-smoker, and current 
smoker (Amount of cigarettes smoked as <10 cigarettes/day, 10 to 19 cigarettes/day and 
≥20 cigarettes/day were presented in the baseline table. However, due to the small 
number of women who smoked ≥10 cigarettes/day, current smokers were collapsed into 
one group in the analysis.); 2) age at initiation of smoking was grouped as non-smoker, 
started smoking ≤13, 14 to 15 or ≥16 years; and 3) time initiation of smoking relative to 
age at menarche was categorised as non-smoker, started smoking before or after 
menarche. Other socio-demographic and lifestyle characteristics of the women were 
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collected in each survey and included age, highest level of education, marital status, 
employment, area of residence, BMI, alcohol consumption, illicit drug use and physical 
activity. The following reproductive characteristics were included: use of oral 
contraceptives, number of births (live and still), age at menarche and endometriosis. 
These variables were categorised as shown in Table 1. 
Statistical analysis 
Statistical analyses were performed using SAS version 9.3 for Windows (SAS Institute Inc., 
Cary, North Carolina, USA). Women’s pattern of smoking status at the individual level over 
time was displayed at each survey using a lasagne plot for longitudinal categorical 
variables [177].  
Applying latent class analysis, trajectories for dysmenorrhea were identified using SAS 
PROC TRAJ. Further details of the method have been reported in a previous study [176]. 
Briefly, model selection was based on Bayesian Information Criterion with the model 
having the lowest score chosen [168, 169]. Based on the observed outcomes of each 
individual over time, the posterior probability of group membership was calculated and 
used to assign the individual to the trajectory group, applying the maximum-probability 
assignment rule [178]. Baseline characteristics of the women in different trajectory groups 
were compared using χ2 test. The associations between smoking behaviour at baseline 
and trajectories of dysmenorrhea were investigated by multinominal logistic regression 
analysis. Univariate analysis was performed on all variables, and those which were 
statistically significantly associated with the trajectory groups were entered into 
multivariable-adjusted models. The association of interest was examined after controlling 
for sociodemographic, lifestyle and reproductive factors, sequentially entered into the 
models as clusters of variables. Statistical significance was set at p <0.05. 
Sensitivity analysis was performed by comparing the results based on the observed data 
with results after multiple imputation for missing outcome and covariate data. Multiple 
imputation procedure in SAS was used as following: 1) PROC MI (Markov chain Monte 
Carlo method) to create a series of imputed data sets; 2) logistic regression analysis on 
each of the imputed data set; and 3) PROC MIANALYZE to generate a final single set of 
parameter estimates. All variables included in the final model, except for smoking variables, 
and some additional variables providing relevant information, were imputed to examine the 
change in the direction and strength of the associations.  
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6.3 Results 
At baseline, when the women were aged 22 to 27 years, the majority (59%) were never 
smokers, with 26% being current smokers (Table 6-1). As shown in Figure 6-1, smoking 
rate declined steadily over time and was more than halved when the women were age 34 
to 39 years. Approximately 7% of the women had started smoking by age 13, with a further 
14% starting smoking at 14 to 15 years of age, and 8% reported that they started smoking 
before menarche.  
 
Figure 6-1: Self-reported smoking status among the 1973–78 cohort of the ALSWH from year 2000 (Survey 2) to 2012 (Survey 6) 
(Percentages may not add up to 100% due to rounding). 
One in four women reported dysmenorrhea at baseline (Table 6-1). A modestly increased 
prevalence of dysmenorrhea was seen with smoking status, rising from 23% in women 
who had never smoked to 29% among those who currently smoked. The prevalence did 
not vary significantly among women with different age of smoking initiation.  
Latent class analysis showed that the four-group model fitted the data best. Trajectories of 
dysmenorrhea are presented in Figure 6-2, with prevalence by age displayed. Overall, 
approximately 60% of women reported dysmenorrhea some time during the study. The 
‘normative’ group included 42% of women defined by no or few symptoms throughout the 
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study. The ‘late onset’ group comprised 11% of women characterised by an increasing 
probability over time, from approximately 15% to nearly 70%. The ‘recovering’ group 
consisted of 33% of women who were defined by a decreasing probability of 
dysmenorrhea from 40% at age 22 to 27 years to 10% at age 34 to 39 years. Finally, the 
‘chronic’ group consisting of 14% of women was characterised by a high probability of 
dysmenorrhea, between 70% to 80%, throughout the study. 
 
Figure 6-2: Trajectories of dysmenorrhea for the 1973–78 cohort of the ALSWH,  2000 (Survey 2) to 2012 (Survey 6) (N = 9,067) 
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Table 6-1: Baseline smoking behaviour, other characteristics, and the prevalence of dysmenorrhea among women from the 1973–78 
cohort of the ALSWH, aged 22 to 27 years in 2000 
Characteristics at baseline  Percenta Prevalence of dysmenorrhea (24.5%) 
(N = 9068)  %a 95% CI 
Smoking behaviour    
Smoking status (n = 7,962)    
 Never-smoker 59.3 22.5 21.3, 23.7 
 Ex-smoker 14.3 24.6 22.1, 27.1 
 Current smoker 26.4 29.0 27.0, 30.9 
 Smoke <10 cigarettes/day 14.2 26.8 24.3, 29.4 
 Smoke 10–19 cigarettes/day 8.2 30.9 27.4, 34.5 
 Smoke ≥20 cigarettes/day 4.1 32.5 27.4, 37.6 
Age initiation of smoking (years) (n = 7,611)    
 Never smoker 58.0 22.7 21.5, 24.0 
 ≤13 7.3 28.8 25.0, 32.5 
 14–15 13.5 27.6 24.9, 30.4 
 ≥16 21.2 26.6 24.4, 28.8 
Time age initiation of smoking relative to menarche (n = 7,557)    
 Never smoker 58.0 22.8 21.6, 24.1 
 Before menarche 8.1 27.5 24.0, 31.1 
 After menarche 33.9 27.2 25.5, 28.9 
Other baseline characteristics    
Age (years) (n = 8,023)    
 22–23 37.0 26.5 24.9, 28.1 
 24–25 40.1 24.6 23.1, 26.1 
 26–27 22.9 21.3 19.4, 23.2 
Highest education (n = 7,773)    
 Less than high school 9.6 26.4 23.3, 29.6 
 High school/trade certificate 26.2 26.7 24.8, 28.6 
 Diploma or higher 64.1 23.3 22.1, 24.5 
Employment status (n = 7,947)    
 Employed 42.1 21.3 19.9, 22.7 
 Unemployed 57.9 27.0 25.7, 28.3 
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Characteristics at baseline  Percenta Prevalence of dysmenorrhea (24.5%) 
(N = 9068)  %a 95% CI 
Marital status (n = 7,988)    
 Single 53.0 26.8 25.4, 28.1 
 Married/De facto 45.7 22.1 20.8, 23.5 
 Separate/divorced/widowed 1.3 18.5 11.0, 25.9 
Area of residence (n = 7,986)    
 Urban 55.2 25.4 24.1, 26.7 
 Rural 41.1 23.8 22.3, 25.2 
 Remote 3.8 21.2 16.6, 25.8 
Language spoken at home (n = 7,956)    
 English 93.4 24.0 23.1, 25.0 
 European other than English 4.6 32.2 27.4, 37.0 
 Asian 1.3 26.0 17.4, 34.6 
 Other 0.8 36.1 24.0, 48.1 
BMI (kg/m2) (n = 7,367)    
 Underweight (<18.5) 6.5 29.7 25.6, 33.8 
 Normal weight (18.5 to <25) 63.2 23.5 22.3, 24.7 
 Overweight (25 to <30) 19.9 26.0 23.7, 28.2 
 Obese (≥30) 10.4 28.1 24.9, 31.3 
Physical activity (n = 7,848)    
 Sedentary 10.1 25.9 22.8, 28.9 
 Low 43.8 24.0 22.6, 25.4 
 Moderate 23.7 24.9 23.0, 26.9 
 High 22.4 24.9 22.9, 26.9 
Alcohol consumption (n = 7,976)    
 None/rarely 36.5 25.8 24.2, 27.4 
 Low-risk drinking 59.9 23.5 22.3, 24.7 
 Risky/high-risk drinking 3.5 28.7 23.4, 34.0 
Illicit drug use (n = 7,907)    
 Never 36.0 23.3 21.8, 24.9 
 Not in last 12 months 22.0 23.0 21.0, 24.9 
 Used in last 12 months 42.1 26.4 24.9, 27.9 
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Characteristics at baseline  Percenta Prevalence of dysmenorrhea (24.5%) 
(N = 9068)  %a 95% CI 
OCPs (n = 7,922)    
 Not use 42.5 30.1 28.5, 31.6 
 Used 57.5 20.2 19.1, 21.5 
Number of births (n = 8,017)    
 0 83.1 25.3 24.2, 26.3 
 1 10.3 22.1 19.3, 25.0 
 ≥2 6.7 18.9 15.6, 22.2 
Age at menarche (years) (n = 7,964)    
 8–11 13.3 29.9 27.1, 32.7 
 12–14 74.8 23.8 22.7, 24.9 
 ≥15 11.9 23.3 20.6, 26.0 
Endometriosis (n = 7,953)    
 No 97.0 23.4 22.4, 24.3 
 Yes 3.0 61.4 55.3, 67.6 
a Percent may not add up to 100% due to rounding. 
Baseline characteristics of the women by trajectory groups of dysmenorrhea are presented 
in Table 6-2. Compared with women who had never smoked, women who were current 
smokers and who started smoking ≤13 years were more likely to be in the chronic group 
and less likely in the normative group. Age, area of residence and physical activity were 
not associated with trajectory groups. However, statistically significant associations were 
detected between a range of other socio-demographic, lifestyle and reproductive factors 
and trajectory groups. Women who had a diploma or higher education or used OCPs were 
more likely to be in the normative group and less likely to be in the chronic group, whereas 
women who were unemployed, obese, spoke a European language at home, had an early 
menarche age, or had endometriosis were more likely to be in the chronic group and less 
likely to be in the normative group.  
The univariate analysis showed a dose-response relationship for smoking status and the 
odds of being in the chronic group, with the corresponding OR of 1.45 (95% CI: 1.16, 1.80) 
for ex-smokers and 1.71 (1.45, 2.02) for current smokers (Table 6-3). However, the pattern 
largely disappeared in the multivariable-adjusted models, although significantly higher 
odds remained for all smokers. Both ex- and current smokers at baseline also showed 
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higher odds of being in the recovering group. No consistent relationship was evident 
between smoking status and the odds of being in the late onset groups.  
An inverse relationship was revealed for age at initiation of smoking and the odds of being 
in the chronic group in the univariate analysis, with women who started smoking by age 13 
having almost twice the odds of being in this group (OR 1.98, 95% CI: 1.51, 2.62) 
compared with those who had never smoked. This relationship was partly attenuated in 
the full model. Similarly, an increasing likelihood of being in the chronic group was also 
seen for initiation of smoking relative to menarche in the adjusted model, with initiation of 
smoking before menarche having higher odds. No clear pattern with respect to smoking 
initiation was detected for the other trajectory groups.  
The results from multiple imputation analyses strengthened the reverse relationship for 
age at initiation of smoking and being in the chronic group (see Appendix F). No other 
substantial changes in the estimates were observed.  
6.4 Discussion 
Dysmenorrhea was reported in 25% of young Australian women, which is in line with the 
rate reported for severe dysmenorrhea in a recent review [6]. This study identified four 
groups of women who followed distinct trajectories of dysmenorrhea over 13 years. To our 
knowledge, no previous study has examined the association between smoking behaviour 
and trajectories of dysmenorrhea. Although the associations of smoking behaviour and the 
risk of persistent dysmenorrhea were attenuated after controlling for a range of socio-
demographics and other lifestyle factors, significant, albeit moderate, associations 
remained for all smoking variables. Compared with women who had never smoked, those 
who smoked were at significantly higher odds of experiencing the chronic symptom, with 
those who had initiated smoking by age 13 years having 60% higher odds. Our results are 
compatible with previous findings showing adverse effects of smoking in that the risk 
and/or severity of dysmenorrhea increased with smoking [55, 57, 175], and that women 
who were smokers were more likely to have severe pain lasting longer than two days [43]. 
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Table 6-2: Baseline smoking behaviour and other characteristics of the women aged 22 to 27 years in 2000 among the 1973–78 cohort of 
the ALSWH, according to the trajectory groups of dysmenorrhea from 2000 to 2012 
Characteristics at baseline Dysmenorrhea trajectory group (%) 
Total (N = 9067) Normative 
(42.3%) 
Late onset 
(10.7%) 
Recovering 
(33.3%) 
Chronic 
(13.7%) 
Smoking behaviour     
Smoking status (n =7,970)     
 Never-smoker 56.9 6.9 24.3 11.9 
 Ex-smoker 50.8 7.1 27.7 14.5 
 Current smoker 48.1 7.7 27.5 16.7 
Age initiation of smoking (years) (n = 8,588)     
 Never smoker 57.5 6.5 23.7 12.3 
 ≤13 47.3 7.3 25.7 19.7 
 14–15 49.3 8.3 26.1 16.2 
 ≥16 52.7 6.6 25.4 15.3 
Time initiation of smoking relative to menarche (n = 
7,565) 
    
 Never smoker 56.8 6.6 24.5 12.0 
 Before menarche 50.3 7.8 25.7 16.1 
 After menarche 49.5 7.6 27.4 15.6 
Other baseline characteristics     
Age (years) (n = 8,031)     
 22–23 52.7 6.4 27.2 13.7 
 24–25 53.7 7.5 25.3 13.5 
 26–27 55.4 7.7 23.6 13.3 
Highest education (n = 7,780)     
 Less than high school 46.5 8.8 28.4 16.3 
 High school/trade certificate 49.3 7.9 28.1 14.7 
 Diploma or higher 56.8 6.4 24.2 12.6 
Employment status (n = 7,955)     
 Employed 58.4 6.3 24.8 10.5 
 Unemployed 50.2 7.7 26.3 15.8 
Marital status (n = 7,996)     
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Characteristics at baseline Dysmenorrhea trajectory group (%) 
Total (N = 9067) Normative 
(42.3%) 
Late onset 
(10.7%) 
Recovering 
(33.3%) 
Chronic 
(13.7%) 
 Single 52.6 6.7 26.3 14.4 
 Married/de facto 55.2 7.5 24.9 12.5 
 Separate/divorced/widowed 48.1 9.6 25.0 17.3 
Area of residence (n = 7,994)     
 Urban 53.6 7.0 25.3 14.1 
 Rural 53.3 7.2 26.5 13.0 
 Remote 57.6 7.3 22.5 12.6 
Language spoken at home (n = 8,980)     
 English 54.8 7.0 24.4 13.8 
 European other than English 48.5 5.5 26.5 19.5 
 Asian 56.5 3.5 26.1 13.9 
 Other 46.2 7.7 30.8 15.4 
BMI (kg/m2) (n = 7,374)     
 Underweight (<18.5) 52.0 5.2 26.0 16.8 
 Normal weight (18.5 to <25) 55.9 6.2 25.7 12.2 
 Overweight (25 to <30) 50.0 9.0 27.1 13.8 
 Obese (≥30) 47.9 8.6 24.2 19.3 
Physical activity (n = 7,856)     
 Sedentary 50.3 7.7 25.6 16.5 
 Low 53.3 7.6 25.7 13.5 
 Moderate 55.3 6.6 24.6 13.5 
 High 54.5 6.1 26.7 12.7 
Alcohol consumption (n = 7,984)     
 None/rarely 50.8 8.0 26.5 14.7 
 Low-risk drinking 55.8 6.6 24.9 12.6 
 Risky/high-risk drinking 46.8 7.1 29.8 16.3 
Illicit drug use (n = 7,915)     
 Never 55.8 6.6 25.4 12.1 
 Not in last 12 months 55.1 7.4 25.0 12.4 
 Used in last 12 months 51.2 7.2 26.3 15.3 
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Characteristics at baseline Dysmenorrhea trajectory group (%) 
Total (N = 9067) Normative 
(42.3%) 
Late onset 
(10.7%) 
Recovering 
(33.3%) 
Chronic 
(13.7%) 
OCPs (n = 7,930)     
 Not use 47.2 7.4 28.7 16.7 
 Used 58.7 7.0 23.3 11.1 
Number of births (n = 8,025)     
 0 54.2 6.7 25.8 13.3 
 1 51.8 9.8 23.3 15.2 
 ≥2 51.2 8.2 26.5 14.0 
Age at menarche (years) (n = 7,972)     
 8–11 45.6 7.5 29.3 17.5 
 12–14 54.7 7.0 25.1 13.2 
 ≥15 56.6 7.5 24.8 11.1 
Endometriosis (n = 7,955)     
 No 54.7 7.2 25.3 12.7 
 Yes 19.9 5.0 33.6 41.5 
* Percent may not add up to 100% due to rounding. 
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Table 6-3: Univariate and multivariable-adjusted association from multinominal logistic regression analysis between baseline smoking 
behaviour (year 2000) and being in the trajectory groups of dysmenorrhea from 2000 to 2012 among the 1973–78 cohort of the ALSWH (N 
= 9067)* 
Group Sample (n) OR (95% CI) 
  Univariate Multivariable-adjusted 
Smoking status 6,675 p <0.0001 p = 0.001 
Late onset    
 Never-smoker  1 1 
 Ex-smoker  1.10 (0.82, 1.49) 0.94 (0.69, 1.29) 
 Current smoker  1.34 (1.07, 1.67) 1.12 (0.88, 1.43) 
Recovering    
 Never-smoker  1 1 
 Ex-smoker  1.33 (1.12, 1.58) 1.30 (1.09, 1.56) 
 Current smoker  1.31 (1.15, 1.50) 1.19 (1.03, 1.38) 
Chronic    
 Never-smoker  1 1 
 Ex-smoker  1.45 (1.16, 1.80) 1.33 (1.05, 1.68) 
 Current smoker  1.71 (1.45, 2.02) 1.41 (1.17, 1.70) 
Age initiation of smoking (years)  6,402 p <0.0001 p = 0.003 
Late onset    
 Never smoker  1 1 
 ≤13  1.41 (0.95, 2.10) 1.13 (0.75, 1.72) 
 14–15  1.54 (1.16, 2.06) 1.31 (0.96, 1.78) 
 ≥16  1.17 (0.91, 1.52) 1.06 (0.81, 1.39) 
Recovering     
 Never smoker  1 1 
 ≤13  1.31 (1.03, 1.66) 1.19 (0.92, 1.53) 
 14–15  1.39 (1.16, 1.66) 1.29 (1.07, 1.56) 
 ≥16  1.20 (1.03, 1.39) 1.15 (0.99, 1.35) 
Chronic     
 Never smoker  1 1 
 ≤13  1.98 (1.51, 2.62) 1.59 (1.18, 2.15) 
 14–15  1.70 (1.36, 2.11) 1.50 (1.18, 1.90) 
 ≥16  1.37 (1.13, 1.65) 1.26 (1.03, 1.55) 
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Group Sample (n) OR (95% CI) 
  Univariate Multivariable-adjusted 
Time initiation of smoking relative to menarche 6,402 p <0.0001 p = 0.005 
Late onset    
 Never smoker  1 1 
 Before menarche  1.22 (0.83, 1.78) 0.98 (0.65, 1.47) 
 After menarche  1.35 (1.09, 1.67) 1.19 (0.94, 1.50) 
Recovering     
 Never smoker  1 1 
 Before menarche  1.18 (0.94, 1.48) 1.15 (0.90, 1.46) 
 After menarche  1.29 (1.14, 1.47) 1.21 (1.05, 1.39) 
Chronic     
 Never smoker  1 1 
 Before menarche  1.55 (1.18, 2.04) 1.49 (1.10, 2.00) 
 After menarche  1.57 (1.33, 1.84) 1.36 (1.14, 1.63) 
* ORs are estimated using normative group as the reference group. Multivariable-adjusted analysis estimates the effect of the exposure of interest 
(smoking status or age initiation of smoking) after controlling for sociodemographic characteristics (education, employment, marital status, and 
language spoken at home), lifestyle factors (BMI, alcohol consumption and illicit drug use), and reproductive factors (use of OCP, parity, age at 
menarche and endometriosis). 
The primary disease pathogenesis for dysmenorrhea has been related to increased 
prostaglandin E2 (PGE2) and PGF2α in the menstruating uterus, leading to reduced 
endometrial blood flow, uterine hypoxia, hyperactive myometrial contractions and 
subsequent pain [24]. Although the biological mechanisms of the effects of smoking on 
dysmenorrhea have not been well elucidated, cigarette smoking has been shown to cause 
vasoconstriction, potentially resulting in dysmenorrhea [57]. Alternatively, smoking is also 
suggested to have a direct effect on endocrine control of menstruation since it is often 
related to other menstrual problems such as prolonged periods, and having prolonged 
periods has been associated with dysmenorrhea [57]. Different pathways have been 
proposed for this. One is related to an anti-estrogenic extra-ovarian effect of smoking 
through altered binding of oestrogens by serum proteins or oestrogen receptors, enhanced 
exogenous oestrogen metabolism, or its impact on oestrogen production by reduced 
conversion of circulating androgens to oestrogens [179, 180]. Alternatively, a directly toxic 
effect of smoking to ovaries was suggested due to observed ovarian atrophy in smoke-
exposed animals, although this is not fully supported by the observed reversible effects 
after smoking cessation [179].  
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In addition, pain ‘catastrophising’, the role of central nervous system contributions to 
increased menstrual pain intensity, was also suggested as potential cause for 
dysmenorrhea [24]. Under this theory, there may be psychological differences in pain 
perception and sensitivity between smokers and non-smokers which may result in a 
different subjective experience of pain [55]. However, this does not seem to be supported 
by the observation that the risks of dysmenorrhea among ex-smokers were more similar 
with never smokers compared with other smoking categories [56]. Furthermore, there 
might be a reversed causal relation as women might use nicotine to relieve symptoms of 
dysmenorrhea due to its persistent inhibition of automatic ganglia and the neuromuscular 
junction, resulting in reduced uterine contractibility [80].  
An increased odds of experiencing chronic symptom was detected for earlier smoking 
initiation, and trend analysis showed evidence of a trend for both age of smoking initiation 
(p = 0.0003) and time of initiation of smoking relative to menarche (p = 0.002). There are 
some plausible explanations for the relationship. First, women who started smoking earlier 
may have a longer duration of cigarette smoking, which has been related to increased risk 
of dysmenorrhea in a previous study [57]. Second, smoking before menarche, one marker 
of advanced level of pubertal development, may have a stronger impact on the endocrine 
system controlling menstruation. Many of the physical and hormonal changes associated 
with the functional maturation of the adrenal glands and the hypothalamic-pituitary-gonadal 
(HPG) axis, which in turn regulates menarche, occur prior to menarche. During the 
maturation of HPG axis, pulsatile secretion of gonadotropins (luteinizing and follicle-
stimulating hormones) markedly increases, causing a cascade of events including 
menarche and ultimately establishment of cyclic ovarian function that leads to the maturity 
of the female reproductive system [181]. Therefore, according to the life course 
epidemiological approach, the time before menarche maybe a sensitive period for 
establishing normal menstruation, when smoking has a stronger effect on the development 
and, therefore, disease risk than it would have at other times [182]. However, the 
hypothesis and the biological mechanisms require further research.  
Despite continuous efforts with public anti-smoking campaigns, cigarette smoking remains 
common among young women, including adolescent girls. Although it is well-known that 
smoking is associated with high risk of a range of diseases [183], it may be difficult to 
convince young women to avoid smoking due to the remote nature of its adverse health 
consequences. This study conveys some important messages that smoking may 
predispose women to repeated, distressing period pain immediately after menstruation 
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and throughout their reproductive life, thus providing greater incentive for young women to 
abstain from smoking. Adding to a limited body of evidence on the immediate adverse 
health outcomes of smoking [56, 133], our results provide further support for smoking 
prevention campaigns and emphasis the need to target young women, particularly in 
adolescence.  
Some women who were smokers at baseline, on the other hand, did become symptom-
free over time, indicating there is possibility of recovering from dysmenorrhea. This may be 
explained, at least partially, by the observation that a large proportion of women who 
smoked at baseline gave up smoking during the study period. A further examination of the 
data showed that women who quit smoking after baseline were more likely to be in the 
normative and recovering groups and less likely to be in the chronic and late onset groups 
(results in Appendix G). Therefore, smoking cessation should be strongly promoted as it 
may benefit women suffering from dysmenorrhea by relieving symptoms; however, further 
research needs to confirm the results. 
This is the only population-based longitudinal study which has investigated the effect of 
smoking at baseline and the odds of following different trajectories of dysmenorrhea. The 
representative sample makes the results generalisable to women with similar 
characteristics. Nevertheless, there are a number of limitations. First, all the data are self-
reported based on questionnaires, which may be subject to reporting bias. However, self-
reported dysmenorrhea has been correlated well with prospectively recorded data [184], 
and our estimated prevalence of dysmenorrhea is in line with that reported in the literature 
[6], providing justification for the validity of the data. In addition, given the longitudinal 
nature and large size of the study, self-report may be the most feasible means of data 
collection. Second, data over the past 12 months were collected retrospectively at each 
survey wave, which may subject the data to recall bias. However, daily symptom reporting 
over an extended evaluation period may not be practical in this large population setting. 
The long period of observation and repeated measures may also offset the disadvantage 
of the absence of daily rating. Third, a high attrition (32%) at Survey 2 may have 
introduced potential selection bias. Comparison of the prevalence of dysmenorrhea at 
Survey 1 among respondents (44.6%) and non-respondents (42.8%) showed no evidence 
of differential drop-out, indicating the random nature of attrition for the outcomes of interest. 
Furthermore, we grouped current smokers as one category, thus were unable to examine 
the effects of number of cigarettes smoked per day on trajectories of dysmenorrhea. 
However, the potential misclassification of smoking status as a result of retrospective self-
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reporting and the small number of heavy smokers (323 women smoked ≥20 cigarettes/day) 
make the results from multiple smoking categories less reliable. Further research to 
investigate the effect of quantity of cigarettes smoked per day on the trend of 
dysmenorrhea will be useful. 
This study linked smoking, especially early initiation, with increased risk of dysmenorrhea 
over time. It addressed the immediate health effects of smoking, further strengthening the 
message that anti-smoking programs should target young women, particularly teenagers. 
In addition, smoking cessation should be strongly encouraged as women may recover 
from dysmenorrhea after quitting smoking. 
What this paper adds 
 Dysmenorrhea is a common menstrual disorder among women of reproductive age. 
 Despite the well-known harmful long-term health consequences of smoking, it is still 
prevalent among young women. 
 Previous evidence on the relationship between smoking and dysmenorrhea is mixed 
and mostly based on cross-sectional studies. 
 This is the first population-based longitudinal study relating baseline smoking 
behaviour to the trajectories of dysmenorrhea. 
 Smoking can predispose women to repeated, distressing period pain immediately 
after menstruation and throughout their reproductive life, with women initiating 
smoking earlier at a greater risk. 
 This study provides evidence on the immediate adverse reproductive health effects of 
smoking; thus the evidence may provide a greater incentive for young women to 
abstain from smoking. 
 Smoking cessation may benefit women suffering from dysmenorrhea by relieving 
symptoms; however, this requires further research. 
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Chapter 7. Illicit drug use and PMS (Paper 4) 
Although both illicit drug use and PMS are common among young Australian women [176, 
185], few studies have examined the relationship as indicated in the literature review in 
Chapter 3. As illicit drug use was identified as another significant lifestyle risk factor 
associated with the risk of PMS in the ALSWH population, this chapter aims to fill the 
literature gap on this topic. It presents a paper investigating whether pattern of drug use 
and the age at first drug use are related to reporting of PMS over time. The paper was 
published in the peer-reviewed journal Drug and Alcohol Dependency in 2015. 
Ju, H, M Jones and GD Mishra (2015). Illicit drug use, early age at first use and risk of 
premenstrual syndrome: A longitudinal study. Drug Alcohol Depend. 2015 Jul 1;152:209-
17. doi:10.1016/j.drugalcdep.2015.03.037. Epub 2015 Apr 17. 
Website: http://www.sciencedirect.com/science/article/pii/S0376871615001933 
Reproduced with permission of ELSEVIER IRELAND LTD in the format Republish in a 
thesis/dissertation via Copyright Clearance Centre. 
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Abstract 
Background: PMS is common among women of reproductive age. Limited studies have 
investigated the long-term association between illicit drug use and PMS. 
Methods: The 1973–78 cohort from the Australian Longitudinal Study on Women’s Health, 
a prospective cohort study, was followed up for 13 years from 2000 to 2012. Data were 
collected through self-reported questionnaires on all variables, including PMS, illicit drug 
use and a range of sociodemographic, lifestyle, reproductive and psychological factors. 
Results: When the women were 22 to 27 years of age, over 40% used illicit drugs in the 
last 12 months, 9% first used drugs before age 15 years, and approximately 35% reported 
PMS. Over the study period, the prevalence of drug use in the last 12 months declined, 
whereas that of PMS remained fairly stable except an increase when they were 34 to 39 
years old. GEE analysis showed that, compared with those who had never used drugs, 
significantly higher odds of reporting PMS were detected for those who had used illicit 
drugs in the last 12 months: multiple drugs (OR 1.31, 95% CI: 1.21, 1.43) or exclusively 
Marijuana (OR 1.23, 95% CI: 1.08, 1.40). A higher odds of PMS was identified for age at 
first drug use before 15 years (OR 1.20, 95% CI: 1.03, 1.40).  
Conclusions: Illicit drug use in the last 12 months, especially early age at first use and 
multiple drug use, is associated with increased risk of PMS. However, the current study is 
unable to prove causality. 
Key words: premenstrual syndrome, PMS, illicit drugs, substance use, longitudinal studies 
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7.1 Introduction 
Up to 90% of menstruating women may experience PMS [9] and approximately 20% to 40% 
experience moderate to severe PMS that substantially impairs functioning and 
relationships [13, 127]. A small proportion, 3 to 8%, suffers from PMDD, a severe form of 
PMS [9]. The core emotional symptoms characterising PMS include depressed mood, 
anxiety, affective lability, anger or irritability, and feeling out of control; and typical physical 
symptoms include bloating, breast tenderness and headache [5].  
Compared with women without PMS, decreased work productivity, increased work 
absenteeism and healthcare use have been reported for women with PMS, resulting in 
considerable economic losses [16, 17]. Partly due to the repeated occurrence of the 
symptoms, previous studies have suggested that the health-related quality-of-life burden 
associated with PMDD is comparable with other chronic conditions such as back pain and 
depressive disorders [13, 16]. 
Despite a large body of literature on PMS/PMDD, few population-based longitudinal 
studies examined the association of PMS with potential lifestyle risk factors, especially 
drug use. One community study on the trend of PMDD reported on its co-existing 
conditions, including drug abuse, in 1,488 young German women [26]. Despite being part 
of a longitudinal study, the paper only reported the association in a cross-sectional nature. 
It detected an increased (OR 2.2), albeit not statistically significant, association between 
drug abuse or dependence and PMDD. However, the lack of power due to the small 
number of PMDD cases (n = 74) included in the study may be one of the explanations. 
Further analysis conducted by the authors revealed a significant association (OR 3.3, p 
<0.05) between drug abuse, or dependence, and sub-threshold PMDD, defined as cases 
short of just one PMDD diagnostic criteria based on the modified DSM-IV. Most cases 
lacked persistent impairment associated with premenstrual symptoms to be fully classified 
as PMDD [26].  
PMS was common among Australian women, affecting over a third of the women included 
in a study with a large population sample [186]; however, little is known about the 
association between illicit drug use and PMS. The aim of this longitudinal study is to 
investigate the association between illicit drug use and PMS among Australian women 
followed over 13 years. We hypothesise that illicit drug use and early age at first use are 
associated with PMS. 
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7.2 Methods 
Population 
The 1973–78 cohort of the ALSWH, a prospective cohort study, formed the study 
population. ALSWH randomly sampled women registered on the national Medicare 
database, which includes almost all permanent residents in Australia. The detailed study 
methods have been previously reported [28]. The women included in this study, who were 
aged 18 to 23 years at baseline (1996), were found to be reasonably representative of 
Australian women of the same age from the national census, although women included in 
the survey were more likely to have tertiary education and less likely to be in the labour 
force [28]. Questionnaires were sent to participants every three to four years, with the most 
recent survey being conducted in 2012.  
For this study, Survey 1 was not included as data on illicit drug use were not collected. 
Therefore, data over 13 years from Survey 2 in 2000 to Survey 6 in 2012 were used. 
Hereafter, baseline refers to Survey 2 with 9,688 women included.  
ALSWH was approved by the Human Research Ethics Committee of The University of 
Newcastle. For this study, permission to use the data was granted from the Publications, 
Analyses and Substudies Committee of the ALSWH in August 2012. 
Measurements 
At each survey, data were collected through self-report. The presence of PMS was based 
on the question: ‘In the last 12 months have you had premenstrual tension?’ Women were 
considered to have had a recent history of PMS if their response was ‘sometimes’ or 
‘often’, and to be symptom-free if their response was ‘never’ or ‘rarely’. 
The main exposure of interest was illicit drug use. It was measured by 1) pattern of drug 
use which was classified into five groups: never used, ex-exclusive Marijuana use (used 
but not in last 12 month), ex-multiple drug use (including multiple drugs or a single drug 
other than Marijuana), recent exclusive Marijuana use (use in last 12 months), and recent 
multiple drug use; and 2) age at first drug use was categorised as never used, started <15, 
15 to 17 or ≥18 years of age. As shown in Table 7-2, other socio-demographic and lifestyle 
characteristics of the women were collected, and included age, highest level of education, 
marital status, management on income, area of residence, language spoken at home, BMI, 
smoking status, alcohol consumption and physical activity. The following reproductive and 
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psychological characteristics were included: use of oral contraceptives, number of births 
(live and still), age at menarche, history of abuse (physical, emotional or sexual) and self-
reported depression.  
Statistical analysis 
Statistical analyses were performed using SAS version 9.4 for Windows (SAS Institute Inc., 
Cary, North Carolina, USA). Women’s pattern of illicit drug use at the individual level over 
time was displayed at each survey, using lasagne plots for longitudinal categorical 
variables [177]. The prevalence of PMS, weighted for area of residence to correct for 
oversampling of women in rural and remote areas, was displayed in a histogram to show 
the trend over time. 
Baseline characteristics of the women in relation to illicit drug use and PMS status were 
compared using χ2 test. The longitudinal association between illicit drug use and PMS was 
investigated by GEE, taking into account the repeated measures of variables over time. 
PMS was modelled on concurrent illicit drug use from the same survey. Univariate analysis 
was performed on all exposure variables mentioned above, one at a time, and those which 
were statistically significantly associated with PMS were entered into multivariable-
adjusted models, except for some known risk factors for PMS such as education. The 
association of interest was examined after controlling for sociodemographic, lifestyle, 
reproductive and psychological factors, sequentially entered into the models in blocks of 
variables. Statistical significance was set at p <0.05. 
Two sets of sensitivity analysis were performed to test the robustness of the study results. 
First, the association between age at first drug use and PMS was re-examined restricting 
the analysis to drug users in the last 12 months to compare the results with those from the 
main analysis. Second, as a number of self-reported never drug users had age at first drug 
use recorded (n = 558 in Survey 6, 342 in Survey 5, 470 in Survey 4, and 239 in Survey 3), 
the models were rerun by recoding these women as ex-drug users to evaluate its impact 
on the study results.  
7.3 Results 
At baseline, about 65% of the included women reported ever use of any illicit drugs and 
over 40% used drugs in the last 12 months (Table 7-1), of which 37% were multiple drug 
users and 5% exclusive Marijuana users (Table 7-3). The most commonly used drug was 
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Marijuana, with more than half of the women reporting ever use at baseline. The other 
more commonly used drugs were ecstasy/designer drugs, amphetamines and LSD. The 
mean age at first drug use was earlier for Marijuana (17.2 years) than other common drugs, 
with 9% of the women first using any drug before 15 years of age. As shown in Table 7-2, 
women who used illicit drugs in the last 12 months were more likely to be single or 
separated/divorced/widowed, to smoke and be risky alcohol drinkers; and those who used 
multiple drug in the last 12 months were also more likely to have difficulty coping with 
income, to have a history of abuse, and to feel depressed. Over the study period, a 
decreased proportion of women reported use of any illicit drugs in the last 12 months, with 
the rate halving from 2000 to 2003 when the women were 25 to 30 years of age, followed 
by a more steady decrease afterwards (Figure 7-1). Likewise, percentage of Marijuana use 
in the last 12 months decreased substantially from 2000 to 2012 (Figure 7-2).  
Table 7-1: Ever and recent Illicit drug use in 2000 among women from the 1973–78 cohort of the ALSWH (N = 9,518) 
 Percentagea 
Mean age at first use (years) 
Ever used Recent useb 
Marijuana 56.7 24.4 17.2 
Ecstasy/designer drugs 14.5 9.2 20.8 
Amphetamines 16.4 8.5 19.6 
LSD 14.0 3.1 18.7 
Cocaine 6.0 2.8 21.1 
Hallucinogens 5.0 0.8 18.6 
Tranquillizers 5.0 1.9 19.9 
Inhalants 1.8 0.3 16.2 
Heroin 1.2 0.4 19.9 
Any illicit drug 65.3 43.5  
a Weighted for area of residence  
b Use of illicit drugs in the last 12 months 
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Figure 7-1: Self-reported any illicit drug use among women from the 1973–78 cohort of the ALSWH from year 2000 (Survey 2) to 2012 
(Survey 6) 
Approximately 35% of the women reported PMS in 2000 when they were aged 22 to 27 
years (Figure 7-3). The prevalence remained fairly stable over the next few surveys before 
a noticeable increase to just over 40% in 2012. Baseline characteristics of the women with 
PMS are presented in Table 3. Compared with women who had never used drugs, women 
who were multiple drug users and who first used drugs before 15 years of age, were more 
likely to report PMS. Age, BMI and physical activity were not related with PMS. However, 
women who were single and urban residents, had difficulty coping with income, spoke a 
European language other than English at home, who were current smokers, risky drinkers 
and nulliparous, who had an early menarche and a history of abuse, and who felt 
depressed were more likely to report PMS.  
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Figure 7-2: Self-reported Marijuana use among women from the 1973–78 cohort of the ALSWH from year 2000 (Survey 2) to 2012 (Survey 
6) 
A total of 8,919 women were included in the model of pattern of illicit drug use. The 
univariate analysis revealed a dose-response relationship for pattern of illicit drug use, with 
women who had used drugs in the last 12 months showing higher odds of PMS than those 
who no longer used drugs; and women with multiple drug use having higher odds than 
those with exclusive Marijuana use (Table 7-4). Relative to women who had never used 
drugs, the highest risk of PMS was seen among women who used multiple drugs in the 
last 12 months with a 55% higher odds, followed by those who used exclusive Marijuana in 
the last 12 months showing a 40% higher odds. The relationships were partly attenuated in 
the multivariable-adjusted models. However, statistically significantly higher risks remained 
for all women who used drugs in the last 12 months, with ORs of 1.31 (95% CI: 1.20, 1.43) 
and 1.23 (95% CI: 1.08, 1.40) for both multiple drug and exclusive Marijuana use, 
respectively. No significant association was shown for ex-drug use and PMS.  
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Table 7-2: Baseline demographics by illicit drug use among women from the 1973–78 cohort of the ALSWH, aged 22 to 27 years in 2000a 
 Percentage of illicit drug use (%)b 
 Never Ex- 
exclusive 
marijuana use 
Ex- 
multiple 
drug usec 
Recent 
exclusive 
marijuana use 
Recent 
multiple 
drug usec 
 (35.8) (13.2) (8.8) (5.2) (37.0) 
Age (years) (n = 9,518)*      
 22–23 37.5 13.5 7.9 5.9 36.8 
 24–25 36.1 12.7 9.4 5.3 36.6 
 26–27 35.4 13.4 9.5 3.8 37.9 
Highest education (n = 9,176)*      
 Less than high school 33.1 13.4 9.7 5.7 38.2 
 High school/trade certificate 33.1 12.8 10.3 5.1 38.7 
 Diploma or higher 37.8 13.3 8.1 5.1 35.6 
Marital status (n = 9,473)**      
 Single 35.1 11.8 7.8 6.1 39.3 
 Married/de facto 37.0 14.9 10.0 4.1 34.1 
 Separate/divorced/widowed 23.1 11.2 14.7 7.0 44.1 
Number of births (n = 9,497)*      
 0 35.9 12.9 5.5 8.4 37.3 
 1 35.2 15.2 3.6 10.9 35.1 
 ≥2 35.8 13.4 3.9 11.2 35.7 
Coping with income (n = 9,487)**      
 Impossible 33.9 11.0 9.6 5.1 40.4 
 Difficult all the time 25.7 12.5 10.6 5.2 46.0 
 Difficult sometimes 33.5 13.0 9.6 5.9 38.0 
 Not too bad 39.4 13.2 8.3 4.7 34.4 
 Easy 42.0 14.6 6.6 4.8 32.0 
Area of residence (n = 9,476)**      
 Urban 34.0 12.4 9.2 5.4 39.1 
 Rural 38.4 14.1 8.5 5.0 34.0 
 Remote 35.7 13.9 8.6 3.6 38.2 
Language spoken at home (n = 9,425)**      
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 Percentage of illicit drug use (%)b 
 Never Ex- 
exclusive 
marijuana use 
Ex- 
multiple 
drug usec 
Recent 
exclusive 
marijuana use 
Recent 
multiple 
drug usec 
 (35.8) (13.2) (8.8) (5.2) (37.0) 
 English 34.4 13.5 8.9 5.3 37.9 
 European other than English 43.7 11.1 7.9 3.9 33.5 
 Asian 80.0 2.8 6.2 2.1 9.0 
 Other 64.7 7.1 5.9 9.4 12.9 
BMI (kg/m2) (n = 8,581)      
 Underweight (<18.5) 36.6 12.3 6.7 5.2 39.2 
 Normal weight (18.5 to <25) 34.9 13.3 9.0 5.6 37.3 
 Overweight (25 to <30) 35.5 13.1 9.2 5.4 36.9 
 Obese (≥30) 37.2 13.4 8.1 4.3 37.1 
Smoking status (n = 9,443)**      
 Never-smoker 50.8 11.7 6.1 4.2 27.2 
 Ex-smoker 18.0 20.0 16.7 4.3 41.1 
 Current smoke <10 cigarettes/day 14.6 11.8 11.4 7.8 54.5 
 Current smoke 10–19 cigarettes/day 14.7 14.3 8.9 7.4 54.8 
 Current smoke ≥20 cigarettes/day 16.0 12.7 10.0 7.1 54.1 
Alcohol consumption (n = 9,456)**      
 None/rarely 48.1 11.6 8.2 3.1 29.0 
 Low-risk drinking 29.3 14.6 9.3 6.5 40.4 
 Risky/high-risk drinking 15.3 7.8 8.1 5.6 63.3 
History of abuse (n = 9,459)**      
 Yes 25.3 13.1 11.0 5.6 45.0 
 No 42.5 13.4 7.3 5.0 31.9 
 Don’t want to answer 44.9 9.7 9.7 4.4 31.3 
Depressed (n = 9,255)**      
 No 37.6 14.2 8.5 5.2 34.5 
 Yes 31.9 10.9 9.5 5.2 42.6 
* p < 0.05; ** p < 0.0001. 
a Recent use is use of illicit drugs in the last 12 months. 
b Percent may not add up to 100% due to rounding. 
c Used multiple drugs or a single drug other than marijuana. 
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Among the 7,102 women included in the model of age at first drug use, an inverse 
relationship was revealed for age at first drug use and the odds of PMS in the univariate 
analysis. As shown in Table 7-4, women who first used drugs before age 15 years were 
about 1.5 times more likely to report PMS compared with those who had never used drug. 
Once again, albeit attenuated in the final model, this association remained whereas the 
relationships disappeared for other age groups.  
Sensitivity analysis restricting the analysis on the association of age at first drug use and 
PMS to those who used drugs in the last 12 months revealed a 40% higher odds of 
reporting PMS for women who first used drugs before age 15 years. No other significant 
changes were observed. When never drug users who reported an ‘age at first drug use’ 
were recoded as ex-drug users, similar results were obtained as those in the main analysis 
(Appendix H).  
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Table 7-3: Baseline prevalence of PMS by illicit drug use and other characteristics among women from the 1973–78 cohort of the ALSWH, 
aged 22 to 27 years in 2000 
Characteristics at baseline  
(N = 9,688) 
Sample (N) Percentb Prevalence of PMS (35%) 
%b 95% CI 
Illicit drug use     
Pattern of any illicit drug** 9,502    
 Never  35.8 28.0 26.5, 29.5 
 Ex-exclusive Marijuana use  13.2 30.3 27.7, 32.8 
 Ex-multiple drug usec   8.8 35.7 32.4, 38.9 
 Recent exclusive Marijuana use  5.2 32.5 28.4, 36.7 
 Recent multiple drug usec  37.0 38.8 37.2, 40.4 
Age first drug use (years)* 7,515    
 Never  17.9 29.7 27.2, 32.2 
 <15  9.0 37.8 34.2, 41.5 
 15–17  37.6 34.3 32.5, 36.1 
 ≥18  35.5 35.5 33.7, 37.3 
Other characteristics     
Age (years) 9,671    
 22–23  37.4 33.1 31.6, 34.6 
 24–25  39.9 33.1 31.7, 34.6 
 26–27  22.7 33.0 31.1, 35.0 
Highest education** 9,325    
 Less than high school  11.3 27.8 25.1, 30.5 
 High school/trade certificate  27.3 30.9 29.1, 32.7 
 Diploma or higher  61.5 35.1 33.9, 36.4 
Marital status** 9,623    
 Single  53.3 35.2 33.8, 36.5 
 Married/de facto  45.2 30.7 29.3, 32.0 
 Separate/divorced/widowed  1.5 31.7 24.1, 39.3 
Coping with income* 9,641    
 Impossible  3.1 32.1 26.8, 37.4 
 Difficult all the time  13.7 35.7 33.1, 38.3 
 Difficult sometimes  32.2 34.3 32.7, 36.0 
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Characteristics at baseline  
(N = 9,688) 
Sample (N) Percentb Prevalence of PMS (35%) 
%b 95% CI 
 Not too bad  37.4 32.3 30.8, 33.8 
 Easy  30.2 30.2 27.7, 32.7 
Area of residence** 9,629    
 Urban  55.1 36.4 35.1, 37.7 
 Rural  41.2 29.1 27.7, 30.5 
 Remote  3.8 30.3 25.6, 35.0 
Language spoken at home** 9,574    
 English  92.8 32.7 31.8, 33.7 
 European other than English  4.7 42.9 38.3, 47.5 
 Asian  1.5 26.0 18.9, 33.1 
 Other  0.9 35.6 25.7, 45.4 
BMI (kg/m2) 8,699    
 Underweight (<18.5)  6.7 36.6 32.7, 40.5 
 Normal weight (18.5 to <25)  62.9 35.3 34.0, 36.6 
 Overweight (25 to <30)  19.8 32.5 30.2, 34.7 
 Obese (≥30)  10.6 32.8 29.8, 35.9 
Smoking status* 9,591    
 Never-smoker  57.5 31.4 30.2, 32.6 
 Ex-smoker  14.5 33.9 31.4, 36.4 
 Current smoke <10 cigarettes/day  14.5 37.7 35.1, 40.2 
 Current smoke 10–19 cigarettes/day  8.9 35.1 31.9, 38.3 
 Current smoke ≥20 cigarettes/day  4.7 34.3 29.9, 38.7 
Alcohol consumption** 9,606    
 None/rarely  38.0 29.7 28.2, 31.2 
 Low-risk drinking  58.2 34.9 33.7, 36.2 
 Risky/high-risk drinking  3.8 38.6 33.6, 43.6 
Physical activity 9,421    
 Sedentary  10.5 30.1 27.3, 33.0 
 Low  43.8 33.6 32.2, 35.1 
 Moderate  23.4 34.7 32.7, 36.7 
 High  22.3 32.5 30.5, 34.5 
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Characteristics at baseline  
(N = 9,688) 
Sample (N) Percentb Prevalence of PMS (35%) 
%b 95% CI 
OCPs* 9,532    
 Not used  43.9 34.5 33.1, 35.9 
 Used  56.1 32.2 31.0, 33.5 
Number of births** 9,650    
 0  82.2 35.4 34.4, 36.5 
 1  10.9 23.0 20.5, 25.6 
 ≥2  6.9 20.9 17.8, 24.0 
Age at menarche (years)* 9,570    
 8–11  13.3 37.0 34.4, 39.7 
 12–14  74.5 33.1 32.0, 34.2 
 ≥15  12.2 30.2 27.6, 32.8 
History of abuse** 9,526    
 Yes  39.0 38.8 37.2, 40.4 
 No  58.6 29.5 28.3, 30.7 
 Don’t want to answer  2.4 30.6 24.6, 36.5 
Depressed** 9,316    
 No  70.0 29.7 28.6, 30.8 
 Yes  30.0 42.1 40.2, 43.9 
* p < 0.05; ** p < 0.0001. 
a Recent use is use of illicit drugs in the last 12 months. 
b Percent may not add up to 100% due to rounding. 
c Used multiple drugs or a single drug other than Marijuana. 
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Figure 7-3: Weighted prevalence of PMS over time, from 2000 to 2012, among women from the 1973–78 cohort of the ALSWH 
7.4 Discussion 
In 2000, nearly every two in three Australian women aged 22 to 27 years reported use of 
illicit drugs in their lifetime which increased modestly over the study period, and almost 10% 
first used drugs before reaching age 15 years. However, use of illicit drugs in the last 12 
months decreased considerably over time especially during the earlier surveys. Marijuana 
was the most commonly used drug, but the majority of women used it together with one or 
more other drugs. The patterns of recent drug use over time are largely comparable with 
those reported for the same age group in the 2010 National Drug Strategy Household 
Survey [185]. A different trend for PMS was observed with over one-third of women 
reporting PMS at baseline which remained fairly stable over time except an increase to just 
over 40% when the women were 34 to 39 years. The different trend observed may be 
related to the different effects of age versus time on drug use and PMS, with drug use in 
the last 12 months decreasing markedly with both age and time; whereas no clear age 
effect was detected for PMS with only a modest decrease with time detected, except 
Survey 6 (results not presented). The prevalence is consistent with that reported for 
moderate to severe PMS in the literature [9, 13], and appears in line with the finding from a 
global epidemiological study indicating a peak age of around 35 years for some 
premenstrual symptoms [21].  
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Table 7-4: Univariate and multivariable-adjusted ORs of PMS by patterns of illicit drug use (n = 8,919) and age at first drug use (n = 7,102) 
from GEE analyses among women from the 1973–78 cohort of the ALSWH, 2000–2012a 
 Univariate Multivariable-adjusted 
 OR 95% CI OR 95% CI OR 95% CI 
   Pattern of drug use Age at first drug use 
Pattern 2 of any illicit drug use     Not applicable 
 Never 1  1    
 Ex-exclusive marijuana use 1.07 1.00, 1.14 1.03 0.96, 1.11   
 Ex-multiple drug useb 1.24 1.15, 1.35 1.14 1.05, 1.25   
 Recent exclusive marijuana use 1.39 1.23, 1.57 1.23 1.08, 1.40   
 Recent multiple drugs useb 1.55 1.43, 1.67 1.31 1.20, 1.43   
Age at first drug use (years)   Not applicable   
 Never 1    1  
 <15 1.48 1.28, 1.71   1.20 1.03, 1.40 
 15–17 1.21 1.10, 1.34   1.07 0.96, 1.20 
 ≥18 1.14 1.03, 1.26   1.00 0.90, 1.11 
Age  1.02 1.00, 1.04   1.04 1.01, 1.07 
Highest education        
 Less than high school 1  1  1  
 High school/trade certificate 1.02 0.91, 1.15 1.01 0.89, 1.14 1.00 0.87, 1.14 
 Diploma or higher 1.06 0.95, 1.19 1.02 0.91, 1.14 1.01 0.89, 1.15 
Marital status        
 Single 1  1  1  
 Married/de facto 0.86 0.81, 0.92 1.07 1.01, 1.14 1.06 0.99, 1.13 
 Separate/divorced/widowed 0.93 0.82, 1.05 1.03 0.91, 1.17 1.02 0.89, 1.17 
Coping with incomed        
 Impossible 1.01 0.84, 1.21 0.99 0.82, 1.19 0.98 0.80, 1.20 
 Difficult all the time 1.17 1.07, 1.27 1.17 1.07, 1.28 1.19 1.08, 1.31 
 Difficult sometimes 1.10 1.02, 1.17 1.17 1.09, 1.25 1.16 1.07, 1.25 
 Not too bad 1.03 0.97, 1.10 1.09 1.02, 1.16 1.09 1.01, 1.16 
 Easy 1  1  1  
Area of residence#       
 Urban 1  1  1  
 
133
 Univariate Multivariable-adjusted 
 OR 95% CI OR 95% CI OR 95% CI 
   Pattern of drug use Age at first drug use 
 Rural 0.87 0.82, 0.92 0.93 0.87, 0.98 0.93 0.88, 1.00 
 Remote 0.87 0.75, 1.00 0.93 0.81, 1.08 0.95 0.81, 1.11 
Language spoken at home       
 English 1  1  1  
 European other than English 1.39 1.21, 1.61 1.31 1.13, 1.52 1.38 1.17, 1.62 
 Asian 0.78 0.58, 1.04 0.79 0.59, 1.06 0.88 0.60, 1.29 
 Other 0.91 0.61, 1.34 0.87 0.59, 1.30 0.92 0.57, 1.48 
BMI (kg/m2)       
 Underweight (<18.5) 1.21 1.07, 1.36 1.19 1.05, 1.35 1.19 1.04, 1.36 
 Normal weight (18.5 to <25) 1  1  1  
 Overweight (25 to <30) 0.92 0.87, 0.98 0.91 0.86, 0.97 0.92 0.86, 0.99 
 Obese (≥30) 1.01 0.93, 1.09 0.97 0.90, 1.05 0.97 0.89, 1.06 
Smoking status       
 Never-smoker 1  1  1  
 Ex-smoker 1.14 1.07, 1.23 1.05 0.97, 1.13 1.09 1.00, 1.18 
 Smoker <10 cigarettes/day  1.30 1.25, 1.49 1.13 1.03, 1.24 1.20 1.09, 1.33 
 Smoker 10-19 cigarettes/day 1.25 1.12, 1.39 1.03 0.92, 1.15 1.09 0.96, 1.23 
 Smoker ≥20 cigarettes/day 1.20 1.04, 1.39 0.97 0.84, 1.13 1.04 0.88, 1.22 
Alcohol consumption       
 None/rarely 1  1  1  
 Low-risk drinking 1.17 1.11, 1.23 1.10 1.04, 1.16 1.09 1.03, 1.16 
 Risky/high-risk drinking 1.40 1.24, 1.59 1.14 1.01, 1.30 1.20 1.05, 1.37 
OCPs        
 Not use 1  1  1  
 Used 0.87 0.83, 0.91 0.83 0.78, 0.87 0.82 0.78, 0.87 
Number of births       
 0 1  1  1  
 1 0.48 0.45, 0.52 0.46 0.42, 0.49 0.45 0.42, 0.49 
 ≥2  0.70 0.65, 0.75 0.67 0.62, 0.72 0.66 0.61, 0.71 
Age at menarche (years)       
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 Univariate Multivariable-adjusted 
 OR 95% CI OR 95% CI OR 95% CI 
   Pattern of drug use Age at first drug use 
 8–11 1.20 1.10, 1.31 1.19 1.09, 1.31 1.18 1.07, 1.31 
 1214 1  1  1  
 ≥15 0.87 0.79, 0.96 0.85 0.77, 0.94 0.84 0.75, 0.93 
History of abuse        
 Yes 1.44 1.35, 1.53 1.31 1.22, 1.40 1.30 1.21, 1.40 
 No 1  1  1  
 Don’t want to answer 1.04 0.83, 1.29 0.97 0.78, 1.21 0.92 0.71, 1.20 
Depressed        
 No 1  1  1  
 Yes 1.54 1.46, 1.62 1.47 1.39, 1.56 1.45 1.36, 1.54 
a Recent use is use in the last 12 months. 
b Used multiple drugs or a single drug other than Marijuana. 
Significant, albeit moderate, associations were demonstrated for multiple drug use in the 
last 12 month with a 30% higher odds of reporting PMS, after adjusting for potential 
confounders including smoking and alcohol consumption. Women with multiple drug use 
showed higher risk of PMS than those with exclusive Marijuana use. The findings are in 
line with previous evidence indicating that drug dependency, mortality and other acute and 
long-term harmful health effects may be greater for people with multiple drug use than 
those with single drug use [187]. More importantly, early age at first drug use (<15 years), 
particularly those who used drugs in the last 12 months, also showed a 40% higher odds 
of PMS. Given that most women started using Marijuana earlier than other common drugs, 
and coupled with the evidence that early onset of cannabis use is a risk factor for later 
multiple drug use [188], the findings support antidrug campaigns targeting young people to 
avoid, or at least to delay, illicit drug use [189]. Ex-drug use, on the other hand, was 
generally not associated with PMS.  
Little is understood about the underlying mechanism for the association between illicit drug 
use and PMS, possibly due to limited research on the subject. Currently, most available 
evidence appears to point to the observed drug–hormone interactions, although these may 
vary across different drug classes and, possibly, between women with and without PMDD 
[190]. Examples of evidence supporting the biological plausibility of the relationship are 
that Marijuana was shown to disrupt the menstrual cycle [191], whereas opioids suppress 
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gonadal hormone secretion primarily through acting on the hypothalamus [192]. Shared 
actions of illicit drugs and gonadal hormones (oestrogen and progesterone) on serotonin, 
dopamine or other neurotransmitters have been suggested as supported by the 
observation that both stimulant drugs (especially amphetamine and cocaine) and gonadal 
hormones directly affect dopamine neurotransmission [190]. Furthermore, large doses of 
the active ingredient of Marijuana, delta-9-tetrahydrocannabinol, have been shown to 
affect serotonin and other neurotransmitters in a way that produces depressive symptoms 
[193]. As the interactions of fluctuating levels of ovarian steroids or their metabolites with a 
number of neurotransmitters, particularly serotonin, have currently been proposed as the 
main aetiology of PMS [8, 12], it is plausible that the drug-hormone interactions may be 
involved in the pathogenesis of PMS.  
A reverse causation was also suggested for illicit drug use to cope with menstrual 
symptoms including PMS [194]. Although no consistent relation between the patterns of 
illicit drug use and menstrual cycle has been observed, there are studies showing 
increased drug use during the late luteal phase in women with PMDD [190, 194, 195]. 
However, there is also some evidence of a lack of intra-subject correlations between 
symptomatology and drug intake, and peak intake of illicit drugs failed to coincide with 
peak symptomatology in women with PMDD [196]. The different trend observed for drug 
use in the last 12 months and PMS, and the different associations detected between age 
at first drug use and PMS in this study (significant association for early starters versus no 
association for later starters) provides little support for the self-medication hypothesis. 
Nevertheless, it is currently not possible to revoke the reverse causation. As proposed on 
the relationship between Marijuana use and psychosis [189], a bidirectional relationship 
may exist in that PMS might result in Marijuana use at an early stage, whereas repeated 
drug use over time may increase the occurrence of PMS. Further research enabling the 
assessment of the relative timing of the events is needed to test the hypothesis. 
In addition, as the hypothesis on the association between heavy Marijuana use and 
depression [193], it is possible that the association of interest is mediated by common 
social, family and contextual factors that increase the risks of both drug use and PMS, 
such as history of abuse. Indeed, women who had a history of abuse were more likely to 
use multiple drugs and to report PMS in this study. However, the association of interest 
remained after adjusting for a range of sociodemographic and psychological factors 
including history of abuse, depression, smoking and alcohol consumption. Nevertheless, it 
is currently premature to rule out the theory. A genetic predisposition to PMS, similar as 
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that proposed in the association between drug use and psychotic disorders, may also be 
one of the potential factors that influence the link between illicit drug use and PMS [189]. 
The increased odds for PMS among women with an age at first drug use before 15 years 
is of interest. There may be plausible explanations for the relationship. First, women who 
first used illicit drug earlier comprise a high-risk group since they may have a longer and 
more consistent exposure to illicit drugs. Our study shows that they were more likely to 
report drug use in the last 12 months (results not presented), which is shown to be 
associated with a higher risk of PMS. Alternatively, although our final model has adjusted 
for a range of potential confounders, the association may be mediated by other factors that 
were missed. Furthermore, early use of illicit drugs may have a stronger impact on the 
endocrine system controlling menstruation. Many of the physical and hormonal changes 
associated with the functional maturation of the hypothalamic-pituitary-gonadal axis, which 
in turn regulates menarche and, ultimately, the establishment of cyclic ovarian function, 
occur prior to menarche [181]. According to a life course epidemiological approach, the 
time prior to age of 15 years, which has been suggested to represent the 95–98th 
percentile for menarche [197], maybe a sensitive period for establishing normal 
menstruation, when illicit drugs have a stronger effect on the development and, therefore, 
disease risk than they would have at other times [182]. However, the hypothesis and the 
biological mechanisms would need to be validated by further research. 
Despite continuous public efforts on anti-drug campaigns, illicit drug lifetime use remains 
common among young Australian women, including adolescent girls. Given that illicit drug 
use is one of the leading health risks in Australia [27] and that PMS is a common disorder 
among young Australian women, the gap in the literature on the association between the 
two deserves more research attention. Only with a better understanding of the association, 
can preventative health policies be initiated for women to enjoy a better reproductive life, 
resulting in improved population health. As a first step, this longitudinal study 
demonstrates higher odds of reporting PMS among women who used multiple drugs in the 
last 12 months, especially those with an early age of first drug use; but it only 
demonstrates association, not causality. Future research is needed to replicate the study 
findings and to further clarify the nature of the association between drug use and PMS. 
Future neurobiological research to investigate the potential pathways of the observed 
relationship may be useful to advance our understanding of the complex association.  
Strengths and limitations 
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This is the only population-based longitudinal study which has investigated the association 
between illicit drug use and PMS, enriching the limited body of evidence in the field. The 
representative sample makes the results applicable to women with similar characteristics 
and settings. However, the study has a number of limitations. First, all the data are self-
reported, which may be subject to reporting bias. The results from both sensitivity analysis 
and multiple imputations (results not present) showed minimal changes in the estimates, 
indicating the robustness of the results. Given the longitudinal nature and large size of the 
study, self-report may be the most practical way for data collection. Further, our estimated 
prevalence of drug use in the last 12 months is very similar to that reported in the similar 
age group from the most recent national survey of household drug use [185] and the 
prevalence of PMS is consistent with that reported in the literature [9, 13], providing further 
confidence in the self-reported data. 
Second, no specific diagnostic criteria for PMS were used apart from the subjective 
responses (no, rarely, sometimes, often) to the survey question (have you had 
premenstrual tension in the last 12 months), thus no details on the timing in the cycle and 
severity of the symptoms are available. This may raise the question of the reliability of the 
data. However, premenstrual tension is a widely used term in both clinical settings and in 
media in Australia (personal communication with local specialist). Therefore, using the 
questionnaire to ascertain PMS status is unlikely to impact substantially on the reliability of 
our data. Furthermore, currently there is no definitive, universally accepted criterion 
adopted for PMS, work is underway to reach such a consensus especially in research 
setting [19]. 
Third, data over the past 12 months were collected retrospectively at each survey wave, 
which may subject the data to recall bias. Although daily symptom reporting is currently the 
gold standard for evaluating PMS, it may not be feasible in this large population setting. 
The repeated measures over a long follow-up period may also offset the disadvantage of 
the absence of daily rating. Fourth, limited data on drug use were collected in the surveys 
and the frequency and continuity of drug use are not available, so we are not able to 
ascertain the regularity of drug use and examine its relationship with PMS. It is also not 
possible to conduct the analysis by different classes of drug use due to lack of data on 
other drug use apart from Marijuana in later surveys. Nevertheless, this is the first 
population-based longitudinal study to investigate the association between drug use and 
PMS in Australian women. Based on the demonstrated association, further studies are 
justified to replicate the results and to understand the nature of the association. Last, 
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although we have attempted to control for a range of potential confounding factors, it is 
possible that some important cofounders have been omitted. Such omission may lead to 
an overestimation of the association reported.  
In conclusion, this study demonstrates illicit drug use in the last 12 months, especially 
where there is early age at first use and multiple drug use, is associated with an increased 
risk of PMS. However, given the complex relationship, this study only demonstrates 
association but cannot establish causality. Further longitudinal study is called for to 
replicate the findings and to test the temporal relation of the association. 
 
139
Chapter 8. The U-shaped relationship between body 
mass and dysmenorrhea (Paper 5) 
Obesity is one of the leading contributors to health loss in Australia [27] and its prevalence 
is rapidly increasingly around the world [18]. As highlighted in the literature review in 
Chapter 3, its association with dysmenorrhea is not well-understood with mixed results 
generated from a few longitudinal studies. As the last part of the series of lifestyle risk 
factors identification, this chapter presents a study examining the long-term association 
between BMI and dysmenorrhea over time. Further, it explores the relationship between 
BMI transition over time and dysmenorrhea. This paper is in press in peer-reviewed 
Journal PLOS ONE in 2015.  
Hong Ju, Mark Jones, Gita D Mishra. A U-shaped relationship between body mass index 
and dysmenorrhea: a longitudinal study. 2015. Submitted to PLOS ONE (in press) 
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Abstract 
Background: Both obesity and dysmenorrhea are prevalent among women. Few 
population-based longitudinal studies investigate the association between BMI and 
dysmenorrhea yielding mixed results, especially for obesity. This study aims to investigate 
the long-term association between BMI and dysmenorrhea. 
Methods: 9,688 women from a prospective population-based cohort study were followed 
for 13 years. Data were collected through self-reported questionnaires. The longitudinal 
association between dysmenorrhea and BMI or BMI change was investigated by logistic 
regression analysis using generalized estimating equations to account for the repeated 
measures. 
Results: When the women were aged 22 to 27 years, approximately 11% were obese, 7% 
underweight, and 25% reported dysmenorrhea. Compared with women with a normal 
weight, significantly higher odds of reporting dysmenorrhea were detected for both women 
who were underweight (OR 1.34, 95% CI 1.15, 1.57) and obese (OR 1.22, 95% CI 1.11, 
1.35). Compared with women who remained normal weight or overweight over time, 
significant risk was detected for women who: remained underweight or obese (OR 1.33, 95% 
CI 1.20, 1.48), were underweight despite weight gain (OR 1.33, 95% CI 1.12, 1.58), or 
became underweight (OR 1.28, 95% CI 1.02, 1.61). However, the higher risk among 
obese women disappeared when they lost weight (OR 1.06, 95% CI 0.85, 1.32).  
Conclusions: A U-shaped association was revealed between dysmenorrhea and BMI, 
revealing a higher risk of dysmenorrhea for both underweight and obese women. 
Maintaining a healthy weight over time may be important for women to have pain-free 
periods. 
Key words: dysmenorrhea, painful period, body mass index, obesity, underweight, 
longitudinal 
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8.1 Introduction 
Dysmenorrhea is defined as a severe, painful, cramping sensation in the lower abdomen 
occurring just before or during the menses [198]. It is a common gynaecological complaint, 
affecting the majority of women of reproductive age with 2% to 29% having severe pain [6]. 
As a debilitating condition, it has a major impact on women’s health-related quality-of-life 
and social and occupational roles, resulting in significant work and school absences [1, 24]. 
Considerable economic losses due to dysmenorrhea were estimated resulting from 
decreased productivity, costs of medications and medical care [23].  
Obesity is one of the leading contributors to health loss in Australia [27]. A rapidly 
increased prevalence was observed over the last decade with 63% of Australian adults 
being overweight or obese in 2011–2012 [199]. Although obesity has been associated with 
multiple adverse reproductive health outcomes [200], mixed results have been obtained on 
its relationship with dysmenorrhea [6]. An earlier systematic review examined the risk 
factors predisposing women to chronic pain, including 63 studies on dysmenorrhea [76]. It 
found that BMI <20 kg/m2 was associated with dysmenorrhea, whereas no relationship 
was demonstrated between BMI >24 kg/m2 and dysmenorrhea. Significant heterogeneity 
was detected among the studies on the association of dysmenorrhea and BMI >24 kg/m2. 
A more recent review including mainly community-based cross-sectional studies yielded 
inconsistent results on the association between BMI and dysmenorrhea, with a large 
Japanese study revealing a positive association between them and the other smaller 
studies failing to show any association [6].  
To date, only a few population-based longitudinal studies have investigated the 
association between BMI and dysmenorrhea. Being overweight was found to be a risk 
factor for the probability of experiencing pain and for increased duration of pain in one 
study [43], but others failed to show an association between the incidence of 
dysmenorrhea with BMI [69] or the severity of dysmenorrhea with either weight or height 
[55].  
Given the prevalence of the problems and the mixed findings on their relationship, this 
study has been undertaken to investigate the longitudinal association between BMI and 
dysmenorrhea in a large sample of Australian women followed over 13 years.  
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8.2 Methods 
Subjects 
The study population was from the 1973-78 cohort of the ALSWH, a prospective cohort 
study with random sampling from the national Medicare database. The 1973–78 cohort 
included 14,247 women aged 18 to 23 years at baseline (1996) who were found to be 
reasonably representative of Australian women of the same age group from the national 
census despite that women included in the survey were more likely to have tertiary 
education and less likely to be in the labour force [28]. Questionnaires were sent to 
participants every three years from Survey 2 onwards, with the most recent survey 
conducted in 2012. The detailed study methods have been reported elsewhere [29]. 
ALSWH was approved by the Human Research Ethics Committee of The University of 
Newcastle and The University of Queensland. Permission to use the data was granted for 
this study from the Publications, Analyses and Substudies Committee of the ALSWH in 
August 2012. 
As discussed in a previous study [176], data from Survey 1 was not included due to 
evidence of considerable over-reporting of dysmenorrhea known as ‘telescoping’ effect 
common in self-reported data [42]. Therefore, data from the last five waves of the survey 
over 13 years (from Survey 2 in 2000 to Survey 6 in 2012) were included in this study, 
except that BMI from Survey 1 was used when calculating BMI transition from Survey 1 to 
2. Women who were pregnant at Survey 1 to 3 were excluded as the reported weight was 
not based on their pre-pregnancy weight. Baseline refers to Survey 2 (N = 9,688) hereafter. 
Measurements 
All data were collected through self-report at each survey. The outcome of interest, 
presence of dysmenorrhea, was based on the question: ‘In the last 12 months have you 
had severe period pain?’ Women were considered to have had a recent history of 
dysmenorrhea if their response was ‘sometimes’ or ‘often’, and to be symptom-free if their 
response was ‘never’ or ‘rarely’.  
The main exposure of interest was BMI which was calculated as weight in kilograms 
divided by the square of height in metres. Two measurements in BMI were used to 
examine its association with dysmenorrhea. First, BMI in kg/m2 was categorised as 
underweight (< 8.5), normal (18.5 to 24.99), overweight (25 to 29.99) or obese (≥30) based 
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on the recommendations from the WHO [32]. Second, BMI transition was created based 
on the change of BMI categories in two successive surveys. As overweight showed no 
association with dysmenorrhea, it was grouped together with normal BMI in creating BMI 
transition. Seven BMI transition groups were derived as: 1) remained normal or overweight 
(reference group); 2) remained underweight or obese; 3) from underweight to normal or 
overweight; 4) from normal or overweight to underweight; 5) from normal or overweight to 
obese; 6) from obese to normal or overweight; and 7) varied between normal and 
overweight.  
Other socio-demographic and lifestyle characteristics of the women were collected in each 
survey and included age, highest level of education, employment, marital status, area of 
residence, management on income, history of abuse, smoking status, alcohol consumption, 
illicit drug use and physical activity. The following reproductive characteristics were 
included: use of oral contraceptives, number of births (live and still), age at menarche and 
endometriosis. The detailed categorisations of these variables are shown in Table 8-1. 
Statistical analysis 
Statistical analyses were performed using SAS version 9.4 for Windows (SAS Institute Inc., 
Cary, North Carolina, USA). Women’s BMI status at the individual level over time was 
displayed at each survey using a lasagne plot for longitudinal categorical variables [38]. 
The prevalence of dysmenorrhea, weighted for area of residence to correct for 
oversampling of women in rural and remote area, was displayed in a histogram to show its 
trend over time. 
Baseline characteristics of the women in relation to BMI and dysmenorrhea status were 
compared using χ2 test. The longitudinal association between BMI and dysmenorrhea was 
investigated by logistic regression, taking into account the change of status and the 
repeated measures of variables over time using GEE. In the BMI transition model, the 
prevalence of dysmenorrhea at a given survey was modelled in relation to BMI transition 
between the index survey and the immediately preceding survey. Univariate analysis was 
performed on all exposure variables, and those which were statistically significantly 
associated with dysmenorrhea were entered into multivariable-adjusted models. The 
association of interest was examined after controlling for sociodemographic, lifestyle and 
reproductive factors, sequentially entered into the models in blocks of variables. Statistical 
significance was set at p <0.05. 
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Due to between 10% to 32% of women with missing BMI at different time points, sensitivity 
analysis was performed by comparing the results based on the observed data with results 
after multiple imputations (MI) for missing data on outcome and covariates. MI procedure 
in SAS was used as follows: 1) PROC MI (fully conditional specification method) to create 
a series of 20 imputed data sets; 2) GEE analysis on each of the imputed data set; 3) 
PROC MIANALYZE to generate a final single set of parameter estimates.  
8.3 Results 
At baseline, when the women were aged 22 to 27 years, the majority had a BMI in the 
normal range whereas approximately 20% were overweight and 11% obese (Table 8-1). A 
small proportion of women (7%) were underweight. Over time, an increase in the 
prevalence of both overweight and obese was observed, especially for obesity (Figure 8-1). 
A substantial decrease was detected in the proportion of women classified as normal 
weight or underweight. 
 
Figure 8-1: Change of BMI categories among women from the 1973–78 cohort of the ALSWH from year 2000 (Survey 2) to 2012 (Survey 6) 
(Percentages may not add up to 100% due to rounding) 
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Table 8-1: Baseline BMI, other characteristics, and the prevalence of dysmenorrhea among women from the 1973–78 cohort of the 
ALSWH, aged 22 to 27 years in 2000 
Characteristics at baseline  Percenta Prevalence of dysmenorrhea (24.5%)  
(N = 9,688)  %a p value 
BMI (kg/m2) (n = 8,699)   0.001 
 Underweight (<18.5) 6.7 30.4  
 Normal (18.5 to <25) 62.9 24.3  
 Overweight (25 to <30) 19.8 26.5  
 Obese (≥30) 10.6 28.1  
Other baseline characteristics    
Age (years) (n = 9,671)   <0.0001 
 22–23 37.4 27.3  
 24–25 39.9 25.2  
 26–27 22.7 21.5  
Highest education (n = 9,325)   0.0091 
 Less than high school 11.3 26.5  
 High school/trade certificate 27.2 27.0  
 Diploma or higher 61.5 24.0  
Employment status (n = 9,541)   <0.0001 
 Employed 41.0 22.0  
 Unemployed 59.0 27.3  
Marital status (n = 9,623)   <0.0001 
 Single 53.0 27.4  
 Married/de facto 45.7 22.7  
 Separate/divorced/widowed 1.3 20.7  
Area of residence (n = 9,629)   0.05 
 Urban 55.1 26.1  
 Rural 41.1 24.1  
 Remote 3.8 22.7  
Language spoken at home (n = 9,576)   <0.0001 
 English 92.8 24.5  
 European other than English 4.7 33.6  
 Asian 1.5 27.4  
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Characteristics at baseline  Percenta Prevalence of dysmenorrhea (24.5%)  
(N = 9,688)  %a p value 
 Other 0.9 40.0  
Coping with income (n=9,641)   <0.0001 
 Impossible 3.1 26.4  
 Difficult all the time 13.7 33.2  
 Difficult sometimes 32.2 26.5  
 Not too bad 37.4 22.2  
 Easy 13.6 21.7  
History of abuse (n=9,526)   <0.0001 
 Yes 39.0 30.8  
 No 58.6 21.0  
 Don’t want to answer 2.4 30.6  
Smoking status (n =9,591)   <0.0001 
 Never-smoker 57.4 23.0  
 Ex-smoker 14.5 25.3  
 Smoke <10 cigarettes/day 14.5 27.2  
 Smoke 10-19 cigarettes/day 8.9 31.6  
 Smoke ≥ 20 cigarettes/day 4.7 32.7  
Alcohol consumption (n = 9,606)   0.04 
 None/rarely 38.0 25.8  
 Low-risk drinking 58.2 24.4  
 Risky/high-risk drinking 3.8 29.8  
Illicit drug use (n = 9,502)   0.0004 
 Never 35.8 23.6  
 Not in last 12 months 22.0 23.6  
 Used in last 12 months 42.2 27.1  
Physical activity (n = 9,421)   0.44 
 Sedentary 10.5 25.8  
 Low 43.8 24.5  
 Moderate 23.4 25.2  
 High 22.3 26.3  
OCPs (n = 9,532)   <0.0001 
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Characteristics at baseline  Percenta Prevalence of dysmenorrhea (24.5%)  
(N = 9,688)  %a p value 
 Not use 43.9 30.5  
 Used 56.1 20.8  
Number of births (n = 9,650)   <0.0001 
 0 82.2 26.2  
 1 10.8 21.8  
 ≥2  6.9 17.9  
Age at menarche (years) (n = 9,570)   <0.0001 
 8-11 13.3 30.5  
 12-14 74.5 24.4  
 ≥15 12.2 24.1  
Endometriosis (n = 9,576)   <0.0001 
 No 96.9 24.0  
 Yes 3.1 61.3  
a percent may not add up to 100% due to rounding. 
Approximately 25% of the women reported dysmenorrhea when they were aged 22 to 27 
years, which remained stable over the study period before a slight increase was observed 
when they reached 34 to 39 years of age (Figure 8-2). Baseline characteristics of the 
women by dysmenorrhea status are presented in Table 8-1. Women reporting 
dysmenorrhea were more likely to be underweight or obese, younger, single, employed, 
heavy smokers, to speak a European language other than English, to have a history of 
abuse, to have difficulty managing income, an early age of menarche and to have 
endometriosis. Women who used OCPs and who had given birth were less likely to report 
dysmenorrhea. 
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Figure 8-2: Prevalence of dysmenorrhea among women from the 1973–78 cohort of the ALSWH from year 2000 (Survey 2) to 2012 (Survey 
6) 
Over the study period, approximately 77% of women maintained a stable BMI, and 11% 
changed between healthier (normal or overweight) and high-risk (underweight or obese) 
categories (Table 8-2). The annual average weight change of the women varied according 
to their BMI transition status. Over time, women who maintained a BMI within the normal 
or overweight group had the most stable weight with an average weight gain of 0.3 kg/year. 
However, a much greater gain of 3.9 kg/year was observed for women whose BMI 
changed from normal or overweight to obese, and an average weight loss of 3.8 kg/year 
was seen among women whose BMI changed from obese to overweight or normal. 
Table 8-2: Annual average weight change according to BMI transition groups among the 1973–1978 cohort of the ALSWH from 1996 to 
2012 
 Percent Annual average weight change (kg)a 
BMI transition  
(n = 8,667) 
 Survey  
1-2 
Survey  
2–3 
Survey 
3–4 
Survey 
4–5 
Survey 
5–6 
Overall 
 Remain normal or overweight 62.7 0.4 ± 1.3 0.5 ± 1.6 0.4 ± 1.6 0.5 ± 1.6 0.3 ± 1.6 0.3 ± 1.2 
 Remain underweight or obese 14.0 1.2 ± 2.4 1.5 ± 3.0 1.2 ± 3.1 0.8 ± 3.7 0.5 ± 4.0 0.9 ± 2.9 
 Underweight → normal or  
 overweigh 
1.4 0.6 ± 1.4 0.7 ± 1.7 0.5 ± 1.7 0.4 ± 1.7 0.4 ± 1.5 1.7 ± 1.3 
 Normal or overweight →  
  underweight 
5.1 -0.5 ± 1.3 0.1 ± 1.8 0.3 ±1.8 0.2 ± 1.9 0.1 ± 1.6 -1.5 ± 1.3 
 Normal or overweight → obese 2.8 1.7 ± 2.4 1.6 ± 3.1 1.3 ± 3.1 1.3 ± 3.1 1.1 ± 3.4 3.9 ± 2.3 
 Obese → overweigh or normal 1.7 0.8 ± 2.8 0.7 ± 3.6 0.5 ± 3.8 0.4 ± 4.1 -0.5 ± 4.1 -3.8 ± 2.9 
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 Percent Annual average weight change (kg)a 
BMI transition  
(n = 8,667) 
 Survey  
1-2 
Survey  
2–3 
Survey 
3–4 
Survey 
4–5 
Survey 
5–6 
Overall 
 Normal ↔ overweight 12.2 0.8 ± 1.8 0.8 ± 2.4 0.7 ± 2.3 0.8 ± 2.3 0.5 ± 2.3 1.1 ± 2.6 
a mean ± SD 
A total of 8,931 women were included in the BMI model. The univariate analysis showed 
that, compared with those who had a normal BMI, women who were underweight or obese 
were both at over 40% higher odds to report dysmenorrhea (Table 8-3). Overweight, 
however, was not related to dysmenorrhea. After adjusting for potential confounders, the 
associations were attenuated; however, significantly higher odds of reporting 
dysmenorrhea remained for women who were underweight and obese, with 34% and 22% 
higher odds respectively. 
Table 8-3: Univariate and multivariable-adjusted association from GEE analysis between BMI and dysmenorrhea among the 1973–1978 
cohort of the ALSWH from 2000 to 2012  
 Sample (N) Univariate Multivariable-adjusted 
BMI  OR 95% CI OR 95% CI 
BMI category (kg/m2) 8,931 p <0.0001 p<0.0001 
 Underweight (<18.5)  1.41 1.22, 1.64 1.34 1.15, 1.57 
 Normal weight (18.5 to <25)  1  1  
 Overweight (25 to <30)  1.05 0.98, 1.14 0.99 0.91, 1.07 
 Obese (≥30)  1.46 1.33, 1.60 1.22 1.11, 1.35 
BMI transition 8,579 p <0.0001 p <0.0001 
 Remain normal or overweight  1  1  
 Remain underweight or obese  1.54 1.41, 1.72 1.33 1.20, 1.48 
 Underweight → normal or overweigh  1.36 1.16, 1.60 1.33 1.12, 1.58 
 Normal or overweight → underweight  1.38 1.10, 1.73 1.28 1.02, 1.61 
 Normal or overweight → obese  1.21 1.06, 1.37 1.07 0.93, 1.22 
 Obese → overweigh or normal  1.22 0.99, 1.51 1.06 0.85, 1.32 
 Normal ↔ overweight  1.08 0.99, 1.19 1.01 0.92, 1.11 
Multivariable-adjusted analysis estimates the effect of the exposure of interest (BMI) after controlling for sociodemographic characteristics (age, 
education, employment, marital status, language spoken at home, managing income, and history of abuse), lifestyle factors (smoking, illicit drug 
use and alcohol consumption), and reproductive factors (use of OCP, parity, age at menarche, and endometriosis). 
Among the 8,579 women included in the BMI transition model, women who remained 
underweight or obese showed the highest odds of reporting dysmenorrhea compared with 
women with a BMI staying normal or overweight (Figure 8-3). Following this, women 
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whose BMI changed from underweight to normal or overweight, and vice versa, also had 
more than 30% higher odds of reporting dysmenorrhea. These associations were once 
again attenuated but remained significant in the multivariable-adjusted model. No 
association was detected for other BMI transition groups. 
 
Figure 8-3: Odds ratio of reporting dysmenorrhea at a survey by BMI transition groups between index surveys and the immediately 
preceding survey. (Reference group = BMI remained as normal or overweight) 
Results of the sensitivity analysis from the multiple imputed data are presented in 
Appendix I. Significant association between dysmenorrhea and both underweight and 
obese remained despite being slightly attenuated, especially for underweight (OR 1.27, 95% 
CI 1.09, 1.49). For BMI transition, similar results were obtained. 
8.4 Discussion 
When this group of Australian women were aged 22 to 27 years, every one in 10 was 
obese. The prevalence of obesity more than doubled to over 23% during the 13 years 
follow-up, which is consistent with the overall trend in Australia [199]. The prevalence of 
underweight, however, decreased substantially. Dysmenorrhea affected one-fourth of the 
women, which remained relatively stable over time. The prevalence is in line with the rate 
reported for severe dysmenorrhea in a recent review [6]. 
This study revealed a U-shaped relationship between BMI and dysmenorrhea, with both 
underweight and obese significantly associated with dysmenorrhea. The result agrees with 
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previous studies on the relationship between low body mass and dysmenorrhea in 
adolescents and young adult women [201-203]. However, previous findings were mixed on 
the association between dysmenorrhea and overweight or obese, probably due to the 
varying population included, exposure and outcome measured, and the power of the study 
[43, 55, 68, 69, 76, 204]. Among the few longitudinal studies investigating the relationship, 
two did not demonstrate any relationship between BMI and either the prevalence or the 
severity of dysmenorrhea [55, 69]. However, overweight was shown to be a risk factor for 
dysmenorrhea, doubling the odds of having severe pain or pain lasting longer than two 
days in another study of 165 college women [43]. Our results are in line with this later 
study since overweight was referred to women with a weight-for-height index above the 
90th centile in that study. 
We further explored the relationship of BMI transition over time and dysmenorrhea. 
Compared with women whose BMI remained normal or overweight, women whose BMI 
remained within the high-risk categories, namely underweight and obese, showed 33% 
higher risk of dysmenorrhea. The association between dysmenorrhea and obesity 
disappeared if obese women lost weight, at an average rate of 3.8 kg/year, and moved to 
a healthier BMI range. However, no statistically significant association with dysmenorrhea 
was shown for women who became obese over the study period. We hypothesised that 
this may be partly explained by the observation that obese women were more likely to 
have missing BMI. However, it was not confirmed in the sensitivity analysis using multiple 
imputed data. 
On the contrary, women who were previously underweight, despite gaining weight at an 
average of 1.7 kg/year and moving to a healthier BMI category, still showed a 30% higher 
risk of dysmenorrhea. Similarly, higher risk was shown for normal or overweight women 
who lost weight and became underweight. The reason for this consistently higher risk of 
dysmenorrhea for underweight women, despite weight gain, is not apparent. It may be that 
underweight imposes a stronger and lasting impact on ovarian function at an earlier age or 
that this group of women may have other underlying conditions that confound or mediate 
the association. The analyses have adjusted for endometriosis, OCP use, parity and 
history of abuse (including sexual, emotional and physical). We further examined the 
relationship between BMI and a number of other potential underlying conditions and found 
that although they were more prevalent among underweight women compared with normal 
weight women, they were not different among women who were underweight or obese. 
Nevertheless, contrasting the radical changes in the perception of body size which have 
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pressured women to be super slim [204], this study shows that very thin women may suffer 
from distressing period pain repeatedly over their reproductive life. There is sparse 
literature on the association of dysmenorrhea and BMI transition, which may be an area for 
future study. 
There is complex interaction between body fat and steroid hormones, thus the endocrine 
control of menstruation [200, 205]. The underlying mechanisms of the association between 
BMI and dysmenorrhea are not well understood, and they may differ in underweight and 
obese women. Nevertheless, despite some disagreement [206], a certain amount of body 
fat appears to be important to maintain normal ovulatory cycles with both too much and too 
little fat being associated with the disruption of their reproductive health [205, 207]. There 
are several known mechanisms on the influence of adipose tissue on ovulation and the 
menstrual cycle: 1) adipose tissue converts androgens to oestrogen by aromatisation; 2) 
body weight influences the direction of oestrogen metabolism with very thin women 
making less potent and obese women more potent forms of oestrogen; 3) obese women 
have a diminished capacity for oestrogen to bind to sex-hormone binding globulin (SHBG) 
which inactivates oestrogen, resulting in an elevated percentage of free serum oestradiol 
[208]. 
The primary disease pathogenesis for dysmenorrhea has been related to increased 
prostaglandins in the menstruating uterus, leading to reduced endometrial blood flow and 
subsequent pain [24]. There is suggestion that endometrial thickness may be influenced 
by adiposity through its oestrogen-mediated effect [43, 200]. Body weight has been 
inversely correlated with serum SHBG concentrations [209], and diminished SHBG or 
elevated serum oestrogen potentially increases oestrogenic stimulation of the 
endometrium, prompting proliferation of tissues that produce prostaglandins, particularly 
PGF2α [210]. However, an inverse relationship was also shown between BMI and total 
oestrogen [148], supporting the theory that oestrogen/progesterone ratio, instead of 
oestrogen alone, may underlie the pathogenesis of dysmenorrhea [211]. Alternatively, 
adipose tissue produces adipokines, the signalling molecules which vary in their 
production with adipose mass and may directly cause impaired ovarian function through 
altering the hypothalamic-pituitary-ovarian axis signalling, resulting in disrupted 
menstruation [200]. There is evidence that menstrual irregularity is higher in both girls with 
low and high BMI [204, 208], and having menstrual irregularity has been associated with 
dysmenorrhea [76]. 
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Furthermore, pain ‘catastrophising’, the role of central nervous system contributions to 
increased menstrual pain intensity, was also suggested as a potential cause for 
dysmenorrhea [24]. Under this theory, there may be psychological stress related to being 
underweight or obese which may cause differences in pain perception and sensitivity 
between these women and normal weight women, resulting in different subjective 
experiences of pain [206, 208]. In addition, there is evidence that ovarian hormones 
(especially oestrogens) play a role in modulating a range of chronic pain conditions 
through affecting concentration of oestrogen receptors in the spinal cord or the 
corresponding brain regions, or through interacting with different neurotransmitters that 
modulate pain perception [212]. Generally, a low oestrogen milieu is suggested to 
exacerbate the severity of chronic pain [212], which may be particularly relevant in the 
association between underweight and dysmenorrhea. 
Strengths and limitations 
This is the first large population-based longitudinal study to investigate the association 
between BMI and the risk of dysmenorrhea, revealing higher risk for both extreme ends of 
BMI. It further explored the association of BMI transitions over time and dysmenorrhea. 
The representative sample makes the results generalisable to women with similar 
characteristics. Nevertheless, the study has a number of limitations. First, all the data are 
self-reported questionnaire responses, which may be subject to reporting bias. However, 
self-reported dysmenorrhea has been correlated well with prospectively recorded data 
[184], and our estimated prevalence of dysmenorrhea is in line with that reported in the 
literature [6], providing justification for the validity of the data. In addition, given the 
longitudinal nature and large size of the study, self-report may be the most feasible means 
of data collection. Second, data over the past 12 months were collected retrospectively at 
each survey wave, which may subject the data to recall bias. However, daily symptom 
reporting over an extended evaluation period may not be practical in this large population 
setting. The long period of observation and repeated measures may also offset the 
disadvantage of the absence of daily rating. Third, data on other measures of adiposity 
(e.g. waist-to-hip ratio, abdominal circumference) were not routinely collected in the survey, 
rendering our ability to stratify our analysis according to markers of visceral adiposity and 
explore their relationship with dysmenorrhea. Fourth, given that surveys were conducted 
every three years, there is possibility that some women may have transited among BMI 
categories in-between surveys. Fifth, a high attrition (32%) at Survey 2 may have 
introduced potential selection bias. Comparison of the prevalence of dysmenorrhea at 
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Survey 1 among respondents (44.6%) and non-respondents (42.8%) showed no evidence 
of differential drop-out, indicating the random nature of attrition for the outcome of interest.  
In conclusion, this longitudinal study demonstrates a U-shaped association between 
dysmenorrhea and BMI, revealing higher risk of dysmenorrhea for both underweight and 
obese women. Further, women who remained underweight or obese over time maintained 
the higher risk, whereas the risk disappeared when obese women lost weight and acquired 
a healthier BMI. On the other hand, women with a healthier BMI but became underweight 
appeared to acquire a higher risk of dysmenorrhea. However, future research is needed to 
replicate the findings. From a public health perspective, obesity certainly contributes to a 
greater burden of disease than underweight, given the larger proportion of women affected. 
Maintaining a healthy weight over time may be important for women to have pain-free 
periods, and thus an improved reproductive health. 
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Chapter 9. Discussion and conclusions 
9.1 Summary of findings 
Guided by the results from the literature reviews in Chapter 3, a range of analyses using 
ALSWH data were performed. First, the prevalence and the long-term trend of 
dysmenorrhea and PMS in a representative sample of Australian women were examined 
(Chapter 4). This was followed by a series of analyses on the associations between a 
number of potential risk factors and dysmenorrhea or PMS, focusing on modifiable lifestyle 
risks identified as leading contributors to health loss in Australia in 2003 (Chapters 5–8).  
As shown in Chapter 4, dysmenorrhea and PMS affected approximately 21% to 26% and 
33% to 41%, respectively, of Australian women of reproductive age over the 13-year 
follow-up. The prevalence was relatively stable over the study period at the population 
level, except for an increase in the prevalence of PMS when the women reached 34 to 39 
years of age. At the individual level, however, substantial variation was observed for both 
dysmenorrhea and PMS over time. Overall, approximately 40% of the women were free 
from dysmenorrhea and 22% free from PMS over the 13-year follow-up. Among women 
reporting the conditions, similar patterns of change were observed for both dysmenorrhea 
and PMS. Only a small group of women reported the conditions consistently over the study 
period, whilst the vast majority of women experienced dysmenorrhea or PMS intermittently 
from survey to survey. 
Applying latent class analysis, this research identified subgroups of women with unique 
symptom trajectories for the first time. Four trajectories were identified for both conditions 
(Figure 9-1): normative (38.3%), low (28.0%), recovering (17.2%) and chronic (16.5%) 
groups for dysmenorrhea after adjusting for OCP use and pregnancy and/or giving birth in 
the past 12-months; and normative (22.1%), late onset (21.9%), recovering (26.5%) and 
chronic (29.5%) groups for PMS. Women in the chronic trajectory groups were those who 
had a consistently high probability of experiencing the respective conditions over time, 
whereas women in the normative groups were unlikely to experience the conditions. 
Women in the other two groups had increasing (late onset/low) or decreasing (recovering) 
probabilities of reporting the conditions over time.  
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Figure 9-1: Trajectories of dysmenorrhea and PMS for the 1973–78 cohort of ALSWH from year 2000 (Survey 2) to 2012 (Survey 6) 
In Chapter 4 the impact of the menstrual conditions on women’s self-reported quality-of-life 
using the SF-36 was also explored. The results revealed that, for dysmenorrhea, both 
physical and mental health summary scores were inversely related with women’s 
dysmenorrhea status (p <0.0001). Compared with women without dysmenorrhea, women 
with dysmenorrhea reported significantly lower summary scores in both physical and 
mental health (p <0.0001) consistently across all five surveys, with a mean difference of 
one point in physical and two points in mental health summary scores. On the other hand, 
only mental health was related with women’s PMS status (p <0.0001). Compared with 
women without PMS, women who reported PMS had significantly lower mean summary 
score for mental health with a difference of three points. However, no substantial 
difference in physical health was found between women with and without PMS. 
Chapter 5 presents potential population-level lifestyle risk factors for dysmenorrhea and 
PMS in the ALSWH 1973–78 cohort, taking into consideration other potential confounding 
factors. Among the five leading lifestyle risks of health loss in Australia in 2003 examined, 
neither physical activity nor alcohol consumption was related to dysmenorrhea or PMS in 
this group of young Australian women. However, after adjusting for potential confounders, 
significant associations with dysmenorrhea were demonstrated for tobacco smoking and 
BMI, and between PMS and illicit drug use. These associations were investigated in more 
detail in subsequent chapters. 
In Chapter 6 the relationship between smoking and dysmenorrhea was examined. When 
the women were 22 to 27 years of age, approximately 26% were current smokers and 25% 
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reported dysmenorrhea. Compared with never smokers, smokers—especially those with 
an early age of initiation (≤13 years)—were more likely to be in the chronic trajectory group 
of dysmenorrhea and thus experience repeated period pain over time. A 40% higher odds 
of being in the chronic group was detected for current smokers, after adjusting for socio-
demographic, lifestyle, and reproductive factors. Moreover, women with an earlier age of 
smoking initiation showed 60% higher odds of being in the chronic group. Similar results 
were shown for women who started smoking before menarche, with 50% higher odds of 
being in the chronic group. In contrast, a preliminary comparison showed that women who 
quit smoking after baseline were more likely to be in the normative or recovering groups.  
The association between illicit drug use and PMS was then investigated in Chapter 7. Illicit 
drug use was common among young Australian women aged 22 to 27 years with over 40% 
reporting illicit drug use in the last 12 months, mainly multiple drug use, and 9% first used 
drugs before age 15 years. The prevalence of illicit drug use in the last 12 months, 
however, decreased dramatically over time. A dose-response, albeit moderate, association 
was observed between illicit drug use and PMS with women reporting recent and multiple 
drug use showing a higher risk of PMS. Compared with women who had never used drugs, 
women who used illicit drugs in the last 12 months showed higher risks of PMS: 30% 
higher odds for multiple drug use and 23% higher odds for exclusive Marijuana use. 
Similar to cigarette smoking, earlier age (<15 years) at first drug use was related to 20% 
higher odds of reporting PMS and an even higher, 40%, risk was revealed among early 
starters who used illicit drugs in the last 12 months. 
Obesity, as another common health risk with rapidly increasing prevalence, affected 11% 
of the study population when they were 22 to 27 years of age. The prevalence doubled 
over the 13 years follow-up. The prevalence of being underweight, on the other hand, 
reduced substantially over the same period from 7% to 3%. When the relationship 
between BMI and dysmenorrhea was examined in Chapter 8, a U-shaped relationship was 
demonstrated between BMI and dysmenorrhea. Both underweight and obesity were 
related with a moderately higher risk, 34% and 22% respectively, of reporting 
dysmenorrhea. Further explorative investigation showed that, compared with women with 
BMI staying within the healthier range (normal or overweight) over time, women who 
remained underweight or obese maintained a more than 30% higher risk of dysmenorrhea. 
Similarly, women who were underweight, despite gaining weight, and those who became 
underweight both showed approximately 30% higher risk of dysmenorrhea. On the other 
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hand, the risk disappeared among obese women when they lost weight and acquired a 
healthier BMI.  
9.2 Discussion 
9.2.1 Magnitude	and	burden	of	dysmenorrhea	and	PMS	
This population-based prospective longitudinal study showed that dysmenorrhea and PMS 
were common menstrual problems, affecting approximately a quarter and over a third of 
Australian women of reproductive age, respectively. Both conditions had a relatively stable 
prevalence over the study period, although there was a slight decline in the trend for 
dysmenorrhea at the population level. However, both exhibited considerable variation at 
the individual level, with majority of women experiencing the conditions intermittently. 
There is wide variation in the literature on the estimates of the prevalence of these 
common menstrual disorders, partially attributable to the lack of well-defined objective 
diagnostic criteria and tools for both dysmenorrhea and PMS [6, 107]. This is particularly 
problematic in the case of PMS, with various classification systems used such as the ICD-
10 code [90], the ACOG [92] and the DSM criteria [91, 93]. However, there appears to be 
consensus that a large proportion of women of reproductive age are affected, albeit a 
smaller group experiencing moderate to severe symptoms [6, 13, 19]. The observed trend 
for both conditions in this research appears to be in line with findings from limited number 
of earlier longitudinal studies. Dysmenorrhea is a condition during reproductive years with 
prevalence declining with age [11, 55]; whereas the influence of age on PMS is less clear, 
with a high level of intra-individual variation demonstrated but severe cases appear to be 
more stable over time [25, 26]. 
This research also identified four population subgroups that followed unique symptom 
trajectories for both dysmenorrhea and PMS: with the group of women most troubled being 
those having a consistently high probability of experiencing the conditions (chronic 
trajectory group). Overall, PMS was experienced by nearly 80% of women at some time 
during the study period, and it tended to be a long-lasting problem in nearly 30% of the 
women studied; whereas approximately 40% of women were symptom-free from 
dysmenorrhea and only a relatively small group of women (16%) were likely to experience 
it repeatedly over time. This implies that a greater disease burden may be anticipated from 
PMS than dysmenorrhea in the population. If the research results are replicated in future 
studies, this information may inform healthcare providers caring for these women in their 
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service planning as previous literature indicates that women with menstrual complaints 
tend to have increased use of medical care and alternative treatments [17, 127]. Clinicians 
consulting women who repeatedly present with PMS should be aware that there is over 70% 
probability that these women are likely to experience the symptoms again, as shown in this 
research, resulting in long-lasting complaints. For women who present with dysmenorrhea, 
however, some assurance can be given that only a small group is likely to continuously 
experience the symptoms in the long term. Consultation should take into account that this 
group of women are more likely to have a diploma or higher education, to be underweight 
or obese, to be smokers at baseline, to start smoking before 15 years of age, and to have 
an early age at menarche.  
Burden of disease has become an area of great interest to public health practitioners, 
policy makers and health insurance providers as it enables them to describe the 
magnitude of a condition in the population, to rationalise the allocation of the limited 
healthcare resources, and to estimate the potential costs and benefits of medical care for 
individuals [13]. Although dysmenorrhea has been identified among women under 30 
years of age as a common reason for absenteeism or reduced productivity at work or 
school, the personal, economic and societal costs related to it are yet to be well-quantified 
[74, 213]. A relatively larger body of literature exists on the impact of PMS/PMDD, 
suggesting that the burden of PMS/PMDD is more substantial than that of back pain, and 
is comparable to the burden of depression, migraine headaches and irritable bowel 
syndrome. The high burden may be due to affected women being in the reproductive age 
groups which have school, family and workplace responsibilities [1, 15, 141, 171, 214-216]. 
The associated reduction in HRQoL and work productivity impairment is present 
regardless of the diagnostic criteria used [174]. Despite this, there is suggestion that 
menstrual symptom-associated burden is likely to be underestimated, partly due to the 
lack of accurate estimates on the magnitude of the problems and the frequent occurrence 
of the symptoms because of their cyclical nature [1, 19]. All these findings are in marked 
contrast to the historically dismissive view held by many health care practitioners, and 
perhaps the public in general, that these problems are trivial and not deserving medical 
attention by describing it as something that the women have to put up with or it is ‘all in 
their heads’ [13, 217].  
In line with the findings from previous studies [1, 141, 171, 172], our exploratory analysis 
on the impact of menstrual disorders on women’s HRQoL showed that women with either 
dysmenorrhea or PMS reported worse HRQoL compared with women without the 
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conditions. Significantly worse physical and mental health was reported for women with 
dysmenorrhea consistently over time; whereas worse mental health, but not in physical 
health, was reported for women reporting PMS compared with women without PMS. 
Limited previous studies showed worse physical health only for women with dysmenorrhea 
and worse physical and mental health for women with PMS, although greater impact on 
mental health was evident [1, 141, 171, 174]. The adjusted difference of 1–3 points are 
smaller than the 5–12 points previously reported [174], questioning the clinical 
meaningfulness of the differences. Future studies should try to establish clinical 
meaningful differences in SF-36 scores between women with and without the conditions. 
Furthermore, studies that compare the impairment of the conditions on women’s daily 
activities using the individual domains of SF-36 are also needed.  
Apart from a pronounced impact on an individual’s quality-of-life, previous literature has 
also demonstrated that dysmenorrhea and PMS may be a burden to society beyond the 
increased healthcare use [16, 171, 218]. Indeed, an earlier study indicated that the 
estimated annual economic loss amounted to 600 million hours and US$2 billion due to 
loss of productivity among women who suffer from severe dysmenorrhea [218]. Similarly, a 
prospective study from the United States, using women’s administrative claims and the 
Medicare Fee Schedule, found that, from the employer’s perspective, the economic costs 
of PMS primarily manifested in indirect costs. The reported productivity loss was 
associated with an estimated annual increase of US$4,333 per patient in indirect costs, 
compared with a modest annual increase in direct medical costs of US$59 per patient [17]. 
The total economic loss can be immense since—based on the experience of women from 
the United States, United Kingdom and France—an average 6.1 days of severe PMS per 
month were estimated for affected women, which manifests to a total of 2,800 days (7.67 
years) throughout their reproductive life [219]. Conservatively, reducing the affected days 
by half would still present a huge burden. According to the 2000 United States census, 
over 3.7 million women probably met the criteria for PMDD [13].  
Little is known about the economic impact of the conditions in Australia due to the context-
specific nature of costs and the lack of local data. Unfortunately, this aspect is outside the 
scope of this thesis. Nevertheless, it is reasonable to assume that, like in many other 
western countries, these conditions are associated with significantly decreased 
productivity, increased work absenteeism, and increased healthcare costs [171, 220]. This 
would constitute an important area for future research using linked data from Medicare and 
industry. Given the frequent occurrence of the conditions, their personal and societal 
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burden may be reduced if regulatory authorities and clinicians take the conditions more 
seriously, become aware of their associated impairments, and inform and encourage 
women to participate in the management of their symptoms [13, 46]. Evidence shows that 
effective doctor-patient communication is critical for the effective treatment of cyclic 
symptoms, with patients whose health care providers communicate well with them and 
engage them in decision-making obtaining more relief and being more satisfied with their 
health care [46]. 
In this context, the American Psychiatric Association recently released DSM-V which lists 
PMDD in the main text as having a full diagnostic status [93]. Despite some concerns 
about the economic, political, legal and domestic harms that may be caused by labelling 
women with PMDD, the listing has recognised the significant suffering and its impact on 
affected women and has enabled women who suffer from PMDD to receive the benefits of 
recognition and proper care [217]. Despite only 3% to 8% of the population are considered 
to meet the criteria for PMDD [5, 13], clinically significant PMS is estimated to be much 
more prevalent. Among women of reproductive age, 13% to 18% will have dysphoric 
symptoms severe enough to result in distress and impairment [13]. Because of the design 
of the ALSWH questionnaire, we are unable to determine the prevalence of PMDD in this 
study population. However, our literature review reveals a higher prevalence of up to 29% 
reporting moderate to severe PMS with significant functional impairment. At this stage, 
whether the inclusion of PMDD in the DSM-V depressive disorder chapter as a full criteria 
condition will encourage research on the topic as expected is still to be seen [221]. 
9.2.2 Modifiable	lifestyle	risk	factors	
As the first longitudinal study, this thesis investigated the long-term association between 
dysmenorrhea or PMS and five of the six lifestyle risks identified as leading contributors to 
health loss in Australia in 2003 [27]. Among them, smoking and BMI showed significant 
association with dysmenorrhea, and illicit drug use with PMS, after adjusting for a range of 
potential confounders, in ALSWH population.  
9.2.2.1 Substance use 
Smoking remained prevalent among young Australian women aged 22 to 27 years with 26% 
reporting smoking despite continuous public efforts in anti-smoking campaigns. In 
Australia, tobacco smoking was the largest contributor to disease burden both in terms of 
mortality and disability-adjusted life years in 2003 [27]. This concurs with the 2010 global 
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burden of disease study which identified tobacco smoking as the leading risk (2nd rank 
order) [222]. This research showed that smokers, especially those who started smoking at 
an early age, were more likely to experience dysmenorrhea repeatedly over their 
reproductive life. These findings are compatible with previous literature showing that the 
risk and/or severity of dysmenorrhea increased with smoking [55, 175], with a dose-
response relation observed for the risk of dysmenorrhea and the number of cigarettes 
smoked per day (smoking 10 to 30 cigarettes per day doubled the risk) or the duration of 
smoking (smoking duration of 10 to 20 years almost tripled the risk) [57, 62]. This study 
complements the current evidence base on the well-known long-term harmful effects of 
tobacco smoking [183, 223], demonstrating the potential immediate harms of smoking. It 
further suggests that smoking cessation may benefit women who suffer from 
dysmenorrhea by relieving symptoms; however, additional research is needed to verify the 
findings.  
Although not well elucidated, there is biological plausibility in this observed relationship. 
The proposed theories have been discussed in detail in Chapter 6. Briefly, 
vasoconstriction effect of cigarette smoking is currently the better-understood hypothesis, 
which may cause reduced endometrial blood flow, uterine hypoxia, hyperactive myometrial 
contraction and subsequent pain [24]. Alternatively, a number of other mechanisms have 
also been proposed such as a direct effect of smoking on endocrine control of 
menstruation [179, 180] or the role central nervous system contributes to increased 
menstrual pain intensity [55]. However, this research has not established causality. Future 
research is needed to separate the effects of age at initiation of smoking from current 
smoking status and to investigate the association between smoking cessation and 
dysmenorrhea. If the results are replicated in future research, they will provide stronger 
support for anti-smoking campaigns and greater incentives for young women to abstain 
from smoking.  
Despite the well-known harmful effects of illicit drug use, their use remained common 
among young Australian women, including adolescent girls. This longitudinal study 
showed that almost every two in three Australian women aged 22 to 27 years ever used 
illicit drugs, with nearly 10% initiating drug use before 15 years of age. A significant, albeit 
moderate, association was demonstrated between recent illicit drug use, particularly 
multiple drug use, and PMS after accounting for potential confounders including history of 
abuse, smoking and alcohol consumption. No significant interactions between drug use 
and smoking or alcohol consumption were detected. Early age (before 15 years) at first 
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drug use showed a higher risk of reporting PMS, especially among those who used drugs 
in the last 12 months. These findings are in line with a previous study showing significant 
association between drug abuse or dependence and higher risk of sub-threshold PMDD, 
defined as cases short of one diagnostic criterion to be fully classified as PMDD, with most 
cases lacking persistent impairment [26].  
Due to limited research on the subject, little is understood about the underlying 
mechanisms of the observed association between illicit drug use and PMS. The details of 
the hypotheses were discussed in Chapter 7. The interactions of fluctuating levels of 
ovarian steroids or their metabolites with a number of neurotransmitters, particularly 
serotonin, have currently been proposed as the main aetiology of PMS [8, 12]. Although 
the association with PMS may vary across different drug classes, shared actions by illicit 
drugs and gonadal hormones (oestrogen and progesterone) on serotonin, dopamine or 
other neurotransmitters has been observed [190]. A reverse causation is also unable to be 
ruled out at present [194]. It is possible that a bidirectional relationship may exist in that 
PMS might result in Marijuana use at an early stage, whereas repeated drug use over time 
may increase the occurrence of PMS. In addition, the observed association may be 
mediated by common social, familial and contextual factors that increase the risks of both 
illicit drug use and PMS. Much remains to be done to understand the observed association. 
Future studies also need to test the temporal relation between drug use and the 
development of PMS to clarify the nature of the association. Only then, evidence-based 
health policies and advice may be supported to help women suffering from PMS to better 
self-manage their symptoms.  
Of interest are the findings on the association between early age at first use of substances 
(both cigarettes and illicit drugs) and the higher risk of menstrual disorders, since there 
may be some common pathways underlying the observed associations. Women who first 
used substances earlier may comprise a high-risk group who are more likely to be socially 
disadvantaged, have adverse early life experiences, or have longer and lasting exposure 
to substances. A previous study has related longer duration of smoking to increased risk of 
dysmenorrhea [57]. Despite this, the sensitive period theory from the life course 
epidemiology approach, where substance use has a stronger effect on the development 
and, therefore, disease risk than they would have at other times [182], may also deserve 
some attention. Early substance use may have a stronger impact on the endocrine system 
controlling menstruation. Many of the physical and hormonal changes associated with the 
functional maturation of the HPG axis, which in turn regulates menarche and the 
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establishment of cyclic ovarian function, occurs prior to menarche [181]. According to this 
approach, the time prior to age of 15 years may be a sensitive period for establishing 
normal menstruation. As shown in this research, initiation of smoking before menarche is 
related to a higher risk of dysmenorrhea over time than both never smoking and starting 
smoking after menarche. However, the hypothesis and the biological mechanisms would 
need to be validated by further research.  
Currently, there is evidence that both early initiation of and continued tobacco use double 
the risk of cannabis abuse/dependence [224]. Therefore, tobacco smoking not only can 
cause immediate and long-term harms to the individuals and those around them, but it 
may also act as a gateway for cannabis use which is a risk factor for later multiple illicit 
drug use with greater individual and social harms [188, 225]. In light of the continuous 
debate on legalising recreational Marijuana use [189], policy makers should be made 
aware of this phenomenon in making drug policy so the impact and consequences of a 
drug policy in both social and financial terms can be fully assessed. Furthermore, public 
health interventions on the prevention and cessation of substance use should integrate 
programs on cigarette smoking, illicit drug use and alcohol consumption since their use is 
closely correlated and evidence shows that women who are exposed to one of these risk 
factors are less likely to achieve reduction in their use of the others [226].  
9.2.2.2 Body mass index 
Unlike smoking and illicit drug use, which showed a declining trend of current use over 
time, BMI has increased rapidly worldwide despite some regional differences [222]. 
Obesity has been ranked as one of the leading risks for health loss both in Australia and 
globally [27, 222]. This research demonstrated a U-shaped relationship between BMI and 
dysmenorrhea, with both underweight and obesity being associated with moderately 
higher risk of dysmenorrhea. However, obesity is nonetheless the major contributor to 
disease burden at the population level given the much higher proportion of people being 
affected. Previous studies have been fairly consistent in demonstrating the relationship 
between low body mass and dysmenorrhea [76, 201, 203]. However, the findings on the 
association between overweight or obese and dysmenorrhea are less consistent, probably 
due to the varying populations included, exposure and outcome measured, and the power 
of the study [43, 55, 69, 76]. Our results support the findings from a longitudinal study 
showing that weight-for-height index above the 90th centile doubled the odds of having 
severe pain or pain lasting longer than two days in college women [43]. 
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This research further explored the association between BMI transitions and the risk of 
dysmenorrhea. It showed that the higher risk of dysmenorrhea among obese women 
disappeared when they lost weight and acquired a healthier body mass, whereas women 
who remained underweight or obese or who lost weight and became underweight showed 
a higher risk of dysmenorrhea. Maintaining a normal weight over time, therefore, appears 
to be important for women to enjoy healthy menstruation. Interestingly, a consistently 
higher risk of dysmenorrhea was demonstrated for women who were previously 
underweight despite obtaining a healthy weight over time. The reason for this is not 
apparent. It may be that underweight imposes a stronger and lasting impact on ovarian 
function at an earlier age or that this group of women may have other underlying 
conditions that confound or mediate the association. We explored the relationship between 
BMI and a number of other potential underlying conditions such as self-perceived general 
health, depression and other mental health problems, age at first intercourse, irregular 
periods, sexually transmitted diseases and eating disorders, however they were not 
different among women who were underweight or obese. We are not aware of any study 
which has investigated the topic, which may be an interesting area for future research. 
Due to the known relation between BMI and smoking and that both were associated with 
increased risk of dysmenorrhea, the potential interaction between BMI and smoking was 
also examined. However, statistical testing showed no evidence of significant interaction 
between the two (p = 0.68). Further stratified analysis by women’s smoking status 
indicated that there appeared to be an independent association between BMI and 
dysmenorrhea. Compared with the main analysis, the relationship between underweight 
and dysmenorrhea remained largely unchanged; whereas slightly strengthened 
associations were shown between obesity and dysmenorrhea among women who had 
never smoked (ORs 1.27 vs 1.22 in the adjusted analysis) and ex-smokers (ORs 1.26 vs 
1.22), but the association disappeared among women who were current smokers.  
The underlying mechanisms of the association between BMI and dysmenorrhea are yet to 
be fully understood, given the complex interaction between body fat and steroid hormones 
[200, 205], and they may differ in underweight and obese women. The details of the 
proposed hypotheses have been discussed in Chapter 8. Briefly, a certain amount of body 
fat appears to be important to maintain normal ovulatory cycles [205], although there is 
some disagreement [206]. Adiposity influences the production and direction of oestrogen 
metabolism and the ability of oestrogen to bind to SHBG (which inactivates oestrogen) 
[208, 227]. Body weight is also inversely correlated to serum SHBG concentrations [209]. 
 
166
In obese women, the net result is elevated serum oestrogen, or oestrogen/progesterone 
ratio, potentially increasing oestrogenic stimulation of the endometrium, prompting 
proliferation of tissues that produce prostaglandins, particularly PGF2α [209-211]. 
Alternatively, adipokines produced by adipose tissues may alter the hypothalamic-pituitary-
ovarian axis signalling, resulting in disrupted menstruation in both girls with low and high 
BMI [200, 208], which is closely correlated with dysmenorrhea [76]. Other factors such as 
psychological stress related to being underweight or obese or a low oestrogen milieu have 
also been suggested to play a role in the causal pathways but are yet to be proven [206, 
208, 212].  
Realising that obesity is a complex, multifaceted problem with no quick fix and that current 
strategies have failed to mitigate this risk, new approaches to reduce obesity are critical. A 
fundamental policy shift has been suggested to widen responsibility for the prevention of 
diet-, activity- and weight-related problems across the world, and the individual approach 
can no longer be taken alone to try to alleviate this major public health problem [228]. 
Much can be learned from the successful campaigns against smoking. In a nutshell, 
policy-makers need to move from the basic provision of information and advice, through 
facilitation of healthier choices and active discouragement of unhealthy behaviour such as 
taxation and advertising restriction, and onto regulatory action [229]. However, it is also 
important to acknowledge the differences between smoking (eg. second-hand smoking) 
and obesity (eg. no direct harm to others), so rational policy decisions may be fully justified. 
In light of the U-shaped relationship revealed between BMI and dysmenorrhea, caution 
should apply to ensure that population-based interventions must be sensitive to the need 
to promote a healthy body weight, not excessive thinness, especially among women 
predisposed to eating disorders [230]. 
9.2.2.3 Association or causality 
It is important to note that this thesis only demonstrates association but does not establish 
causality for a number of reasons. First, it is difficult to prove temporal relationship of the 
exposures and dysmenorrhea or PMS in most cases in the survey. Most women had 
started their menses before the commencement of the first survey and there is no 
information on the time point when the menstrual conditions first occurred. Second, given 
the intermittent occurrence of both dysmenorrhea and PMS, it is difficult to ascertain true 
incident cases in most women so the analyses used prevalent cases. Third, assuming 
women who were symptom-free at Survey 1 were true incident cases, only a very small 
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proportion of women would be eligible to be included in the study, resulting in a huge loss 
of information (the majority of the women) which would greatly reduce the power of the 
study.  
Apart from temporality that has not been demonstrated in most cases in this thesis  there 
are a number of other points which need to be mentioned based on the widely adopted 
criteria for causality [231, 232]. First of all, the strength of the observed associations is 
generally modest to moderate, which does not provide strong support for the argument for 
causation. In terms of consistency of the observed associations, current findings are in 
agreement with the literature on the association between underweight and dysmenorrhea. 
However, most previous findings are mixed on the relationships between smoking or 
obesity and dysmenorrhea, and there is little research on the association between illicit 
drug use and PMS. Nevertheless, this research does demonstrate some dose-response 
relation between smoking and dysmenorrhea, and between illicit drug use and PMS. 
Similarly, based on our current knowledge, there is some biological plausibility underlying 
the observed associations between the lifestyle risk factors and dysmenorrhea or PMS. 
However, none of the underlying hypotheses have been well-established and reverse 
causation, in the case of substance use, cannot be ruled out. On the other hand, the 
biological mechanisms underlying the relationship between BMI and dysmenorrhea appear 
to be more plausible since no rational explanation for reverse causality exists.  
It is recognised that public policies to improve the health of populations will be more 
effective if they address the major causes of disease burden and even small reductions of 
population exposure to large risks can lead to substantial health gains [27]. All of the 
individual health risks examined in this thesis, which are also leading contributors to health 
loss in Australia, are susceptible to modification through behavioural interventions. 
However, given that current evidence does not prove causality, it is unlikely that public 
health interventions to modify these risk factors are justifiable based on the findings from 
this research alone. In addition, the strength of the associations demonstrated between the 
outcomes and the individual health risks are generally moderate. It can thus be argued 
that even if causality is proven, the public health significance of the health gains that can 
be expected through the reductions to these exposures may still be debatable. However, 
given the impact of these conditions on HRQoL of affected women, the significant 
impairment on work/study productivity and the increased healthcare services use 
suggested in the literature, the related economic costs may not be trivial [1, 16, 17, 74, 
233]. It is also worth noting that health gains that are likely to be achieved through realistic 
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reductions in future exposure to these risk factors are not just limited to the improvement in 
dysmenorrhea or PMS alone, but as part of gains due to reduction in health loss related to 
other common non-communicable diseases. 
9.2.3 Strengths	and	limitations	
This research has a number of strengths including: 1) It is a prospective longitudinal study 
with data available from five surveys across 13 years. This provides a unique opportunity 
to study the trend of the conditions by following women as they age and to elucidate 
within-women variability necessary to enable women and clinicians to anticipate the 
course of these menstrual conditions over time. It also provides an opportunity to 
investigate the longitudinal association between time-varying risk factors and the 
corresponding outcomes; 2) This is a population-based study with representative samples 
randomly selected from the national Medicare database; therefore, the estimates are more 
likely to reflect the true magnitude of the problem in the community and the findings are 
more readily generalised to the wider population; 3) The availability of individual level data 
allows us to get a clear picture of the long-term trend of conditions and to clearly display 
the individual-level pattern of change (lasagne plot) of the conditions over time; and 4) The 
large sample size gives the study sufficient power to detect an association, if there is one. 
Despite the strengths of the project, it has a number of limitations. First, this research is 
part of a large prospective cohort study of Australian women, with the aim to examine the 
relationships between biological, psychological, social and lifestyle factors and women's 
physical health, emotional well-being, and their use of and satisfaction with health care 
[28]. It is not designed specifically to study the associations of interest, thus there is a lack 
of comprehensive information on some variables of interest. For example, subjective 
responses such as ‘always’, ‘often’, ‘sometimes’ and ‘never’ to questions regarding 
menstrual disorders are used in the survey, so there is no detailed information on the age 
when the conditions first occurred, the relative time within a cycle when they occurred (e.g. 
late luteal phase for PMS), and the severity of the symptoms. It makes it difficult to 
ascertain the temporal relation of exposure to potential risk factors, such as substance use, 
and the development of dysmenorrhea or PMS. It is also impossible to make differential 
diagnosis especially in the case of PMS. Similarly, no data on the frequency and intensity 
of illicit drug use were collected in the survey, thus it is difficult to differentiate regular and 
occasional drug users. In addition, the study design is generally insufficient to determine 
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causality even when an association is present. Therefore caution should apply when 
interpreting the results on the demonstrated associations. 
Second, all the data are self-reported with no specific diagnostic criteria used, which may 
subject the data to reporting bias. Given the lack of well-defined objective diagnostic tests 
and tools for most menstrual symptoms, even primary care professionals rely on individual 
subjective working models in practice [170]. However, self-reported dysmenorrhea based 
on a single question regarding frequency of menstrual discomfort as ‘always’, ‘often’, 
‘sometimes’ and ‘never’ has correlated well with prospectively recorded data [184]. The 
estimated prevalence for both dysmenorrhea and PMS in this research is also generally in 
line with that reported in the literature [7, 13]. In addition, the SF-36 results indicate worse 
self-perceived health for women reporting the conditions. All these provide some 
justification on the validity of the data. Coupled with the longitudinal nature and large size 
of the study, self-reporting may be a reasonable and the most feasible means for data 
collection.  
Third, data over the past 12 months are collected retrospectively at each survey wave for 
all variables including dysmenorrhea and PMS, instead of being obtained though 
prospective daily symptom ratings. This may subject the data to recall bias. The relative 
timing of symptom occurrence within a cycle, which provides important information for the 
diagnosis of the conditions, especially PMS, is also unable to be confirmed. However, 
despite currently being recommended as the validated method to diagnose premenstrual 
disorder, particularly PMS/PMDD [107], prospective daily symptom reporting has not been 
widely adopted in clinical practice [234]. It may not be practical in this large population 
setting over a long follow-up period. Results from a range of sensitivity analysis in the 
individual papers including multiple imputations for missing data show minimal changes, 
confirming the robustness of the estimates. 
Fourth, although women included in ALSWH were randomly sampled from Medicare and 
were shown to be broadly representative of Australian women of the same age [28], there 
is high attrition (32%) at Survey 2. This may introduce selection bias and impact on the 
representativeness of the sample. However, as discussed in the methodology section, 
comparison of the prevalence of dysmenorrhea and PMS at Survey 1 among respondents 
and non-respondents showed no evidence of differential drop-out, indicating the random 
nature of the attrition for the outcomes of interest. A previous study investigating the 
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impact of the attrition on this cohort of women also suggests that potential biases 
introduced by this attrition are insufficient to preclude meaningful longitudinal analyses [40]. 
Last but not least, although we have adjusted for a range of potential confounders in the 
different analyses, there may be some important familial, social or contextual factors that 
have been missed given the complex and not well-understood relationships studied. As a 
result, the observed associations may be confounded or mediated by some other unknown 
factors. In addition, given the self-report nature of data collection, residual confounding 
due to measurement errors cannot be ruled out. Thus future research to replicate the 
study findings is critical to improve our understanding of the observed associations. 
9.3 Directions for future research 
This is one of the few population-based prospective longitudinal studies on dysmenorrhea 
and PMS and the first in Australian women. The unique trajectories identified, and the 
associations detected between them and a number of modifiable lifestyle risk factors, need 
to be replicated in future studies in different populations. Given the limitation of self-report 
data, it is critical to observe whether the study findings will be replicated in future research 
using well-defined, universally accepted diagnostic criteria. As mentioned previously, the 
ISPMD has proposed a classification system for premenstrual disorders for clinicians and 
researchers [107]. It remains to be seen whether it will be adopted by different regulatory 
agencies and researchers in the field, resulting in a more consistent approach on 
diagnostic criteria for premenstrual disorders in the coming years. More importantly, this 
will make the study results more comparable across different populations. Through 
conducting this research, a number of different areas were identified which deserve further 
research. 
 Studies which enable the determination of relative timing of exposure to risk factors 
and development of dysmenorrhea and PMS are essential to further our 
understanding of the nature of the observed associations. In turn, the evidence 
generated from such studies would better inform preventative public health 
initiatives to reduce risk exposure and to improve women’s health at the population 
level. 
 Although the burden associated with menstrual conditions has been increasingly 
recognised, it is still not well-quantified and is considered to be underestimated. 
Thus the impact of dysmenorrhea and PMS on women’s HRQoL and functional 
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impairment, taking into consideration other comorbidities, deserves more research 
to estimate the burden associated with the conditions. Future studies should aim to 
define clinically meaningful differences in SF-36 scores between the comparison 
groups and the analyses should consider using both component scores and the 
scores for individual domains. 
 Studies to quantify the economic loss in terms of direct medical costs and indirect 
costs related to the lost productivity are important to reflect the personal and 
societal burden posed by the conditions in Australia. This information is essential for 
regulatory bodies and policy makers in their decision-making regarding 
reimbursement and healthcare resource allocation. Improved measurements and 
quantification of relative health and economic impact will help to more accurately 
ascertain the personal and societal burden of the conditions in the Australian 
context.  
 The healthcare seeking behaviour of Australian women affected by these conditions 
should be studied so better health service planning can be facilitated to meet the 
needs of these women. On the one hand, there is literature indicating that only a 
small proportion of women whose daily activities have been severely impaired have 
higher health service usage [13]. On the other hand, there is also evidence 
suggesting that women with more severe symptoms were less likely to believe there 
is any treatment available [219], which may influence their care seeking behaviour.   
 Currently prospective data collection, such as daily symptom rating, remains to be a 
challenge in large epidemiological studies. Therefore, future studies should aim to 
develop new methods to balance the burden and the rigour of data collection. At the 
same time, validation studies comparing the data from daily symptom rating with 
self-reporting are useful to assess the validity of the self-reported data. 
 Further studies to quantify the magnitude of early age of initiation of substance use 
and the associated risk of respective menstrual conditions, taking into account the 
continued substance use, is called for. For illicit drug use, more detailed data on the 
pattern of different drug use, including frequency and length of use, will be useful in 
exploring and interpreting the relationship of drug use with PMS.  
 Future study should be conducted to confirm the associations for menstrual 
conditions with dietary patterns and nutrients. For example, vitamins B and D and 
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calcium have been suggested to be related to PMS in the literature [104, 105, 137], 
and fruit and vegetable intake were shown to be inversely related to dysmenorrhea 
[72].  
 Ongoing neuropathological research to understand the aetiology of the conditions 
will help with the identification of risk factors and targeted management strategies. 
Genetic studies for vulnerability can help to identify women who are predisposed to 
the disorders [13].  
 Apart from their immediate impact on women’s quality of life, work and social 
functioning, menstrual disorders may have long-term consequences. The 
relationships between ovulatory disturbances and some chronic diseases such as 
breast cancer and osteoporosis are better understood [50]; however, their long-term 
effects on cardiovascular diseases (CVDs) appears to be less clear [235, 236]. This 
may be an important area for future investigation. 
9.4 Conclusions 
In conclusion, this longitudinal research demonstrates that dysmenorrhea and PMS are 
common in Australia women of reproductive age. Both were relatively stable conditions 
over time at population level but exhibit great variation at individual level. There were 
population subgroups that followed unique symptom trajectories, with a group likely to 
experience the conditions repeatedly over time. Moderate associations were demonstrated 
between smoking and dysmenorrhea and between illicit drug use and PMS, with a higher 
risk demonstrated for early age at first use of the substance. Both underweight and obesity 
also showed to be associated with moderately increased risk for dysmenorrhea; however, 
the higher risk among obese women disappeared when they lost weight and obtained a 
healthier body weight over time. It should be noted that causality has yet to be proven due 
to study limitations. Future studies with purposeful design to address the specific study 
objectives are called for to determine the type of the observed associations. Giving the 
well-known harms related to these lifestyle risk factors studied in this thesis [183, 187, 237], 
public health campaigns to curb these risks are currently underway, with varying degree of 
success. Therefore, continuous accumulation of evidence on the harms of risk factors, 
especially among young people, appears to be justified to ensure the long-term success of 
the programs. Subsequently, research findings would guide the development of evidence-
based preventative health policies and self-management strategies for women suffering 
 
173
from these conditions. It may be a good practice point that clinicians who provide 
consultations to women should regularly check for menstrual disorders, be aware of the 
observed associations and advise women on lifestyle modifications if indicated. With 
PMDD being listed as a full diagnostic criterion in the recently released DSM-V, it is 
anticipated that greater legitimacy will be provided for the disorder which may encourage 
the growth of evidence-based research, ultimately leading to better and safer management 
[94]. It remains to be seen whether this goal can be achieved. 
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Appendix A: Study quality checklist for prevalence and 
risk factors of dysmenorrhea (paper 1) 
Guidelines and checklist for appraising a medical article 
Guideline Checklist 
1. Study design appropriate for objectives? Objective Common design  
Prevalence Cross-sectional  
Prognosis Cohort  
Treatment Controlled trial  
Cause Cohort, case-control, cross-
sectional 
 
   
2. Study sample representative? Source of sample  
Sampling method  
Sample size  
Entry criteria/exclusions  
Non-respondents  
   
3. Control group acceptable? Definition of controls  
Source of controls  
Matching/randomisation  
Comparable characteristics  
   
4. Quality of measurement and outcomes? Validity  
Reproducibility  
Blindness  
Quality control  
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5. Completeness? Compliance  
Drop outs  
Deaths  
Missing data  
   
6. Distorting influences? Extraneous treatments  
Contamination  
Changes over time  
Confounding factors  
Distortion reduced by analysis  
++ = Major problem, + = Minor problem, 0 = No problem, NA = Not applicable 
Source: Fowkes FG, Fulton PM. Critical appraisal of published research: introductory guidelines. 
BMJ (Clinical research ed). 1991 May 11;302(6785):1136–40.  
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Appendix B: Summary of included primary studies on 
risk factors of dysmenorrhea (paper 1) 
Study ID, 
Country 
Population Prevalence/incidencea Primary outcome Significant risk 
factors 
Effect 
estimates 
Confidence 
intervalb/p 
value 
Longitudinal study 
Ohde et al 
(2008) 
Japan 
823 randomly 
sampled women 
aged 18–51 years 
Follow-up: 1 month 
Incidence: 15.8%:  
(95% CI: 13.3, 18.3) 
Presence of 
dysmenorrhea 
Age <30 years RR 2.25 1.50, 3.37 
Employed RR 1.62 1.10, 2.40 
Wang et al 
(2004) 
China 
388 female textile 
workers, aged 20–
34 years and 
nulliparous 
Incidence: 28% 
Prevalence: 44.4% 
Presence of 
dysmenorrhea 
Self-perceived stress 
during preceding cycle 
(vs low stress) 
  
 High stress OR 2.4 1.4, 4.3 
 High stress + 
dysmenorrhea in 
preceding cycle 
OR 3.6 1.7, 7.8 
Weissman et 
al (2004) 
USA 
404 nursing 
students or 
graduates with 
primary 
dysmenorrhea, 
aged ≥19years  
Follow-up: 6 years 
Primary: 75% 
(mild 53%, moderate 
20%, severe 2%) 
Moderate-severe 
primary 
dysmenorrhea 
Parity 
(increment of 1 birth)  
OR 0.70 0.54, 0.91 
Age 
(increment of 1 year) 
OR 0.94 0.90, 0.99 
Community-based cross-sectional study 
Abenhaim & 
Harlow 
(2006) 
USA 
904 women not 
using OCP, aged 
36–44 years  
36.7% Moderate-severe 
pain 
Livebirth (vs 0)   
 1 OR 0.4 0.3, 0.7 
 2 OR 0.4 0.2, 0.6 
 3+ OR 0.3 0.2, 0.5 
Burnett et al 
(2005) 
Canada 
1546 menstruating 
women from a 
stratified random 
sample, aged ≥18 
years 
Primary: 60% 
Limiting activity: 15% with 
mild & 51% with 
moderate-severe pain 
Presence of 
primary 
dysmenorrhea 
Age Β = -0.96 p <0.001 
Smoking Β = 1.30 p =0.046 
Oral contraception pills Β = -0.72 p =0.017 
Harlow et al 
(2002) 
USA 
976 women with 
intact uteri, aged 
36–44 years 
NR Cycle pain change 
from the 1st 5 
years after 
Tubal ligation   
Became better  
(vs no change) 
OR 0.9 0.5, 1.5 
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Study ID, 
Country 
Population Prevalence/incidencea Primary outcome Significant risk 
factors 
Effect 
estimates 
Confidence 
intervalb/p 
value 
menarche to late 
reproductive years 
 Became worse 
(vs no change) 
OR 1.4 0.8, 2.4 
Tubal ligation >5 years 
ago 
  
 Became better 
(vs no change) 
OR 1.1 0.6, 2.2 
 Became worse 
(vs no change) 
OR 1.9 0.9, 4.1 
Laszlo et al 
(2008) 
Hungary 
2722 working 
women from a 
nation-wide 
representative 
random sample, 
aged <55 years 
15.5% with painful 
menstruation limiting 
activity 
Presence of 
dysmenorrhea 
limiting activity 
Work stress measured 
by 
  
Control at workplace 
(vs none) 
  
 Medium OR 0.67 0.49, 0.91 
 High OR 0.66 0.47, 0.95 
Co-worker-support 
(vs none) 
  
 Medium OR 0.62 0.46, 0.83 
 High OR 0.51 0.35, 0.76 
High job security 
(vs low) 
OR 0.63 0.42, 0.95 
Laszlo et a. 
(2009) 
Hungary 
821 pre-
menopausal, non-
pregnant working 
women, mean age 
about 38 years 
20.1% painful 
menstruation limiting 
activity  
Presence of 
dysmenorrhea 
limiting activity 
Work stress measured 
by 
  
 Effort-reward 
imbalance 
OR 1.42 1.03, 1.94 
 Over commitment OR 1.07 1.02, 1.13 
Nohara et al 
(2011) 
Japan 
2166 Japanese 
female workers 
who are 
menstruating 
78.3% (2.8% very serious 
pain, 25.8% serious pain, 
49.7% tolerable pain) 
Severe-very 
severe pain 
Age (increment of 1 
year) 
OR  0.94 0.93, 0.96 
BMI 
(vs 18.5–25 kg/m2) 
OR 1.42 1.12, 1.80 
Parity (vs 0) OR 0.70 0.52, 0.94 
Stress 
(vs no/very 
little/somewhat stress):  
OR 1.46 1.13, 1.87 
Patel et a. 2262 randomly 54.7% (mild 21.3% (95% Moderate-severe Age   
 
190
Study ID, 
Country 
Population Prevalence/incidencea Primary outcome Significant risk 
factors 
Effect 
estimates 
Confidence 
intervalb/p 
value 
(2006) 
India 
selected women, 
aged 18–45 years 
not on OCP 
CI: 19.6, 23.0), moderate 
to severe 33.4% (95% C:I 
31.4, 35.5) 
pain (vs 18–24 years), 
p<0.001 
 30-34 OR 0.54 0.4, 0.8 
 34-40 OR  0.46 0.3, 0.7 
 40-50 OR 0.43 0.3, 0.6 
Age at menarche 
(vs ≤12 years), P=0.01 
  
 13-14 OR 0.75 0.6, 0.9 
 15+ OR 0.70 0.5, 0.9 
Ever pregnant OR 0.53 0.4, 0.7 
Menorrhagia OR 1.92 1.4, 2.6 
Somatoform symptom 
scorec (vs 0–1),  
p <0.001 
  
 2–3 OR 1.21 0.9, 1.6 
 4-7 OR 2.63 2.0, 3.4 
 >7 OR 3.67 2.7, 4.9 
Violence from others OR 2.23 1.5, 3.4 
Pawlowski 
(2004) 
Mexico 
177 non-smoking 
women living in the 
Mayan village, 
aged 18-45 years 
28% Presence of 
dysmenorrhea 
Age at birth of first child OR 1.15 1.02, 1.30 
Pitts et al 
(2008)  
Australia 
1983 menstruating 
women from a 
random sample, 
aged 16-49 years, 
sexually active, not 
been pregnant in 
the previous 12 
months 
71.7%, among them 15% 
(95% CI: 13.0, 17.1) 
severe pain 
Presence of 
dysmenorrhea 
Age (vs 40-49 years)   
 16–19 OR 2.74 1.49, 5.04 
 20–29 OR 1.58 1.18, 2.12 
 30–39 OR 1.49 1.18, 1.89 
English spoken  
(vs other) 
OR 2.02 1.21, 3.38 
Even been pregnant OR 0.74 0.55, 0.99 
Ever had a live birth OR 0.74 0.56, 0.97 
Santer et al. 
(2005) 
2833 women, aged 
25–44years not 
Severe pain 15% (95% 
CI: 13–16), of which 2% 
Severe-very 
severe pain 
Parity (per child, vs 0) OR 0.87 0.77, 0.98 
Deprivation area (per OR 1.30 1.18, 1.43 
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Study ID, 
Country 
Population Prevalence/incidencea Primary outcome Significant risk 
factors 
Effect 
estimates 
Confidence 
intervalb/p 
value 
UK using IUCD, 
random sampled 
from 19 general 
practices 
very severe unit increase) 
Longstanding illness OR 1.73 1.33, 2.23 
Hormonal 
contraception 
(vs other excl IUCD) 
OR 0.25 0.18, 0.35 
Tavallaee et 
al. (2011) 
Iran 
276 women, aged 
16–56 years not 
having secondary 
dysmenorrhea, 
from a stratified 
random sample 
Primary: 91% (mild 41%, 
moderate 28%, severe 
22%) 
Presence of 
dysmenorrhea 
Age OR 0.91 0.79, 0.92 
SES (vs very low)   
 Less than average OR 0.08 0.00, 0.80 
 Average OR 0.06 0.00, 0.70 
 More than average OR 0.05 0.00, 0.90 
Fruits & veg  
(vs never/low) 
  
 High OR 0.40 0.20, 0.60 
 Very high OR 0.20 0.08, 0.50 
Depressed most of the 
time (vs never) 
OR 13.3 2.0, 86.0 
Family history of 
dysmenorrhea 
OR 3.8 2.20, 6.90 
Unsal et al. 
(2010) 
Turkey 
729 reproductive 
age women 
recruited from two 
family physicians, 
aged 15–49 yrs,  
63.6% Presence of 
dysmenorrhea 
No of birth (vs >3)   
 0 OR 7.83 4.21, 14.57 
 1-2 OR 2.33 1.32, 4.11 
Irregular menstruation OR 1.90 1.22, 32.95 
Family history of 
dysmenorrhea 
OR 20.73 11.48, 37.42 
Systematic review 
Latthe et al 
(2006) 
64,286 women 
(from 63 studies) 
provided 
information on 
dysmenorrhea. No 
details on patients’ 
characteristics 
were reported.  
NR Presence of 
dysmenorrhea 
Age <30 years (3 
studies) 
OR 1.89 1.36, 2.63 
BMI <20 kg/m2 (5 
studies) 
OR 1.42 1.26, 1.59 
High SES (2 studies) OR 1.25 1.04, 1.50 
Smoking (11 studies) OR 1.37 1.19, 1.57 
Fish intake (1 study) OR 0.37 0.18, 0.73 
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Study ID, 
Country 
Population Prevalence/incidencea Primary outcome Significant risk 
factors 
Effect 
estimates 
Confidence 
intervalb/p 
value 
Note that all 
multiple studies are 
reported to be 
heterogeneous 
Exposure to cold at 
work (2 studies) 
OR 2.20 1.31, 3.70 
Slaughterhouse work  
(1 study) 
OR 2.54 1.33, 4.86 
Textile mill work  
(1 study) 
OR 2.05 1.30, 3.24 
Earlier menarche  
(6 studies) 
OR 1.54 1.17, 2.04 
More 
pregnancies/parity  
(12 studies) 
OR 0.64 0.57, 0.72 
Age at birth of first child 
(1 study) 
OR 0.38 0.18, 0.83 
Miscarriage (4 studies) OR 1.29 1.05, 1.59 
Irregular menses  
(2 studies) 
OR 2.02 1.19, 3.44 
Duration of menstrual 
flow (5 studies) 
OR 2.38 1.69, 3.3.7 
Heavy menstrual blood 
loss (3 studies) 
OR 4.73 2.95, 7.58 
Premenstrual 
syndrome (6 studies) 
OR 2.42 1.84, 3.18 
Sterilisation (5 studies) OR 1.35 1.04, 1.75 
Oral contraceptive use 
(10 studies) 
OR 0.65 0.60, 0.71 
Pelvic inflammatory 
disease (2 studies) 
OR 1.58 1.09, 2.30 
Circumcision (1 study) OR 3.75 1.46, 9.67 
Sexual assault 
(4 studies) 
OR 1.60 1.29, 2.00 
Emotional difficulties  
(1 study) 
OR 2.18 1.45, 3.27 
Psychological 
symptoms (1 study) 
OR 3.72 2.10, 6.60 
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Study ID, 
Country 
Population Prevalence/incidencea Primary outcome Significant risk 
factors 
Effect 
estimates 
Confidence 
intervalb/p 
value 
Suicidal tendency  
(1 study) 
OR 2.45 1.48, 4.05 
No-sensuality (1 study) OR 8.12 3.37, 19.54 
Somatisation  
(3 studies) 
OR 3.04 1.42, 6.53 
 
a. Rates are prevalence rates unless otherwise specified 
b. 95% confidence intervals were reported in all primary studies, except the systematic review by Latthe (2006) where 99% confidence intervals 
were reported to account for possible multiple testing 
c. Range 0–40, higher score indicates worse mental health 
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Appendix C: Age-specific prevalence of dysmenorrhea 
and PMS across five ALSWH surveys (paper 2) 
 
Prevalence of PMS and dysmenorrhea when combining all observations across five ALSWH surveys 
from 2000 to 2012 according to women’s age  
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Appendix D: BMJ global press release on smoking and 
trajectories of dysmenorrhea (paper 3) 
On 13 November 2014, the following press release on the smoking and trajectories of 
dysmenorrhea paper published on the journal Tobacco Control were sent out under 
embargo to over 5,000 recipients worldwide. As a result, the paper made headlines in over 
30 newspapers or online publications worldwide.  
BMJ, BMA House, Tavistock Square, London, WC1H 9JR 
T: +44 (0)7980 800 465 
E: cwhite@bmj.com 
W: bmj.com/company 
TOBACCO CONTROL 
Young teen smokers run heightened risk of chronic severe period pain 
[Smoking and trajectories of dysmenorrhoea among young Australian women Online First 
doi 10.1136/tobaccocontrol-2014-051920] 
Young teen smokers run a heightened risk of developing chronic severe period pain, 
suggests research published online in the journal Tobacco Control. 
Most women will experience period pain (dysmenorrhoea) during their reproductive life, 
with the pain severe in up to 29%. 
Smoking has been mooted as a potential risk factor, but the research to date has been 
inconclusive. 
The study authors studied a large population sample of 9000 women, all of whom were 
taking part in the Australian Longitudinal Study on Women’s Health, from 1996 onwards. 
Every 3–4 years between 2000 and 2012, the women were asked about the frequency and 
severity of any period pain they had experienced, and whether they currently or had ever 
smoked. Current and ex-smokers were asked at what age they started. 
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Information was also collected on other key influential factors, such as educational 
attainment, marital status, employment, residential area, weight, lifestyle and reproductive 
history. 
In 2000, when the women were aged between 22 and 27, over half (59%) were non-
smokers and around one in four (26%) were current smokers. 
Around 7% of the women had started smoking by the age of 13, with a further 14% starting 
their habit at the age of 14–15. And 8% said they had started smoking before they began 
having monthly periods. 
In 2000, one in four women said they regularly experienced period pain every month. The 
prevalence of period pain was slightly higher in current smokers (29%) than in non-
smokers (23%). 
The women were divided into four groups according to the type and duration of period pain 
they had.  
The ‘normative’ group comprised 42% of the total sample, defined by no or few symptoms 
throughout the monitoring period; 11% of the women were categorised as ‘late onset,’  
defined by an increasing prevalence of period pain from 15% to nearly 70%. 
The ‘recovering’ group comprised 33% of the women, defined by a decreasing prevalence 
of period pain from 40% at the age of 22–27, to 10% by the age of 34–39. 
Some 14% of the women were categorised as the ‘chronic’ group, defined as a high 
prevalence of period pain of between 70% and 80% throughout the monitoring period. 
Compared with women who had never smoked, current smokers who had started smoking 
by the age of 13 were more likely to be in the chronic group, as were women who were 
unemployed, had started their periods early, who were obese, and who spoke a European 
language at home. 
After taking account of influential factors, current smokers who had started smoking by the 
age of 13, were 60% more likely to fall into the chronic group than non-smokers. 
This is an observational study so no definitive conclusions can be drawn about cause and 
effect, but there are possible explanations for the association, say the authors. 
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Cigarette smoking is known to constrict arterial blood flow, which could potentially cause 
pain. Alternatively, it might have a direct effect on the hormones involved in menstruation, 
which may be particularly important before the onset of puberty and regular menstruation, 
say the authors. 
Contact: 
Dr Hong Ju, Centre for Longitudinal and Life Course Research, School of Population 
Health, University of Queensland, Brisbane, Australia. 
Email: h.ju@uq.edu.au  
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Appendix E: The University of Queensland media 
release on smoking and dysmenorrhea (paper 3) 
Following the publication of the paper on Tobacco control, The University of Queensland 
also issued its own media release. 
21 November 2014 
Smoking linked to painful periods 
A new study from The University of Queensland (UQ) has found that women who smoke 
are at higher risk of experiencing painful periods.  
The study of more than 9,000 Australian women found that 29% of smokers suffered from 
dysmenorrhea—painful periods—compared with 23% of non-smokers.  
And while it is relatively common for most women to experience painful periods at least 
sometimes, researchers found that women who smoked were more likely to suffer painful 
periods regularly over many years.  
‘We found that smokers were 40% more likely to experience ongoing pain throughout our 
12-year study, than non-smokers’, said lead researcher Dr Hong Ju from UQ’s School of 
Population Health (SPH).  
‘We also found that women who started smoking by age 13 were 60 percent more likely to 
have ongoing period pain than non-smokers.’ 
Women who stopped smoking may recover from period pain but still suffered 
dysmenorrhea at a higher rate that those who had never smoked.   
Dr Ju said that, while more research is needed to understand exactly how smoking 
increases the risk of painful periods, one reason may be that smoking narrows the blood 
vessels which could cause pain. 
‘Another theory is that smoking affects hormones or that smoking may be toxic to the 
ovaries,’ she said.  
Dr Ju said that the study’s findings may help build more effective anti-smoking campaigns 
aimed at young women.  
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‘While the links between smoking and cancer and heart and lung diseases are well known, 
some young women may dismiss these risks as too far off into the future to worry about 
now,’ she said.  
‘A greater chance of more painful periods may seem a more compelling reason to quit now 
or not start smoking at all.’ 
The study was conducted with SPH colleagues Dr Mark Jones and Professor Gita Mishra 
and used data from the Australian Longitudinal Study of Women’s Health.  
Media: Vanessa Mannix Coppard, v.mannixcoppard@uq.edu.au, 042 420 7771 
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Appendix F: Sensitivity analysis results for smoking 
and dysmenorrhea (paper 3) 
Multivariable-adjusted odds ratios of being in different trajectory groups of dysmenorrhea from 2000 to 2012 for smoking behaviour 
among ALSWH young cohort aged 22 to 27 years at 2000 (N = 9067), after multiple imputation* 
 Sample (N) Multivariable-adjusted OR (95% CI) 
  Normative Late onset Recovering Chronic 
Smoking status 7,970     
 Never-smoker  1 1 1 1 
 Ex-smoker  1 1.01 (0.77, 1.32) 1.22 (1.04, 1.44) 1.21 (0.98, 1.48) 
 Current smoker  1 1.16 (0.93, 1.45) 1.24 (1.09, 1.42) 1.38 (1.16, 1.64) 
Age started smoking (years) 8,588     
 Never smoker  1 1 1 1 
 ≤13  1 1.17 (0.82, 1.65) 1.19 (0.96, 1.47) 1.59 (1.24, 2.03) 
 14–15  1 1.34 (1.04, 1.74) 1.20 (1.02, 1.41) 1.36 (1.11, 1.65) 
 ≥16  1 1.06 (0.84, 1.33) 1.13 (0.98, 1.29) 1.24 (1.05, 1.47) 
Time started smoke relative to 
menarche 
7,565     
 Never smoker  1 1 1 1 
 Before menarche  1 1.19 (0.84, 1.68) 1.16 (0.93, 1.44) 1.42 (1.09, 1.86) 
 After menarche  1 1.20 (0.98, 1.48) 1.20 (1.06, 1.36) 1.28 (1.09, 1.51) 
* Multivariable-adjusted analysis estimates the effect of the exposure of interest (smoking status or age initiation of smoking) after controlling for 
sociodemographic characteristics (education, employment, marital status, and language spoken at home), lifestyle factors (BMI, alcohol 
consumption and illicit drug use), and reproductive factors (use of oral contraception, parity, age at menarche and endometriosis). 
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Appendix G: Trajectory groups of dysmenorrhea by 
quitting smoking status (paper 3) 
Trajectory groups of dysmenorrhea by smoking quitting status from 2000 to 2012 
 Sample 
n 
Percentage P value 
  Normative Late onset Recovering Chronic  
Quittera 591 49.9 6.8 29.6 13.7 0.0157 
No quitter 510 44.7 9.6 26.5 19.2  
a Quitters were those who quit smoking from a particular survey and remained as ex-smokers afterwards 
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Appendix H: Sensitivity analysis results for illicit drug 
use and PMS (paper 4) 
Sensitivity analysis on the univariate and multivariable-adjusted  of PMS by Illicit Drug Use from GEE Analyses among women from the 
1973–78 cohort of the ALSW H, 2000 to 2012a 
 Sample (N) Univariate Multivariable-adjustedb 
  OR 95% CI OR 95% CI 
Age initiation drug use among recent drug users 
Age initiation drug use (years)c 7,103     
 Never  1  1  
 Ex-user  1.17 1.07, 1.28 1.03 0.94, 1.14 
 <15  1.93 1.48, 2.52 1.41 1.06, 1.88 
 15–17  1.44 1.19, 1.72 1.12 0.92, 1.37 
 ≥18  1.37 1.12, 1.69 1.09 0.88, 1.36 
Recoding never drug users with an age initiating drug use as ex-usersa 
Pattern of any illicit drug use 8,921     
 Never  1  1  
 Ex-use  1.11 1.04, 1.19 1.04 0.97, 1.12 
 Recent use  1.48 1.38, 1.60 1.26 1.16, 1.37 
a Recent use is use in the last 12 months.  
b Multivariable-adjusted analysis estimates the effect of the exposure of interest (illicit drug use) after controlling for sociodemographic 
characteristics (age, education, marital status, area of residence, and language spoken at home), lifestyle factors (BMI, smoking, and alcohol 
consumption), reproductive factors (use of oral contraception, parity, and age at menarche), and psychological factors (history of abuse, self-
reported depression). 
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Appendix I: Sensitivity analysis results for BMI and 
dysmenorrhea (paper 5) 
Results from multiple imputation on the association between BMI and dysmenorrhea, from GEE analysis, among the 1973–1978 cohort of 
the ALSWH from 2000 to 2012  
BMI N OR 95% CI 
BMI category (kg/m2) 9,688  
 Underweight (<18.5)  1.27 1.09, 1.49 
 Normal weight (18.5 to <25)  1  
 Overweight (25 to <30)  1.03 0.96, 1.10 
 Obese (≥30)  1.20 1.10, 1.31 
BMI transition 9,021  
 Stable (normal or overweight)  1  
 Stay underweight or obese  1.33 1.20, 1.47 
 Underweight → normal or overweigh  1.33 1.13, 1.55 
 Normal or overweight → underweight  1.27 1.03, 1.58 
 Normal or overweight → obese  1.08 0.95, 1.23 
 Obese → overweigh or normal  1.09 0.89, 1.34 
 Normal ↔ overweight  1.04 0.95, 1.14 
The estimates on the association of dysmenorrhea and the exposure of interest (BMI and BMI transition) were adjusted for sociodemographics (age, 
education, employment, marital status, managing income, and language spoken at home), lifestyle factors (smoking, illicit drug use and alcohol 
consumption), reproductive factors (use of oral contraception, parity, age at menarche, and endometriosis). 
 
 
